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ABSTRACT 
The Notch signaling pathway is one of the essential mediators of cell-cell communication 
during development of multicellular organisms. Notch signaling is based on receptors and 
ligands that interact between neighboring cells. In recent years Notch has received a lot of 
interest as a promising therapeutic target in cancer and several approaches to intervene 
with the Notch pathway are under pre-clinical and clinical trials. The challenges are 
prominent side effects, lack of specificity and poor knowledge of the underlying 
mechanisms behind deregulated Notch activity. In this thesis, several aspects of Notch 
regulation have been investigated. 
Intermediate filaments (IFs) are cytoskeletal proteins that regulate signaling activities in 
addition to providing structural support for the cell. In study I, we present a novel 
interaction between the intermediate filament vimentin and the Notch ligand Jagged1. The 
use of hybrid Jagged1-Dll4 ligands demonstrates a selective regulation of Notch ligands 
by vimentin. Mouse embryos lacking vimentin display delayed angiogenesis with reduced 
branching. In vitro and ex vivo angiogenesis assays show a reduced sprouting from 
vimentin deficient endothelial cells, a phenotype which can be rescued by addition of 
immobilized Jagged1 ligands. This work implies that IFs can selectively regulate Notch 
ligands to balance Notch activity. In the second study, we have initiated a screening 
approach to identify regulators of Jagged1. A dual label approach allows for visualization 
and measurement of endocytosed Notch extracellular domain peptides bound to Notch 
ligands. A pilot screen based on cell spot microarrays (CSMA) has generated a set of 
potential modulators of Jagged1 endocytosis for further validation and future research. In 
the final part of the thesis, I present the discovery of a novel PKCζ-mediated 
phosphorylation site on Notch1. Phosphorylation of the identified site, S1791, leads to 
enhanced trafficking of Notch to the nucleus and higher Notch signaling activity. Blocking 
PKCζ or using a phospho-deficient form of S1791 leads to less Notch activity and 
localization to intracellular endosomes. Our data also imply that PKCζ-mediated 
phosphorylation of Notch influences differentiation of myogenic cells in vitro and 
neuronal cells in vivo. 
In summary, the work presented in this thesis characterizes various aspects of Notch 
signaling modifications within the context of endocytosis of Notch receptors and ligands. 
These findings contribute to a better understanding of the intricacies of Notch signaling 
regulation and may benefit future studies targeting Notch-related diseases. Additionally, 
the ligand tracking approach lays the groundwork for future work to identify new 
modulators of ligand endocytosis.  
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SAMMANFATTNING (ABSTRACT IN SWEDISH) 
Notch-signaleringen är en av de huvudsakliga förmedlarna av kommunicering mellan 
närliggande celler under utvecklingen av flercelliga organismer. Notch-signaleringen 
baserar sig på Notch-receptorer och ligander vid cellmembranen. De senaste åren har 
Notch-signaleringen fått stor uppmärksamhet som ett potentiellt mål för nya 
behandlingsmetoder mot cancer och flera olika Notch inhiberare är i pre-kliniska och 
kliniska prövningar. De största utmaningarna är starka biverkningar, en brist på 
specificitet och en låg kunskap om de underliggande mekanismerna bakom en felreglerad 
Notch-aktivitet. I denna avhandling undersöks flera olika aspekter av Notch-regleringen. 
Intermediärfilament är strukturella proteiner som även kan reglera olika signaleringsräckor. 
I den första studien presenterar vi för första gången en interaktion mellan 
intermediärfilamentet vimentin och Notch-liganden Jagged1. Genom att använda oss av 
hybrid-ligander bestående av liganderna Jagged1 och Dll4, visar vi att vimentin kan 
reglera dessa ligander på ett selektivt sätt. Vi visar också att möss som saknar vimentin har 
en fördröjd blodkärlsbildning under fosterutvecklingen. Endotelceller som saknar 
vimentin påvisade även färre förgreningar i våra blodkärlsbildningsanalyser. Detta kunde 
motverkas genom en tillsats av externa Jagged1-ligander. Detta arbete visar att 
intermediärfilament specifikt kan reglera olika Notch-ligander. I den andra studien har vi 
använt en högkapacitetsscreen för att identifiera nya Jagged1-reglerare. Med hjälp av en 
tvåfärgad analysmetod kunde vi visualisera och mäta Notch-peptider som binder till 
Notch-ligander som sedan endocyteras in i cellen. En primärscreen har genererat en 
uppsättning av potentiella reglerare av Jagged1-endocytos för framtida verifiering och 
forskning. I den sista delen av avhandlingen presenteras identifieringen av ett nytt PKCζ-
medierat fosforyleringsställe på Notch1-receptorn. Genom att mutera det identifierade 
fosforyleringsstället kunde vi visa att receptorn tar olika rutter i cellen beroende på om den 
är aktiv eller inaktiv. Våra resultat antyder också att PKCζ-medierad fosforylering av 
Notch påverkar differentieringen av muskelceller in vitro och neuronala celler in vivo. 
Sammanfattningsvis kan man säga att arbetet som presenteras i denna avhandling berör 
olika aspekter av Notch-regleringen med ett speciellt fokus på endocytos av Notch-
receptorer och ligander. Dessa fynd bidrar till en bättre förståelse om de komplicerade 
modifieringar som berör Notch. Dessa kan komma att gynna framtida studier som berör 
Notch-relaterade sjukdomar. Analysmetoden som användes för att spåra Notch-ligander 
lägger grunden till att identifiera nya reglerare av ligand-endocytos i framtiden.  
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INTRODUCTION 
Based on current understanding, a surge in the amount of multicellular organisms occurred 
around 600 million years ago during an increase in oxygen on earth (Grosberg and 
Strathmann, 2007). In order for multicellularity to work, individual cells had to be able to 
communicate with each other and coordinate their behavior. One of the signaling 
pathways that has played an essential role during metazoan development is Notch. The 
Notch pathway is based on receptors and ligands spanning across the cell membrane that 
can interact with each other during direct cell-to-cell contact between adjacent cells. The 
core pathway is deceptively simple, where ligand-mediated activation of the receptor leads 
to its proteolysis and subsequent release of a transcriptionally active Notch intracellular 
domain (NICD) that can translocate to the nucleus and activate downstream Notch target 
genes (Kopan and Ilagan, 2009). Despite the apparent simplicity, without secondary 
messengers and amplification steps, Notch is highly context dependent with multiple 
cellular phenotypes from seemingly similar Notch input. Accumulating evidence supports 
a view that Notch signaling is a highly regulated process with a myriad of interacting 
partners and modifications regulating activity and outcome. From the beginning of 2013, 
Notch related therapies have been in clinical trials for a number of different cancers in 
humans (Andersson and Lendahl, 2014). One of the challenges of therapeutic relevance of 
Notch today lies in how to specifically tune Notch signaling in the right context without 
adversly affecting normal tissue homeostasis, where Notch signaling is also crucial. Notch 
also represents a possible therapeutic target in cardiovascular diseases, although 
knowledge of the specific roles of dysregulated Notch signaling in the pathogenesis of 
vascular diseases is still lagging behind that of cancer research (Aquila et al., 2019).  
Post-translational modifications and intracellular trafficking of Notch and its interacting 
partners critically regulate Notch signaling output. This thesis aims to advance the 
knowledge of Notch regulation, and proposes a new interaction between the cytoskeletal 
intermediate filament protein vimentin and the Notch ligand Jagged1. Post-translational 
modifications are also studied in the form of phosphorylation of the Notch receptor and its 
effect on receptor routing and Notch activity. Finally, a fluorescence based screening 
approach has been developed to identify more potential regulators of Notch ligand 
endocytosis that can serve as a basis for future research. 
REVIEW OF THE LITERATURE 
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REVIEW OF THE LITERATURE 
1. The Notch signaling pathway 
Notch signaling is part of a select group of signaling pathways defining development of 
multicellular organisms. During development Notch orchestrates cell fate decisions by 
influencing differentiation, proliferation and apoptosis through physical interactions 
between Notch receptors and ligands on the membranes of neighboring cells. The Notch 
field emerged from genetic studies on development of the fruit fly Drosophila 
melanogaster. The importance of the core Notch pathway is implicated by conservation 
throughout evolution in all metazoans studied to date. More recently, human genetic 
studies have shown that Notch plays a role in numerous and diverse human diseases.  
The Notch receptor is generated as a single precursor protein, but is cleaved by furin-like 
convertase in the Golgi during transport to the cell surface (S1 cleavage). At the cell 
surface, the receptor is presented as a noncovalently bound heterodimer that spans the cell 
membrane. In mammals, there are four Notch receptors (Notch1-4) and five Notch ligands 
(Jagged1-2, Dll1, 3-4). Notch signaling is initiated when a ligand from a juxtaposed cell 
binds the receptor and a sufficient force is generated, which pulls on the receptor and 
induces a conformational change, to allow for two proteolytic cleavages (S2 and S3 
cleavage) that ultimately release the intracellular domain of the receptor. The intracellular 
part of Notch can then translocate to the nucleus where it forms a complex with CSL 
(CBF-1, Su(H), and Lag-1), Mastermind-like (MAML) and transcriptional co-activators to 
activate Notch target genes from the Hairy Enhancer of Split (HES) and Hes-related 
protein (HERP, also known as HEY) families (Kopan and Ilagan, 2009) (for further details 
see chapter 1.4). The complexity of Notch lies in its numerous levels of regulation that 
allow for varied and context-dependent outcomes of its activation. The implications of 
Notch in human disease, especially in cancer, has led to a promise of possible Notch 
therapies in the future, resulting in a wealth of studies relating to Notch during the last few 
decades. 
1.1 A brief history of Notch research 
The term Notch was first used over 100 years ago when John S. Dexter noticed that some 
fruit flies (Drosophila melanogaster) had an inheritable deformity, where the flies had 
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small notches in the tips of their wings (Dexter, 1914). This finding piqued the interest of 
geneticist and embryologist Thomas Hunt Morgan who subsequently identified the first 
Notch gene allele a few years later (Morgan, 1917). In the following years Morgan and 
members of his lab identified several more Notch alleles with various phenotypes, 
including the Notched wing phenotype (Figure 1), but also lethal phenotypes (Mohr, 
1919). In the 1930s, Donald Poulson looked at broader phenotypic effects of removing 
entire chromosomes in fruit fly embryos. In his work, Poulson identified chromosomal 
defects, where parts of the chromosomes were mutated. One of these included the Notch 
gene locus. These mutations led to a disruption in development of the mesoderm and 
endoderm germ layers a few hours into embryogenesis. Poulson describing these Notch 
mutants were some of the first characterizations of how any specific gene, not only Notch, 
affects morphogenesis (Poulson, 1937). Poulson’s discoveries were for many decades left 
without much follow up research. In the early 1980s, Spyros Artavanis-Tsakonas and 
Michael Young independently sequenced the Notch gene in Drosophila (Artavanis-
Tsakonas et al., 1983; Kidd et al., 1983). By comparing the sequences from Notch cDNA 
to other proteins, Artavanis-Tsakonas speculated that Notch was a transmembrane protein 
and later work from his lab detailed that epidermal growth factor like repeats (EGF-
repeats) extend outside of the cell (Wharton et al., 1985). This was at a time when the 
modern molecular biology revolution had just started with the discovery of the polymerase 
chain reaction (PCR) and in the years following, many of the key actors in the Notch 
signaling pathway were characterized. The idea of Notch being a cell-to-cell 
communication signal was sparked in 1987 when the Delta ligand was sequenced and 
discovered to be a transmembrane protein similar to the Notch receptor (Vässin et al., 
1987). Serrate in Drosophila (corresponding to Jagged in mammals) was sequenced a few 
years later (Fleming et al., 1990). In the late 1980s, it was also shown that Notch regulates 
differentiation in both C. elegans and Drosophila (Kidd et al., 1989; Yochem et al., 1988). 
The first description of Notch in humans came in 1991 when Leif Ellisen sequenced a 
gene with a mutation of high occurrence in leukemia cells. This human sequence was 
remarkably similar to the Notch gene discovered in Drosophila and he further showed that 
truncated Notch1 proteins could contribute to cancer in vitro (Ellisen et al., 1991). Notch 
research gained great interest after this point and one of the most notable examples of 
Notch in human disease came when it was discovered that more than 50% of T-cell 
lymphoblastic leukemia (T-ALL) patient samples had Notch-activating mutations (Weng 
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et al., 2004). The implications of Notch in other cancer forms as well as various other 
diseases have been substantial since then (Aster et al., 2017; Louvi and Artavanis-
Tsakonas, 2012). In the last few decades researchers have tried to understand how Notch 
can be so context dependent, how Notch is regulated, what the crosstalk is with other 
signaling pathways and if Notch can be targeted in disease. Combining research from 
Drosophila, C. elegans and mice together with clinical data from humans have established 
a detailed understanding of many aspects of Notch signaling. However, equally many 
questions remain in truly understanding the context dependent output of Notch and the 
finetuning of signaling activity within the pathway, as well as its interactions with other 
proteins.  
 
 
1.2 Notch receptors 
Notch receptors are large heterodimeric proteins spanning across the cell membrane. The 
general structure has been conserved throughout evolution, from the simplest invertebrates 
to humans. Much of the initial work on Notch was done in Drosophila Melanogaster, 
which has only one Notch receptor, in contrast to mammals that have four Notch receptors 
(Notch1-4) (Figure 2). Notch receptors are synthesized in the ER and processed further in 
the Golgi apparatus. During this processing step, the Notch precursor protein is 
Figure 1. The Notch mutant. 
Thomas Hunt Morgan describes a 
female fruit fly carrying a “notch” 
mutation in one of her X-
chromosomes. The notched wing 
phenotype was a dominant trait 
and could only been seen in 
females, as half of her male 
offspring would get the mutant X-
chromosome and die, while the 
other half would get the normal X-
chromosome and develop 
normally, as described in “The 
theory of the gene”, American 
Naturalist in 1917 (Adapted from 
Morgan, 1917). 
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proteolytically cleaved by furin-like convertase (Site 1 or S1 cleavage), producing a 
heterodimer, which is further modified by glycosylation and other post-translational 
modifications before the receptor is presented at the cell membrane. The receptor at this 
point consists of an extracellular domain (ECD) and an intracellular domain (ICD) 
(Blaumueller et al., 1997; Gordon et al., 2008). The modification of the extracellular 
domain by O-linked glycans during synthesis is a key modification for the proper structure 
of the receptor and its interaction with its ligands. The EGF-repeats consist of 
approximately 40 aminoacids, including 6 conserved cysteines, which form three 
disulphid bonds between cysteines C1-C3, C2-C4 and C5-C6. The major glycosylation 
sites of the receptor are found on consensus sites between these cysteines (Harvey and 
Haltiwanger, 2018). Glycosylation, other post-translational modifications and their 
regulation of Notch are discussed further in chapter 2.1. The extracellular domain of 
Notch consists of 29-36 epidermal growth factor repeats (EGF), of which some interact 
directly with the Notch ligands, most notably EGF8-12 (Luca et al., 2017, 2015). Many of 
the individual EGF-domains bind calcium ions, which have been known to affect the 
structure of the receptor and affinity to its ligands. Recent structural studies surprisingly 
found a 90-degree angle occuring between EGF-repeat 5 and 6 in the Notch1 receptor 
structure; with EGF6 being a non calcium-binding repeat (Weisshuhn et al., 2015a). 
Nuclear magnetic resonance (NMR) spectroscopy analysis of other EGF-repeats 
confirmed that calcium binding repeats form rigid structures, while non-calcium binding 
may have different tilt angles, giving the overall NECD structure flexibility (Weisshuhn et 
al., 2015b). The model proposed for the structure based on X-ray crystallography of 
EGF4-13 and NMR data, consist of an L shaped 90 degree angle between EGF5-6 and a 
flexible region between EGF9-10, with more minor tilt angles possible between other 
EGF-repeats such as EGF11-12 and EGF12-13 (Weisshuhn et al., 2016). This gives 
updated insight into the shape of Notch receptors, which earlier have generally been 
depicted as a straight rods sticking out of the cell membrane. The EGF-repeats are 
followed by a negative regulatory region (NRR), which is composed of cysteine-rich 
Lin12-Notch repeats (LNR) and a heterodimerization domain (HD) (Gordon et al., 2007). 
The NRR plays a key role in preventing receptor activation when a ligand is not bound by 
hiding the S2 cleavage site deeply within the Notch HD domain, making it unavailable to 
ADAM/TACE-mediated cleavage (Gordon et al., 2007). Mutations in this region can 
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leave the receptors constitutively active without proper ligand activation, which can be 
seen in certain cancers (Malecki et al., 2006; Weng et al., 2004). 
 
Figure 2. Domain organization of human Notch receptors. Mammalian Notch receptors include 
Notch1-4. The extracellular domain of the Notch receptor has a short signaling peptide, 29-36 
epidermal growth factor like repeats (EGF), and a negative regulatory region (NRR). The NRR is 
composed of Lin-12-Notch repeats (LNR) and a heterodimerization domain (HD). The 
transmembrane domain (TM) leads to the Notch intracellular domain (NICD), which is composed 
of a RAM-domain (RBPjk associated module), two nuclear localisation signals (NLS) that flank 
seven ankyrin repeats (ANK). The C-terminal domain of Notch contains a transactivation domain 
(TAD) and a proline, glutamic acid, serine and threonine-rich domain (PEST). Notch3 and Notch4 
lack the TAD domain and Notch4 lacks the second NLS. The S2 site in the HD domain and S3 site 
at the edge of the transmembrane domain (TM) indicate the proteolytical cleavage sites, mediated 
by ADAM-metalloproteases and γ-secretase, respectively.   
The Notch intracellular domain (NICD) is composed of a RAM domain (RBPjk associated 
module) which can bind to the DNA binding protein CSL (CBF-1/RBPjk/Su(H)/Lag-
1)(CSL, also commonly called RBPjk). Following the RAM domain is a nuclear 
localisation sequence (NLS) and seven ankyrin sequences, which are collectively called 
the ANK domain. CSL also interacts with the ANK domain. All mammalian Notch 
receptors, except Notch4, have another NLS following the ANK domain. A 
transactivation domain leads to the last part of the C-terminal end of the receptor, which is 
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the PEST domain. This domain is a conserved domain consisting of proline-glutamic acid-
serine-threonine sequences which function as a degradation signal for NICD (Andersson 
et al., 2011). The PEST domain thereby affects the stability of NICD that has been 
released by receptor activation. 
1.3 Notch ligands 
The Notch ligands have structural similarities to Notch receptors. Notch ligands are also 
transmembrane proteins, which consist of EGF-like repeats in their ECD (D’Souza et al., 
2008). The amount of EGF-repeats varies between 6-16 among the different ligands 
(D’Souza et al., 2008; Kopan and Ilagan, 2009) (Figure 3). There are two families of Notch 
ligands: Delta/Delta-like and Serrate/Jagged. Delta and Serrate are found in Drosophila, 
which has one of each ligand type. In mammals, the corresponding ligands are Delta-like 
(Dll) and Jagged, which include three Delta-like ligands (Dll1, Dll3 and Dll4) and two 
Jagged ligands (Jagged1-2) (D’Souza et al., 2008). Dll3 has been described as a decoy 
ligand, incapable of activating Notch receptors in trans (Ladi et al., 2005). In line with this, 
Dll3 knockout mice have higher Notch activity than WT mice (Chapman et al., 2011).  
Canonical Notch ligands are recognized by their DSL domain (Delta, Serrate and Lag-2), 
which is a small domain similar to the EGF-repeats in structure. The interaction of the 
DSL domain with the Notch receptor EGF-repeats has been demonstrated to be required 
for the activation of Notch signaling (Becam et al., 2010; Luca et al., 2015; Takeuchi et al., 
2018). Recently, the use of an engineered high affinity Dll4-Notch1 complex solved the 
longtime issue of producing a crystal structure of the normally low affinity ligand-receptor 
complex (Luca et al., 2015). Using immobilized EGF1-14 of the Notch receptor bound to 
magnetic beads with the EGF5 to the N-terminal region of Dll4, it was shown that the 
majority of the binding strength comes from the DSL domain of Dll4 binding to EGF11 of 
Notch1, and the C2 (MNNL) domain binding to EGF12 of Notch1 (Luca et al., 2015). 
Jagged1 was later shown to interact with EGF8-12 of Notch1 through its C2, DSL and 
EGF1-3 domains (Luca et al., 2017). Similarly to the Notch1 receptor, the crystal structure 
of Dll1 recently showed that the ligand makes a 90 degree bend around EGF4 and EGF5 
(Kershaw et al., 2015). 
Jagged ligands also have a cysteine-rich region in their ECD next to the transmembrane 
domain (Chillakuri et al., 2012). Furthermore, Jagged1, Dll1 and Dll4 have PDZ binding 
REVIEW OF THE LITERATURE 
 8 
motifs (PSD-95/Dlg/ZO-1) in their ICD, which can interact with the cytoskeleton, while 
Jagged1, Dll1 and Dll3 also have SH2 binding motifs that can interact with proteins 
containing SH2 domains in a phosphorylation dependent manner (Pintar et al., 2007).  
 
Figure 3. Domain organization of human DSL ligands (Delta, Serrate, Lag-2). Notch ligands 
in mammals include Dll1, 3 and 4, which are structural homologues of Delta in Drosophila, as 
well as Jagged 1, and 2, which are structural homologues of Serrate in Drosophila. Notch ligands 
are recognized by their Delta, Serrate, Lag-2 domain (DSL). N-terminally from the DSL domain is 
a short signal peptide and a C2 domain that until recently was known as the Module at the N-
terminus of the ligand (MNNL). The extracellular domains also contain a variable number of 
EGF-like repeats (EGF). The two first EGF-repeats of Jagged1-2 and Dll1 have a slight difference 
in structure and are sometimes identified as the Delta/OSM-11 domain (DOS domain) (not shown 
in the figure). A cysteine-rich domain is also found in Jagged1-2. Jagged1, Dll1 and Dll4 have 
distinct PDZ-binding motifs in their intracellular domain. Dll3 lacks lysines in its intracellular 
domain making it unavailable for ubiquitination (Heuss et al., 2008). 
1.4 Activation of canonical Notch signaling 
Notch signaling is activated during cell-to-cell contact where Notch receptors interact with 
DSL ligands. Notch receptor activation normally occurs when Notch ligands on 
neighboring cells bind and activate the Notch receptor (Figure 4). The ligand-receptor 
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interaction leads to a change in the conformation of the Notch receptor, and the NRR is 
opened for S2 cleavage, which is followed by S3 cleavage in the transmembrane domain 
(Kovall et al., 2017). The mechanical force from endocytosis or cellular movement, which 
pulls on the Notch receptor, opens up the S2 cleavage site for ADAM-like 
metalloproteases such as ADAM17/TACE and ADAM10/Kuzbanian. Of these two, 
ADAM10 seems to be more relevant for canonical signaling physiologically, at least in 
Notch1 (van Tetering et al., 2009), but ADAM17 has been noted especially in aberrant 
ligand-independent signaling (Bozkulak and Weinmaster, 2009). The S2 site is located 12-
13 amino acids before the transmembrane domain, which is well guarded by the negative 
regulatory domain (NRR) in non-activated cells (Gordon et al., 2009). The S2 cleavage 
also releases the NECD, which can be trans-endocytosed into the signal-sending cell 
together with the ligand (Gordon et al., 2008). γ-secretase is a protein enzyme complex 
consisiting of presinilin, nicastrin, PEN2 and APH1 and is required for S3 cleavage of the 
Notch receptor, which takes place just inside the cell membrane close to the cytoplasmic 
side (Bray, 2006). γ-secretase is not specific to Notch, as it is also responsible for cleavage 
of various other proteins such as APP, ErbB4 and CD44 (Selkoe and Wolfe, 2007). 
Inhibiting γ-secretase to curb Notch signaling in disease is therefore problematic, because 
of the wide range of functions for γ-secretase and clinical trials with γ-secretase inhibitors 
have shown unwanted side-effects (Andersson and Lendahl, 2014). The γ-secretase based 
S3 cleavage has also been found to occur in endosomes transporting NICD in the cell, as 
well as directly on the cell membrane (Sorensen and Conner, 2010; Tagami et al., 2008). 
Some studies imply that the γ-secretase activation can be even more efficient in 
endosomes than at the cell surface, due to the more acidic pH in late endosomes that is 
implicated to regulate γ-secretase activity (Vaccari et al., 2008; Windler and Bilder, 2010). 
The cleaved NICD can have a different half-life and activity depending on which amino 
acid is on the N-terminal end of NICD, which can be influenced by the location of the 
cleavage (Tagami et al., 2008). The most common cleavage site in humans is between 
amino acids Glu-1753 and Val-1754 (Val-1744 in mice) (Okochi et al., 2002). Released 
NICD can migrate to the cell nucleus where it can bind the DNA-binding protein CSL 
through its RAM and ANK domains. The ANK domain together with CSL recruits the co-
activator Mastermind-like (MAML), which facilitates transcriptional activation of Notch 
target genes. Other co-activators such as p300 and PCAF can bind to this complex to 
activate Notch target genes.    
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Figure 4. Notch activation overview. Canonical Notch signaling is initiated when a Notch ligand 
interacts with a Notch receptor from a neighboring cell. The tension generated (red arrow) during 
endocytosis of the ligand, changes the conformation of the bound Notch receptor to allow two 
subsequent proteolytic cleavage events, first by ADAM family metalloproteases and then by γ-
secretase, which ultimately releases the transcriptionally active Notch ICD. NICD then 
translocates to the nucleus where it binds CSL, resulting in recruitment of co-activators, instead of 
co-repressors normally bound to CSL. This complex can then induce expression of gene families 
mainly relating to Hairy-Enhancer of Split (HES), and Hes-related proteins (HERP, also known as 
HEY), which themselves are transcription factors with broad effects on gene expression 
influencing various signaling pathways in the cell. During activation, the NECD is trans-
endocytosed into the ligand cell. In addition to generating the conformational change of the 
receptor needed for activation, the effect of NECD endocytosed into the signal-sending cell is 
unclear. While presumably degraded, it is also possible that NECD and the ligand could dissociate 
from each other in the more acidic environment of endosomes in a way that could permit ligand 
recycling back to the cell membrane. 
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These genes include, notably, basic-helix-loop-helix (bHLH) transcription factors from the 
HES and HEY families (Bray, 2016). Other targets include MYC, cyclin D1 and Notch 
receptors and ligands themselves (Bray and Bernard, 2010). In the absence of active NICD, 
CSL is bound to DNA together with co-repressors and histonedeacetylases to function as a 
transcriptional repressor of Notch target genes (Borggrefe and Oswald, 2009; Xu et al., 
2017). There is also evidence showing that CSL is not only present in the nucleus, but also 
exists in the cytoplasm where it can associate with NICD (Krejcí and Bray, 2007). New 
studies further show that Notch activation can affect chromatin remodeling and the 
amount of CSL binding to DNA (Castel et al., 2013; Gomez-Lamarca et al., 2018; Skalska 
et al., 2015). In contrast to models where CSL sits statically on DNA as a repressor and 
switches to an activator when associated to NICD, these studies advocate for a model of 
dynamic DNA binding by the NICD-CSL complex. In vivo responses of Notch-dependent 
transcriptional activation indicate that higher NICD levels increase burst duration of the 
transcriptional response (Falo-Sanjuan et al., 2019; Lee et al., 2019).  
1.4.1 Non-canonical Notch 
The mode of activation described in the previous chapter, based on DSL ligands that 
activate Notch receptors that then act through CSL, is known as canonical Notch signaling. 
There are also indications of Notch activation that do not fit within canonical Notch 
activation (Andersen et al., 2012). These non-canonical Notch modes include: responses 
without Jagged/Dll activation, CSL-independent effects of Notch, as well as Notch-
independent CSL-effects (Ayaz and Osborne, 2014). CSL regulation without Notch has 
been studied in some detail in cases where CSL is switched from a repressor to an 
activator by viruses such as the Epstein-Barr virus EBNA2 in an NICD independent 
manner (Henkel et al., 1994; Zimber-Strobl and Strobl, 2001). CSL has also been found to 
form a complex together with the transcriptional regulators Ptf1a and p48 with effects on 
pancreatic development and differentiation in the nervous system (Beres et al., 2006; Hori 
et al., 2008; Masui et al., 2007; Obata et al., 2001). CSL-independent effects of NICD 
have been documented through the PI3K pathway, Wnt/B-Catenin and through IL-6 
upregulation of NF-kB. Tumor cells have also been shown to escape apoptosis through 
Notch independently of CSL in several studies (Acosta et al., 2011; Jin et al., 2013; Kwon 
et al., 2011; Lee et al., 2013; Perumalsamy et al., 2009; Veeraraghavalu et al., 2005). Non-
canonical ligands that are similar to DSL ligands have been shown to activate Notch and 
REVIEW OF THE LITERATURE 
 12 
include: Delta/Notch-like EGF related receptors (DNER), Delta-like 1 and 2 homologue 
(DLK1-2) as well as members of the contactin family (D’Souza et al., 2008; Eiraku et al., 
2002; Greene et al., 2016; Traustadóttir et al., 2016). It is still unclear how effectively the 
non-canonical ligands can activate Notch compared to Jagged/Dll, or if they mainly inhibit 
canonical ligands through competitive inhibition. Nevertheless, examples such as these 
show that non-canonical signaling mechanisms may lead to outcomes that need to be 
taken into account for a detailed understanding of Notch. 
1.4.2 Cis-inhibition 
In addition to Notch trans-interactions i.e. when the activating ligand is present on another 
cell than the receptor, Notch receptors can also bind to ligands in cis or in the same cell 
(D’Souza et al., 2008). Ligands in cis can bind to the same receptors as trans-ligands and 
are considered inhibitory both in Drosophila development (Jacobsen et al., 1998), and in 
cell culture where cis-inhibition has been studied more meticulously by using controlled 
levels of receptor and ligand (Sprinzak et al., 2010). Cis-inhibition is most likely due to 
ligands and receptors sitting next to each other not being able to generate the force 
necessary to activate the receptor as in normal Notch trans-interactions whilst 
competitively inhibiting ligands from nearby cells (del Álamo et al., 2011). There is also a 
concept of cis-inhibition preventing unwanted ligand-independent activation and non-
canonical ligands from activating Notch (Palmer et al., 2014). Further complicating 
interpretations of Notch signaling output and the theories of cis-inhibition, a new study 
reports cis-activation of Notch. Cells that expressed intermediate levels of Notch ligands 
Dll1 and Dll4 were able to activate Notch in a system with controlled ligand levels and 
cell-cell interactions, whereas only higher ligand levels led to cis-inhibition (Nandagopal 
et al., 2019).   
1.5 Notch signaling during development 
Notch is one of a small group of signaling pathways used extensively during development 
together with pathways such as Wnt, Sonic Hedgehog and TGF-β (Sanz-Ezquerro et al., 
2017). Notch regulates developmental decisions through lateral inhibition, lateral 
induction and asymmetric cell division (Sjöqvist and Andersson, 2019). Lateral inhibition 
is when one cell prevents neighboring cells from adopting the same cell fate through a 
negative feedback loop. A well-known example of Notch in both lateral inhibition and 
REVIEW OF THE LITERATURE 
 13 
asymmetric cell division comes from neural development in Drosophila, where Notch 
influences cells to acquire different fates in a manner where high Notch cells remain either 
as undifferentiated progenitor cells or become cells of non-neural fate, while low Notch 
cells are able to progress through a more and more differentiated state ultimately giving 
rise to a neuron (Chitnis, 2009). The surrounding cells with higher levels of Notch become 
supportive cells such as glial cells. The first phase of the neural lineage decisions 
described above occurs due to lateral inhibition, when some cells within a proneural 
cluster (PNC) begin to express more Delta ligand, which then activates Notch in 
neighboring cells with subsequent activation of Notch target genes within the Enhancer of 
Split gene complex. This activation inhibits proneural gene expression and only the signal-
sending cell adopts a path to become a neural cell. In the central nervous system (CNS) of 
Drosophila this initial neural cell fate is to become a neuroblast. The second phase of 
neural differentiation is an example of asymmetric cell division where the neuroblast 
divides with an asymmetric distribution of proteins, which includes the protein Numb – a 
negative regulator of Notch. Suppressing Notch in one of the daughter cells allow them to 
adopt distinct cell fates. The neuroblasts undergo repeated division to generate one new 
high Notch neuroblast and one low Notch ganglion mother cell (GMC). The GMC can 
then further divide to become neurons or glia. In settings where both are generated, the 
glial cell will have higher Notch and the neuron lower Notch levels (Chitnis, 2009). 
Without proper Notch signaling during these lineage decisions, too many cells become 
neural cells; an embryonically lethal phenotype termed the “neurogenic fate” (Artavanis-
Tsakonas and Muskavitch, 2010; Lehmann et al., 1983). 
During lateral induction, a feed forward response is created where the signal-receiving cell 
adopts the same cell fate as the sending cell, which goes on to induce the same fate in the 
next cell. One example of lateral induction is initiation of arterial wall formation through 
Jagged1 signaling, where endothelial cells of the vascular lumen expressing Jagged1 
induce both vascular smooth muscle cell (VSMC) differentiation and upregulation of 
Jagged1 in the first VSMC layer, which then propagates the signal into the next layer of 
smooth muscle cells, generating an arterial wall of multiple layers of differentiated smooth 
muscle cells (Hoglund and Majesky, 2012; Manderfield et al., 2012). Similar Notch-
dependent positive feedback responses have  been observed during inner ear development 
and ocular lens fiber formation in mammals (Kiernan, 2013; Petrovic et al., 2014; 
Saravanamuthu et al., 2009). 
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1.6 Notch signaling in disease 
Considering the importance of Notch signaling during development, it is not surprising 
that mutations in the Notch signaling pathway can contribute to a number of 
developmental phenotypes and disorders (Louvi and Artavanis-Tsakonas, 2012). These 
phenotypes affect the heart, vasculature, skeleton, kidney, liver, eye, nervous system and 
brain (Penton et al., 2012). Notch related congenital disorders include Alagille syndrome, 
spondylocostal dysostosis, Adams-Oliver syndrome, Dowling-Degos disease and cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL) (Aster et al., 2017). One of the first described congenital heart defects seen 
from NOTCH1 mutations was bicuspid aortic valve, where the aortic valve has only two 
leaflets instead of three, leading to calcification of the aortic valve and aortic aneurysms 
(Garg et al., 2005; Preuss et al., 2016). Aortic aneurysms can also be seen in 
haploinsufficient Notch1 mice (Koenig et al., 2017). Mutations of NOTCH1 have recently 
been observed in patients with a wide variety of pathological cardiac phenotypes 
(Kerstjens-Frederikse et al., 2016).  
Notch is important for homeostasis in adult tissues and both canonical and non-canonical 
Notch signaling modes have been implicated in several human cancers (Aster et al., 2017; 
Ayaz and Osborne, 2014). A landmark study of Notch in cancer demonstrated that more 
than 50% of T-ALL patients had activating NOTCH1 mutations in their HD and PEST 
domains (Weng et al., 2004). We now know that Notch plays an essential role in many 
other hematological cancers as well and that active Notch can drive a survival bias in B 
and T cells, leading to uncontrolled cell division (Aster et al., 2017). Overexpression of 
NOTCH1 is also commonly found in solid tumors including breast, lung, prostate, 
colorectal and pancreatic cancers (Miele et al., 2006; Ranganathan et al., 2011b). However, 
in solid tumors Notch is not necessarily involved through activating Notch mutations as in 
many lymphatic diseases; instead Notch signaling can be deregulated in other ways, such 
as aberrant levels of receptors, ligands or other signaling modifiers (Andersson and 
Lendahl, 2014). Notch signaling has also been identified as a tumor suppressor in cancers 
such as head and neck carcinomas, squamous carcinomas of skin and lung, and pancreatic 
cancers (Avila and Kissil, 2013; Wang et al., 2011; Yap et al., 2015). Somatic mutations 
of Notch have recently been shown to accumulate during aging also in normal esophageal 
epithelial tissues, which surprisingly showed higher mutation rates than in esophageal 
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squamous cell carcinomas (Martincorena et al., 2018). In addition, Notch has been 
implicated to have different roles in different stages of tumor progression depending on 
context (Ranganathan et al., 2011b). Studies in pancreatic cancer, for example, have 
indicated that active Notch signaling can be tumor suppressive during initial stages of 
carcinogenesis (Hanlon et al., 2010) but needed for later stage tumor progression (Plentz 
et al., 2009). Notch signaling is also recognized as a promising target in tumor 
angiogenesis and metastasis as a consequence of the critical roles Notch plays in 
physiological angiogenesis and in vascular homeostasis (Boareto et al., 2015; Garcia and 
Kandel, 2012; Kofler et al., 2011; Li et al., 2007; Oon et al., 2017). Proposed clinical uses 
therefore have to be considering which part of the disease progression they are targeting. 
Notch inhibitors are currently in trials for combination therapies together with 
chemotherapeutic agents, as it has been shown that common chemotherapeutic treatments 
often increase Notch signaling in the tumor cells. Heightened Notch levels can lead to 
improved survival properties and concomitant resistance to chemotherapeutics, ultimately 
leading to relapse of the disease (Kamstrup et al., 2017). Combination therapies with 
Notch inhibitors have indeed been shown to have higher efficiency in killing cancer cells 
than either therapy alone as shown by Notch inhibition in combination with: doxyrubicin 
and trastuzumab in breast cancer, docetaxel in prostate cancer and temozolamide in 
glioma xenograft mice (Cui et al., 2015; Gilbert et al., 2010; Kim et al., 2015; Li et al., 
2015; Osipo et al., 2008). Multiple excellent reviews on Notch in disease alluding to both 
present and future clinical therapies are available for the interested reader (Andersson and 
Lendahl, 2014; Aster et al., 2017; Louvi and Artavanis-Tsakonas, 2012; Ranganathan et 
al., 2011b; Tamagnone et al., 2018). 
1.7 Notch signaling in the vasculature  
The vascular system is crucial for development, homeostasis and disease. Cardiovascular 
diseases are currently the most common cause of mortality in humans (WHO, 2019). The 
vasculature provides all tissues with oxygen and nutrition, while allowing for removal of 
carbon dioxide and waste products. During early development, blood vessels are formed 
from endothelial precursor cells of mesodermal origin in a process termed vasculogenesis 
(Kolte, 2016). During vasculogenesis the vascular plexus is formed, which is a primitive 
endothelial cell vessel network. The vascular plexus is then divided into arteries, veins and 
capillaries during arteriovenous specification and further remodeled through branching of 
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the vasculature by angiogenesis to form a functional vasculature (Kolte, 2016). The 
emerging vasculature also attracts mural cells around the vessels, with vascular smooth 
muscle cells (VSMC) covering arteries/veins and pericytes covering the smaller 
venules/capillaries of the microcirculation.  
There are many signaling pathways regulating vascular function including VEGF, Wnt, 
BMP, TGF-β, angiopoietin and Notch (Tetzlaff and Fischer, 2018). Notch signaling is 
distinct by being involved in all the key steps of vascular development; from initial 
vascular plexus formation, to arteriovenous patterning, to recruitment and maintenance of 
VSMCs and remodeling by angiogenesis (Gridley, 2010). Deletion of critical Notch 
components such as Notch1 (Krebs et al., 2000; Limbourg et al., 2005), Dll4 (Duarte et al., 
2004; Gale et al., 2004; Krebs et al., 2004), Jag1 (Benedito et al., 2009; Xue et al., 1999), 
CSL (Krebs et al., 2004), Notch target genes Hey1/Hey2 (Fischer et al., 2004), S2 cleavage 
mediator Adam10 (Glomski et al., 2011), as well as γ-secretase components nicastrin (Li 
et al., 2003) and presenilin (Herreman et al., 1999) all lead to embryonic lethality in mice, 
with severe defects in the vasculature. The sensitive nature of Notch levels in the 
vasculature is further inferred from the fact that endothelial cell specific expression of 
constitutively active Notch1 (Krebs et al., 2010), Notch4 (Uyttendaele et al., 2001) and 
overexpression of endothelial Jag1 (Benedito et al., 2009) and Dll4 (Trindade et al., 2008) 
also lead to severe vascular defects and embryonic lethality in mice.  
1.7.1 Angiogenesis and Notch 
Angiogenesis is the development of new vessel branches from pre-existing blood vessels 
to maintain a functional circulatory system with adequate blood flow to all tissues. This 
process differs from de novo formation of blood vessels during vasculogenesis. 
Angiogenesis is activated during inflammation, mechanical stress, injury, hypoxia, low pH 
and during the pathophysiology of tumor growth. Especially a lack of oxygen (hypoxia) is 
easily sensed in tissues and leads to VEGF signaling through hypoxia inducible factor 
(HIF) (Kofler et al., 2011). Vascular endothelial cells express VEGF receptors, with 
VEGFR2 and VEGFR3 leading to endothelial sprouting. As VEGF-A (hereafter VEGF) is 
secreted in the hypoxic tissue, the nearby vessel sprouts begin to migrate towards the 
VEGF gradient (Figure 5). Angiogenesis is a multistep process, which includes an initial 
remodeling of the extracellular matrix, endothelial cell migration and tube formation. 
Endothelial cells in the pre-existing vessel initiate the process by migrating out a tip cell, 
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which is followed by stalk cells supporting the newly formed microvessel. The tip and 
stalk cell selection is regulated by Notch signaling in response to VEGF (Gerhardt et al., 
2003). Endothelial cells have been reported to express Notch1, Notch4, Dll1, Dll4, Jag1 
and Jag2 but in variable patterns depending on the vasculature analyzed and its state of 
development (Hofmann and Iruela-Arispe, 2007). Previous studies have identified 
important roles for especially Jag1, Dll4 and Notch1/4 (Kangsamaksin et al., 2015). In a 
similar manner as with knockout of key Notch components, deletion of VEGF or VEGFR 
is embryonically lethal due to vascular defects in mice (Carmeliet et al., 1996; Dumont et 
al., 1998; Ferrara et al., 1996). VEGFR1 is unique from VEFGR2/3 as it acts as a decoy 
receptor for VEGF (Meyer et al., 2006; Siekmann et al., 2013). VEGFR2/3 activate 
endothelial cells to extend filopodia and to invade the basement membrane by secreting 
matrix metalloproteinases (Arroyo and Iruela-Arispe, 2010). This breakdown is based on 
actin-based podosomes. The formation of functional podosomes is also regulated by 
VEGF and Notch (Spuul et al., 2016).  
 
 
Figure 5. The Notch pathway in sprouting angiogenesis. During sprouting angiogenesis, 
migrating tip cells respond to vascular endothelial growth factor (VEGF) through VEGF receptor 
2/3 (VEGFR2/3), which upregulates Dll4 expression in the tip cell. Dll4 then activates Notch1 in 
the trailing stalk cell, which downregulates VEGFR2/3, allowing for a proliferative phenotype that 
supports the formation of the growing vessel. In a mature vessel the stalk cells become quiescent 
phalanx cells. Endothelial cells recruit mural cells such as vascular smooth muscle cells and 
pericytes to support the new vessel sprout (Figure adapted from Masek and Andersson, 2017). 
High levels of VEGF induce expression of the Notch ligand Dll4. Expression of Dll4 in 
tip cells activates Notch in neighboring cells which then downregulates expression of 
VEGFR2/3 (Lobov et al., 2007; Tammela et al., 2008; Taylor et al., 2002) and allows for 
these neighboring cells to adopt a stalk cell fate, forming the vascular lumen. The stalk 
Vascular smooth muscle cells        Pericytes 
 
Mural cells      Notch 1/2/3+  Jag1+  
 
   Endothelial cells     Notch 1/4+  
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VEGFR2/3+ 
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cells are more proliferative and migrate less than the tip cells. Stalk cells also recruit 
pericytes to support the newly formed vessel. ECs that have become quiescent have also 
been distinguished as phalanx cells. Activated Notch signaling in the adjacent stalk cells 
then decrease expression of VEGFR2/3 through Hey1 and Hey2 (Blanco and Gerhardt, 
2013). In other words, the sprouting tip cells have been reported to have high Dll4 and 
VEGFR2/3 expression with low Notch signaling activity, while the proliferating stalk 
cells behind the tip cells have high Notch and low VEGFR2/3 (Figure 5).  
EC specific DLL4 knockouts and DLL4 heterozygote mice show an excessive number of 
tip cells and sprouts with poorly perfused vessels (Hellström et al., 2007; Lobov et al., 
2007; Suchting et al., 2007). Several studies have reported similar phenotypes during 
Notch inhibition and EC specific KO of Notch1 and CSL (Benedito et al., 2012, 2009; 
Hellström et al., 2007; Lim et al., 2019; Lobov et al., 2007; Ridgway et al., 2006). The 
Notch ligands function in distinct ways in the vasculature and Dll1 cannot compensate for 
Dll4 in the vasculature (Preuße et al., 2015). In addition to Dll4, Jagged1 is also expressed 
in the endothelium. Jagged1 is mostly expressed in the stalk cells and there are 
interpretations that Jagged1 can play an inhibitory role of Notch signaling in the tip cells 
by competing with more potent Dll4 ligands to lower Notch signaling in tip cells 
(Benedito et al., 2009). The theory of low Notch required in tip cells has been challenged, 
as loss of Dll4 in endothelial sprouts did not affect tip cell identity in recent studies (Hasan 
et al., 2017; Pitulescu et al., 2017). Furthermore, live cell imaging of sprouting tip cells 
further demonstrated that Notch is first activated in the tip cell and then further increased 
over time (Hasan et al., 2017). A tumor angiogenesis study further suggests that Dll4 may 
be a dominant ligand over Jagged1, but that both are potent activators of Notch signaling 
in the endothelium and that competitive inhibition can not explain the roles of Jagged1 in 
that context (Oon et al., 2017).  
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2. Regulation of the Notch signaling pathway 
Notch signaling combines ligand binding at the cell surface with transcriptional activation 
in the nucleus, in a regulatory pathway based on proteolytic cleavage of the receptor. This 
mode of signaling has a couple of interesting attributes. Because the proteolytical cleavage 
at S2 physically separates the ligand bound extracellular domain from the intracellular 
domain, which upon release, has a limited half-life, means that each receptor can signal 
only once. This means that the level of signaling activity and output is highly dependent 
on the amount of receptors and ligands on the cell surface, as well as their activation 
potential and the subsequent fate of the NICD in the cell. Previous studies have shown that 
both the receptors and the ligands undergo endocytosis, and the trafficking of these 
proteins may regulate the amount of Notch components at the cell surface. Endocytosis is 
also part of the activation mechanism of Notch signaling as endocytosis of Notch ligands 
have been shown to generate the force needed to physically pull on the receptor to change 
its conformation and thus enable proteolytic cleavage by ADAM/TACE (Meloty-Kapella 
et al., 2012; Musse et al., 2012). Furthermore endocytosis of the Notch receptor can 
control the fate of NICD upon activation, and aberrant endosomal trafficking of the 
receptor has also been shown to lead to cleavage of the receptor without ligand activation 
– a form of non-canonical activation of Notch (Vaccari et al., 2008).  
Post-translational modifications (PTMs) of Notch and its interacting partners also have an 
important role in the signaling output. Notch receptor glycosylation is required for 
efficient binding by its ligands, and modifies which ligand interaction is preferred, 
whereas other PTMs regulate the intracellular domain to affect the half-life of NICD 
(Borggrefe et al., 2016). The proteins interacting with Notch do not only block or 
terminate active signaling but also provide the tools needed to fine-tune and control 
Notch-mediated cellular processes. 
2.1 The role of post-translational modifications in Notch signaling 
The core Notch signaling pathway exhibits a deceiving simplicity, with its one-to-one, 
ligand-to-receptor, linear activation mechanism. Despite this, the Notch signaling pathway 
has been shown to be particularly context-dependent with multiple possible outcomes 
from its receptor activation. PTMs regulate the functional response of proteins by addition 
and removal of functional groups to proteins. It is now clear that Notch is tightly regulated 
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and numerous reports over the last few decades point to PTMs being key players in 
increasing the diversity of Notch sigaling output. In addition to their role in influencing 
endosomal trafficking of Notch, some PTMs directly affect the binding of NICD to the 
transcriptional complex, while others modify and alter ligand-receptor preferences 
(Kakuda and Haltiwanger, 2017; Le Bras et al., 2011; Ranganathan et al., 2011a). 
Different PTMs can further act together to fine-tune the response of active NICD in the 
cell (Lee et al., 2015). Notch activity is modified by PTMs such as sumoylation, 
methylation, acetylation, hydroxylation, glycosylation, phosphorylation and ubiquitination 
(Antfolk et al., 2019; Pfeffer et al., 2019) (Figure 6-7). As a consequence of the linearity 
of the pathway, the output is therefore also highly dependent on the half-life of NICD. The 
longevity or stability of NICD affects not only how long NICD stays bound to CSL on the 
DNA allowing for continued transcriptional activation, but also determines if Notch is 
stable enough to enter the nucleus before it is degraded. The ubiquitin-based modifications 
are key regulators of the degradation of NICD (Borggrefe et al., 2016; Fryer et al., 2004). 
In the next chapters, glycosylation, phosphorylation and ubiquitination will be briefly 
described, as they relate most closely to the results presented in this thesis. 
Figure 6. Schematic of post-translational modifications of the Notch intracellular domain 
(NICD). The intracellular domain of the Notch receptor can be modified by phosphorylation, 
ubiquitination, sumoylation, acetylation, hydroxylation and methylation, which affect the signaling 
output of receptor activation. Many of the identified sites still have unknown functional 
consequences. A highlight of functionally important PTM-sites that are also linked to disease are 
shown in table 1. (Figure adapted from Antfolk et al., 2019). 
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Table 1. Highlight of important post-translational modifications of Notch that are also linked to 
disease. (For a complete list of PTMs in Notch signaling and their functions, see Antfolk et al., 
2019).  
Enzyme PTM Domain Functional importance / Disease Reference 
POFUT1 Glycosylation EGF-repeats 
Essential for Notch function and 
ligand-receptor interactions / 
Dowling-Degos disease  
(Li et al., 
2013) 
POGLUT1 Glycosylation EGF-repeats 
Essential for Notch function and 
ligand-receptor interactions / 
Dowling-Degos disease  
(Basmanav 
et al., 2014) 
EOGT Glycosylation EGF-repeats Adams-Oliver syndrome (Cohen et al., 2014) 
Lunatic 
Fringe Glycosylation EGF-repeats  
Regulates ligand binding / 
Spondylocostal Dysostosis 
(Sparrow et 
al., 2006) 
Cyclin C - 
CDK3, 8, 19 Phosphorylation PEST-domain 
Enhances FBXW7-dependent 
ubiquitination and degradation / T-
ALL 
(Li et al., 
2014) 
PIM Phosphorylation Second NLS 
Enhances nuclear localization and 
transactivation of NICD / Breast 
cancer, prostate cancer 
(Santio et 
al., 2016) 
FBXW7 Ubiquitination PEST-domain Induces degradation of Notch / T-ALL 
(O’Neil et 
al., 2007) 
2.1.1 The role of glycosylation in Notch signaling 
The extracellular part of Notch can be modified by several different types of sugar 
modifications, which alter the structure and function of Notch (Figure 7). Serine or 
threonine linked O-glycosylations in particular have been shown to be crucial for Notch 
signaling and several human diseases are also linked to mutations in the 
glycosyltransferases carrying out O-glycan modifications, with multiple Notch linked 
phenotypes (Harvey and Haltiwanger, 2018). These complex sugar modifications can be 
attached to the extracellular domain of Notch during receptor processing in the 
endoplasmic reticulum (ER). There are three main types of O-glycosylation of EGF-
repeats of Notch, which include: O-fucosylation (O-fucose), O-glucosylation (O-glucose) 
and O-GlcNAcylation (O-linked β-N-acetylglucoseamine) (Takeuchi and Haltiwanger, 
2014). Each individual EGF repeat consists of approximately 40 amino acids, which 
include 6 conserved cysteine residues (Kovall et al., 2017). O-glucosylation by Protein O-
Glucosyltransferase 1 (POGLUT1) can occur between the first and the second cysteine 
residues at C1-X-S-X-(P/A)-C2 consensus sequences (where X is any amino acid, and the 
modified serine underlined), O-fucosylation by Protein O-Fucosyltransferase 1 (POFUT1) 
can occur between the second and the third cysteine at the consensus sequence C2-X-X-X-
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X-(S/T)-C3, and O-GlcNAcylation by EGF-domain specific O-GlcNAc Transferase 
(EOGT) between the fifth and sixth conserved cysteine residues at the consensus sequence 
C5-X-X-X-(F/W/Y)-(T/S)-G-X-X-C6 (Takeuchi and Haltiwanger, 2014). Recently, O-
glucosylation between cysteines 3 and 4 by POGLUT2/3 was also identified (Takeuchi et 
al., 2018) after the discovery of a non-POGLUT1 consensus sequence being glucosylated 
in the crystal structure of the DLL4-NOTCH1 complex (Luca et al., 2015). Loss of 
Poglut1 or Pofut1 in mice leads to embryonic lethality with Notch-linked phenotypes 
(Fernandez-Valdivia et al., 2011; Shi and Stanley, 2003). Loss of Pofut1 is similar to loss 
of CSL, which has more severe phenotypes than the loss of any single Notch receptor (Shi 
and Stanley, 2003).  
 
Figure 7. Glycosylation sites on mammalian NOTCH1 EGF-repeats. The extracellular domain 
of the Notch receptor is modified by glycosylation. O-fucosylation by POFUT1 and O-
glucosylation by POGLUT1 crucially regulate Notch structure and the ability to be activated by 
ligands. EGF-repeats predicted to be modified by POFUT1 and POGLUT1-3 on NOTCH1 are 
indicated above. All predicted sites have been confirmed by glycoproteomic methods (Kakuda and 
Haltiwanger, 2017; Rana et al., 2011) except for repeats with diagonal white lines (EGF23, 24 & 
32). The only NOTCH1 EGF-repeat modified by POGLUT2/3 is EGF11 (Takeuchi et al., 2018) 
(Figure adapted from Antfolk et al., 2019). 
The O-linked glycans can be further elongated to di-, tri- or tetra-saccharides, most 
notably: elongation of O-glucose by xyloses (xylosyltransferases), and O-fucose by 
GlcNAc (Fringe enzymes) (Brückner et al., 2000; Moloney et al., 2000; Rampal et al., 
2005; Sethi et al., 2010; Taylor et al., 2014). In Drosophila, deletion of Fringe leads to a 
notched phenotype of its wings and increases activation by Delta while decreasing 
activation by Serrate (Jagged in mammals) (Irvine and Wieschaus, 1994; Panin et al., 
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1997). In mammals, three Fringe orthologs add to the complexity of glycan modifications. 
All three (Lfng, Mfng and Rfng) potentiate Dll1 to Notch1 signaling. Rfng also potentiates 
Jagged1 to Notch1 signaling, but Mfng and Lfng decrease activation of Notch1 through 
Jagged1 (Yang et al., 2005). Recent glycoproteomic analysis indicate that the differential 
effects of the three Fringes may stem from which EGF-repeats they are able to modify 
(Kakuda and Haltiwanger, 2017). Even though all three mammalian Fringes are expressed 
in many tissues during development, only the lack of Lfng has substantial effects on 
viability and fertility of mice (Evrard et al., 1998; Moran et al., 2009, 1999). By contrast 
all three Fringes have been shown to contribute to proper development of B and T cells 
and surprisingly, Lfng/Mfng/Rfng triple knockouts could be rescued by any single Fringe 
allele in this context (Song et al., 2016).  
2.1.2 The role of ubiquitination in Notch signaling 
Ubiquitination (also known as ubiquitylation) is a process of attaching ubiquitin residues 
to target proteins by E1 ubiquitin-activating enzymes, E2 ubiquitin conjugating-enzymes 
and E3 ubiquitin ligases. Ubiquitin E3 ligases recognize the target site and recruit E2 
enzymes to facilitate transfer of the ubiquitin onto a target lysine. Adaptors such as epsins 
can then recognize these ubiquitin tags (Sen et al., 2012). Ubiquitin can be added as 
monomers or extended to poly-ubiquitin chains, where specific lysines of ubiquitin are 
further modified (Komander and Rape, 2012). Although poly-ubiquitination of certain 
lysines is a common tag for proteasomal degradation in the cell, different types of 
ubiquitin modification have various other effects on the targeted protein, such as 
regulation of its location through endocytosis (Swatek and Komander, 2016). 
To generate pulling force by endocytosis, there is a requirement for mono-ubiquitination 
of Notch ligands by the E3 ligases Neuralized (Neur) and Mindbomb 1 (Mib1) in 
Drosophila (Itoh et al., 2003; Lai et al., 2001). Due to differential expression during 
development, the loss of either one gives rise to the neurogenic phenotype, which is 
similar to a loss of Notch phenotype (Le Borgne et al., 2005; Wang and Struhl, 2005). 
Neur and Mib1 are localized to the cell membrane and loss of either, lead to an 
accumulation of signaling incompetent ligands on the cell surface (Itoh et al., 2003; Lai et 
al., 2001; Le Borgne and Schweisguth, 2003). In settings where both are expressed in the 
same cells, deletion of both are required for loss of Notch phenotypes (Lai et al., 2005; 
Wang and Struhl, 2005). However, Mib1 cannot rescue the neurogenic phenotype of Neur 
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in flies (Le Borgne et al., 2005). Neur and Mib1 ubiquitinate both Delta and Serrate, 
thereby affecting ligand endocytosis and trans-activation of both Drosophila ligands (Lai 
et al., 2005; Le Borgne et al., 2005). A second Mib homologue (Mib2) exists in 
Drosophila and mammals (Koo et al., 2005b) and although there is no requirement for 
Mib2 for viability in mice, Mib2 is important for muscle integrity, which cannot be 
rescued by Mib1 or Neur (Nguyen et al., 2007). Mammals have two Neur orthologs 
(NEURL1 and NEURL1B) and one Mib1 ortholog (MIB1). Cell culture assays show that 
all three can regulate Notch in vitro (Koutelou et al., 2008; Teider et al., 2010) but in 
contrast to Drosophila development, only loss of Mib1 has adverse effects on Notch 
signaling in mice (Barsi et al., 2005; Koo et al., 2007). Mice defective for all three Neur1, 
Neur1b and Mib2 have no obvious phenotypes while knock out of Mib1 alone produces 
the characteristic loss of Notch like phenotypes (Koo et al., 2005a; Koo et al., 2007).  
Ubiquitination of Notch also affects trafficking of the receptor, and several E3 ligases 
such as Deltex, AIP4/Itch (human/mouse), Nedd4, Fbxw7 and c-Cbl ubiquitinate Notch 
(Le Bras et al., 2011). The regulatory effects of ubiquitination of the Notch receptor vary 
from stimulatory to inhibitive. Deltex, for instance, can activate Notch in certain settings 
in flies that are linked to ligand-independent γ-secretase cleavage, but promote its 
degradation when complexed with the β-arrestin homolog Kurtz (Hori et al., 2011; 
Matsuno et al., 1995; Mukherjee et al., 2005). Downregulation of Deltex1 in mammalian 
cells has been reported to increase Notch activity and enhance Notch receptor levels at the 
cell surface (Zheng et al., 2013). As an example of degradation of NICD, the E3 ligase 
Fbxw7 can ubiquitinate a specific phosphodegron region of the PEST domain as a 
degradation signal, if it has first been phosphorylated by a kinase such as Cdk8 (Fryer et 
al., 2004; Wu et al., 2001). In line with this, mutations in Fbxw7 that decrease its activity, 
can lead to increased amounts of NICD (Aydin et al., 2014; Malyukova et al., 2007; 
Mansour et al., 2009). Mutations in the FBXW7 gene have been found in different cancers 
such as T-ALL, small cell lung cancer and melanoma (Aydin et al., 2014; George et al., 
2015; Larson Gedman et al., 2009). PEST mutations that truncate the domain so that the 
phosphodegron site is lost have a similar effect as inactivating FBWX7 mutations. 
Although an RNAi screen identified several deubiquitinases that can regulate Notch 
(Zhang et al., 2012), their effects on Notch signaling have only recently started to be 
uncovered. One example comes from the deubiquitinase Usp28, which negates Fbxw7 
ubiquitination and thereby increases Notch levels (Diefenbacher et al., 2015). In addition, 
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USP10 has been shown to affect angiogenesis through regulation of NICD turnover in 
endothelial cells (Lim et al., 2019). 
2.1.3 The role of phosphorylation in Notch signaling 
Phosphorylation is an essential PTM, commonly used for regulation of protein activity. 
During phosphorylation, phosphate groups can be added to specific amino acid residues 
that include serine, threonine and tyrosine residues. The addition of phosphate groups, in a 
reaction catalyzed by enzymes called kinases, can change the conformation and 
functionality of a protein in an ATP dependent process that can later be reversed by the 
action of phosphatases. Several kinases that phosphorylate NICD have been identified in 
various systems (Borggrefe et al., 2016). Notably, many of them affect the stability of 
active NICD by phosphorylating the PEST domain for Fbxw7-mediated degradation. 
Kinases that have been shown to prime PEST for ubiquitin based degradation include; 
CDK1, CDK2, CDK3, CDK8, CDK19 and ILK (Carrieri et al., 2019; Fryer et al., 2004; Li 
et al., 2014; Mo et al., 2007). GSK3-β has been found to phosphorylate N1ICD in several 
studies. One of these studies reported increased stability of N1ICD (Foltz et al., 2002), 
while another showed reduced Notch activity in two different cell lines in vitro (Jin et al., 
2009). A reduction in Notch activity has also been shown in Notch2 (Espinosa et al., 
2003). Many other kinases, such as Nemo kinase can affect the interaction with the 
transcriptional complex by NICD phosphorylation (Ishitani et al., 2010). In a similar 
manner CK2 has been shown to inhibit N1ICD from forming a complex with CSL and 
MAML, reducing transcriptional activity (Ranganathan et al., 2011a). Src kinase has been 
shown to act in a similar fashion by inhibiting MAML recruitment (LaFoya et al., 2018). 
Phosphorylation of N1ICD by Akt (also known as protein kinase B, PKB) has been 
reported to inhibit nuclear localization (Song et al., 2008) with similar findings in Notch4 
where Akt inhibited translocation to the nucleus through 14-3-3 (Ramakrishnan et al., 
2015). PIM kinases on the other hand have been shown to increase nuclear localization of 
N1- and N3ICD (Santio et al., 2016). Global proteomic studies have identified many other 
NICD phosphorylation sites, but the majority of sites discovered are without insight into 
which specific kinases are involved or the outcome of the modifications (Antfolk et al., 
2019) (Figure 6). 
Phosphorylation of other Notch signaling components has also been shown to regulate 
signaling. In mammals, atypical Protein Kinase C (aPKC) regulates endocytosis of Notch 
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through directly influencing Notch regulatory protein Numb (Sato et al., 2011; Smith et al., 
2007), as well as Mindbomb indirectly through PAR-1 (Ossipova et al., 2009). PKC is a 
family of serine/threonine protein kinases, which are divided into three subfamilies that 
include classical, novel and atypical PKCs that all have different requirements for their 
activation (Newton, 2018). The PKC family share high similarities in their catalytic 
domains with Akt (Facchinetti et al., 2008; Franke et al., 1994). Novel PKC isoforms 
require diacylglycerol (DAG) for their activation, classical PKC isoforms require DAG 
and calcium while atypical PKC isoforms require neither calcium nor DAG but do require 
a phosphatidyl serine for their activation (Figure 8). The different subfamilies have slight 
differences in their domains, with aPKCs completely lacking the calcium activated C2 
domain while also having a DAG insensitive C1 domain (Pu et al., 2006) (Figure 8). The 
C1 domain is still important for aPKCs because it affects the localization of aPKC in the 
cell (Pu et al., 2006). Atypical PKCs also have a PB1 domain, which activates aPKCs 
when bound to protein scaffolds such as PAR6 or p62 (Tobias and Newton, 2016).  
Figure 8. Schematic of PKC isozyme domains and their activation. Classical PKC isoforms 
require diacylglycerol (DAG) and calcium for their activation, novel PKC isoforms require DAG, 
while atypical PKC isoforms require neither calcium nor DAG. Phorbol esters activate classical 
and novel isoforms. Atypical PKCs are not activated by phorbol esters but they do require a 
phosphatidyl serine for their activation. (Figure based on Garg et al., 2014) 
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The DAG sensitive PKC isoforms have gathered special attention since it became clear 
that they could also be activated by tumor promoting phorbol esters, which at the time 
characterized PKCs as potential oncogenes (Newton, 2018). It has now become evident 
that PKCs can function as both tumor promoters and tumor suppressors, with the majority 
of data supporting that the correct function of PKC is tumor suppressive (Ali et al., 2016; 
Antal et al., 2015; Dowling et al., 2016; Justilien et al., 2014; Parker et al., 2014; Uhlen et 
al., 2017). Even though phorbol esters activate classical and novel PKC isoforms, they 
also leave their conformation irreversibly open to dephosphorylation and ubiquitin based 
degradation (Hansra et al., 1999; Jaken et al., 1981). This could be an explanation for the 
minimal success achieved with PKC inhibitors in clinical trials over the years (Dowling et 
al., 2016; Zhang et al., 2015).  
Atypical PKC isoforms include PKCζ (zeta) and PKCλ/ι (lamda/iota) (human/mouse) and 
they are especially known for their role as part of a PAR-3/PAR-6/aPKC complex, which 
has key functions during cellular polarity with additional roles in organization of cellular 
junctions and ARP2/3 linked endocytosis (Chen and Zhang, 2013; Georgiou et al., 2008; 
Hapak et al., 2018; Leibfried et al., 2008; Nishizuka, 1992). Atypical PKCs are involved 
in migration and wound healing where they can be found at the leading edge of the cell 
(Etienne-Manneville and Hall, 2001; Xiao and Liu, 2013). Both atypical PKC isoforms are 
linked to cancer. Their roles include invasion promoting properties exemplified by both 
upregulation and activation of matrix metalloproteinase 9 (MMP-9) by PKCζ (Estève et 
al., 2002; Xiao et al., 2010). Similarly, PKCι has also been found to drive growth and 
invasion of lung cancer cells through MMP-10 by Rac1 activation (Frederick et al., 2008). 
However, PKCζ has been indicated to have both tumor suppressive and promoting roles. 
While PKCζ overexpression has been reported in cancers such as prostate and bladder 
cancer (Dhanasekaran et al., 2005; Sanchez-Carbayo et al., 2006), downregulation of 
PKCζ has been indicated in lung, pancreatic and kidney cancers (Galvez et al., 2009; 
Lenburg et al., 2003; Selbie et al., 1993).      
2.2 Endocytosis 
Endocytosis is the process where vesicles bud off from the plasma membrane through 
invagination. Endocytosis controls important processes such as recycling of membrane 
components, protein and nutrient uptake, retargeting and degradation of proteins, signal 
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transduction, cell polarity and migration (Di Fiore and von Zastrow, 2014; Doherty and 
McMahon, 2009). Membrane proteins and lipids can be endocytosed through clathrin-
dependent and clathrin-independent mechanisms (Doherty and McMahon, 2009; Ferreira 
and Boucrot, 2018). Receptor-mediated endocytosis is used for uptake of extracellular 
molecules and trans-membrane proteins based on receptor-ligand binding and the use of 
clathrin attached to the plasma membrane to form clathrin coated pits (McMahon and 
Boucrot, 2011) (Figure 9). Membrane receptors can accumulate in these coated pits. This 
form of transport is very common and more than 20 different receptors have been shown 
to internalize through this endocytic pathway (Xu et al., 2017b). 
Dynamin is a protein that has a key role in pinching off the internalized vesicles from the 
cell membrane. After invagination the clathrin coat is removed by Hsc70 together with 
auxilin (Eisenberg and Greene, 2007). After the vesicles have internalized, the receptors 
can enter a network of endocytic trafficking pathways (Spang, 2009). Endocytosed 
vesicles normally fuse with early endosomes, which can be described as sorting stations 
for which endocytic route the cargo will enter (Jovic et al., 2010). At this stage, proteins 
may be recycled to the plasma membrane, sorted to the lysosomes for degradation or 
delivered to the trans-Golgi network (Jovic et al., 2010). Endosomal trafficking can be 
tracked by analyzing Rab GTPases (RABs), that specify distinct endocytic compartments 
and are heavily involved in trafficking and fusion of vesicles (Zerial and McBride, 2001). 
Early and late endosomes can be identified based on their specific types, where RAB5 
specify early endosomes and RAB7 late endosomes (Rink et al., 2005). Consequently, 
when vesicles transition from early to late endosomes the amount of RAB7 increases, 
while RAB5 is removed at the vesicle membrane (Wandinger-Ness and Zerial, 2014). 
Early endosomes are acidic with a pH in the range of 6.0-6.2, which can lead to the 
dissociation of many ligands from their receptors. Late endosomes are more acidic still 
and further fuse with lysosomal vesicles, which carry acidic hydrolases that degrade 
endocytosed materials (pH 5). The early to late endosomal transition also leads to a 
repackaging of the transmembrane proteins into multivesicular bodies (MVBs) (Doherty 
and McMahon, 2009). Some membrane receptors also show specific signaling from 
endosomes compared to the plasma membrane (Alanko et al., 2015). Proteins that recycle 
back to the plasma membrane normally enter recycling endosomes before returning to the 
cell membrane through compartments commonly including RAB11 and a multiprotein 
complex called the exosyst (Emery et al., 2005; Jafar-Nejad et al., 2005). Some 
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transmembrane proteins can also recycle back to the cell membrane faster by returning 
directly from the early endosomes in a RAB4-dependent manner (Grant and Donaldson, 
2009).    
 
Figure 9. Receptor-mediated endocytosis. In receptor-mediated endocytosis, ligands bind to 
receptors on the cell membrane, which then recruit adaptor proteins and clathrin to form clathrin-
coated pits. Invagination of the plasma membrane produces a clathrin-coated vesicle. 
Internalization is followed by uncoating of the vesicle and fusion with sorting/early endosomes. 
The endocytosed proteins can then be sorted for recycling or fuse with lysosomes for degradation. 
(Figure adapted from Britannica, 2019) 
Endocytosis and endosomal trafficking of Notch receptors and Notch ligands control 
Notch signaling pathway activation. The importance of endocytosis of Notch was first 
shown in Drosophila, where cells from shibire mutant flies (shibire is a homolog of 
mammalian dynamin) were defective in both sending and receiving lateral communication 
through Notch signaling (Seugnet et al., 1997). Further work in Drosophila demonstrated 
how endocytosis of Delta in the signal sending cell is mandatory for activation of Notch in 
adjacent cells, and that the extracellular domain of Notch co-localizes with Delta in the 
signal sending cell upon activation (Parks et al., 2000). Studies have also shown that the 
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force generated by ligand endocytosis is in the same order of magnitude as the force 
required for Notch activation (Gordon et al., 2015; Meloty-Kapella et al., 2012). This form 
of activation is in contrast to general receptor-mediated endocytosis depicted in Figure 9, 
where ligands are internalized with the receptors. In addition to the pulling force model of 
Notch activation, endocytosis and recycling of both Notch ligands and receptors might 
allow for re-distribution of Notch components within the cell membrane to facilitate 
increased receptor activation, as seen with other receptors (Simons and Toomre, 2000). 
Finally, endocytosis can also negatively regulate Notch, by removing ligands and 
receptors from the surface of the cell and target them for degradation in lysosomes and 
proteasomes (Conner, 2016). 
2.2.1 Endocytosis of Notch receptors 
Notch receptors that are not interacting with ligands, have been shown to be constantly 
endocytosed, and then either recycled or degraded (Jehn et al., 2002; McGill et al., 2009). 
Cleavage of the receptor without ligand activation can occur in cases where endocytic 
trafficking from early or late endosomes is restricted by interferences in the fusion to late 
endosomes or lysosomes (Fortini and Bilder, 2009). Such unwanted activation can have 
severe consequences, with similar results as constitutively active mutations of Notch. 
Consequently, ligand-independent activation following endosomal defects has been 
considered as a cause of cancer (Tanaka et al., 2008). It is still unclear whether the S3 
cleavage occurs directly on the cell membrane after the S2 cleavage or predominantly later 
in endosomes, and which alternative is more efficient in generating productive NICD. The 
activity of γ-secretase may be higher in endocytic vesicles where pH is lower (Pasternak et 
al., 2003), which is supported by the fact that mutations in proteins which limit the 
acidification of endosomes, lead to accumulation of Notch in enlarged endosomes in 
Drosophila (Yan et al., 2009). Blocking Rab5 in Drosophila leads to accumulation of 
Notch at the cell surface with an accompanying reduction in NICD produced, which could 
be due to less effective γ-secretase activity at the cell surface (Vaccari et al., 2008), 
although other possibilities also exist. However, studies with Notch extracellular 
truncation (NEXT) peptides (S2 cleaved, but not S3 cleaved Notch) have shown that WT 
NEXT cleaved at the plasma membrane generates mostly the more stable Val-1744 form 
of NICD while cleavage in endosomes generates mostly the unstable Ser-1747 cleavage 
product (Tagami et al., 2008). NEXT fragments harboring a point mutation at K1749R 
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that inhibits monoubiquitination has been considered evidence that K1749 ubiquitination 
and endocytosis is required for activation of Notch (Gupta-Rossi et al., 2004). Tagami and 
colleagues later showed that K1749R does not inhibit Notch receptor activation and that 
NEXT can still be cleaved at the plasmamembrane by y-secretase, but it generates mostly 
the unstable Ser-1747 NICD and even more unstable forms like Arg-1749 that are rapidly 
degraded (Tagami et al., 2008). NICD cleavage has also been observed in late endosomes 
without ligand activation in cases where the acidity has led to a separation of the Notch 
heterodimer (Wilkin et al., 2008).    
In addition to Fbxw7-mediated ubiquitination and proteosomal degradation of NICD, 
AIP4/Itch can also ubiquitinate Notch1 without ligand activation to facilitate lysosomal 
degradation in mammals (Chastagner et al., 2008). Binding of Numb to AIP4/Itch seems 
to further promote its degradation in lysosomes (McGill et al., 2009). Nedd4 and c-Cbl are 
predicted to function in a similar manner as AIP4/Itch by leading to trafficking of Notch 
and subsequent degradation of non-activated Notch in lysosomes (Le Bras et al., 2011). 
ESCRT proteins regulate the routing of Notch through multivesicular endosomes to 
lysosomes, and loss-of-function ESCRT mutations increase Notch signaling activity 
(Conner, 2016).  
2.2.2 Endocytosis of Notch ligands 
Already in early studies in Drosophila, Delta ligands were found in intracellular 
compartments (Kooh et al., 1993) and blocking endocytosis of DSL ligands led to 
impaired Notch signaling activity in Drosophila (Parks et al., 2000). During receptor 
activation and S2 cleavage, the Notch extracellular domain (NECD) is released and can be 
endocytosed into the signal-sending cell together with the ligand (Parks et al., 2000). 
NECD is then presumably degraded together with the ligand in the lysosomes (Hansson et 
al., 2010). It has also been shown that the NECD can be endocytosed into the ligand cell 
upon pulling force even if ADAM metalloproteases have been inhibited (Nichols et al., 
2007). This indicates that the Notch extracellular domain is not released by ADAM 
cleavage but by the mechanical pulling force, which in turn allows the receptor to be 
cleaved at S2. Structural studies show that the S2 cleavage site is buried within the NRR, 
and mutations affecting NRR structure in a way that exposes the S2 site, are consistently 
active without the need for ligand activation (Gordon et al., 2007; Henrique and 
Schweisguth, 2019). Early studies also showed that recombinant secreted ligands interact 
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with Notch, but are not able to activate Notch signaling and instead block signaling by 
acting as decoys (Hukriede et al., 1997; Sun and Artavanis-Tsakonas, 1997). Immobilized 
ligands, however, do activate Notch signaling in cell culture, which also supports tension 
or force being required for Notch activation (Varnum-Finney et al., 2000). More detailed 
work with different molecular force measurement systems in mammalian cells have 
elucidated the actual forces required for the conformational change of the receptor leading 
to its activation. The pulling force model has been further strengthened by the use of 
controlled mechanical force to generate the conformational change needed to allow for S2 
cleavage. The forces documented have been in the 5 to 10 piconewton (pN) range, as 
measured with different molecular force measurement systems (Chowdhury et al., 2016; 
Gordon et al., 2015; Seo et al., 2016). Although forces generated by ligand endocytosis 
have not been determined with comparable detail, optical tweezer studies have shown that 
Dll1 endocytosis can generate forces up to 10 pN (Meloty-Kapella et al., 2012). 
Ubiquitinated ligands can be bound by endocytic adaptor proteins of the epsin family, 
which are known to facilitate both clathrin-dependent and clathrin-independent 
endocytosis (Chen et al., 1998; Sigismund et al., 2005). Epsin has been identified as a 
critical adaptor for endocytosis of Notch ligands in Drosophila and mice (Chen et al., 
2009; Langridge and Struhl, 2017; Meloty-Kapella et al., 2012; Wang and Struhl, 2004). 
Epsin is also linked to regulation of the actin cytoskeleton (Horvath et al., 2007).  
In addition to ligand endocytosis inducing activation of Notch signaling through force, 
ligands have also been found in endosomes of cells that are unable to signal (Wang and 
Struhl, 2005, 2004). It has therefore been considered that ligands are endocytosed 
constitutively without ligand-receptor interactions. Yamamoto and colleagues have shown 
that although Mib1 is required for ligands to activate Notch, a large amount of Jag1 inside 
endosomes do not require Mib (Yamamoto et al., 2010). It has further been shown that 
mutated Dll1 ligands lacking intracellular lysines are still internalized but they are unable 
to recycle back to the cell surface (Heuss et al., 2008). It has been debated whether 
endocytosis only functions to control ligand levels at the cell membrane, if recycling is 
necessary for the ligands to become signaling competent or if it functions to move ligands 
into specific membrane compartments such as specialized lipid domains (Heuss et al., 
2008; Suckling et al., 2017; Yamamoto et al., 2010). There have been no descriptions of 
what an “activated” signaling competent ligand would look like compared to a “non-
activated” ligand. Also, studies in Drosophila cell lines show that loss of Rab5 or Rab11 
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has no effect on Delta-mediated activation of the receptor. As transitioning from early 
endosomes to recycling endosomes requires Rab5 and recycling requires Rab11, this 
indicates that ligand activation through recycling is not required to produce active ligands, 
at least in Drosophila (Windler and Bilder, 2010). There are however studies showing that 
ligands can be relocated to specific parts of the cell through endocytic recycling (Benhra 
et al., 2010; Rajan et al., 2009).  
2.3 Intermediate filaments as regulators of cellular function 
The cytoskeleton is a complex network of protein fibers, which allow cells to maintain 
shape and mechanical integrity, keep organelles in their positions, aid in cellular 
movement and contribute to vesicle and protein trafficking within the cell. In addition, 
various components of the cytoskeleton transmit signaling from outside the cell and can 
help the cell respond to outside stress (Toivola et al., 2010). The cytoskeleton is comprised 
of microtubules, intermediate filaments and microfilaments (also known as actin 
filaments). Microtubules form the thickest filaments with hollow tubes that can guide 
organelle movement and pull the chromosomes apart during cell division. Microfilaments 
have the smallest diameter size of their fibers and they form the cellular cortex and 
function in transport of cellular components, cellular movement and cell division. They 
also maintain the microvilli structures and are key components to functioning muscle cells 
and their contraction (Bezanilla et al., 2015).  
Intermediate filaments (IFs) have fiber sizes (10 nm) in between those of microfilaments 
(7 nm) and microtubules (25 nm) (Buehler, 2013). IFs associate with the plasma 
membrane and provide the cell with structural support and also organize the microtubule 
and actin filament networks (Gruenbaum and Aebi, 2014). IF subunits self assemble into 
nonpolar ropelike structures without a need for ATP/GTP, which is in contrast to 
microtubule and actin filament formation (Herrmann and Aebi, 2016). IF monomers 
consist of a conserved rod domain, flanked by an N-terminal head domain and a C-
terminal tail domain, that vary in structure depending on IF (Kim and Coulombe, 2007). 
Two rod-domains connect to form a dimer, two dimers form a tetramer. The rope like 
fiber is made up from eight tetramers, which is called a unit length filament (ULF), which 
can self assemble into long intermediate filaments (Herrmann and Aebi, 2016) (Figure 10). 
The IF structure observed in the cell is highly dynamic, branched and connects to other 
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parts of the cytoskeleton through binding partners such as plectins (Wiche et al., 2015). 
Phosphorylation of the IF subunits influence assembly and properties of the IF network 
(Eriksson et al., 2004; Snider and Omary, 2014).  
 
Figure 10. Schematic of IF assembly. IF monomers, consisting of a rod domain flanked by a 
head and a tail domain, form coiled-coil dimers. Two dimers form anti-parallel tetramers and eight 
tetramers form a unit-length filament (ULF). ULFs assemble to form an intermediate filament by 
annealing (Figure modified from Dunleavy et al., 2019).  
IFs can be classified into six different types based on sequence similarity, where type I 
and type II keratins that are expressed in epithelial cells represent the largest group of IF 
genes. Keratins form heteropolymers consisting of type I and type II filaments (Jacob et 
al., 2018). Type III IFs can form both homo- and heteropolymer filaments and include 
vimentin, desmin, GFAP and peripherin. Of type III IFs, vimentin is by far the most 
widely expressed filament and found in mesenchymal cells, leukocytes, endothelial cells 
of blood vessels and only occasionally in epithelial cells (Battaglia et al., 2018). The 
abundant expression of vimentin in cells of mesenchymal origin such as fibroblasts, is 
often used as a marker for epithelial to mesenchymal transition (EMT) (Ivaska, 2011; 
Mendez et al., 2010), a process occuring during development and wound healing that is 
highly correlated to the invasive migrating phenotype of cancer cells at the leading edge of 
carcinomas. There are hopes of targeting vimentin in mesenchymal cancers and a small 
molecule (FiVe1) targeting vimentin organization and phosphorylation was recently 
Monomer 
 
Dimer 
 
Tetramer 
 
Unit length filament (ULF)         Eight tetramers 
 
Intermediate filament 
 
Head           Rod                    Tail
    
REVIEW OF THE LITERATURE 
 35 
identified as a potent inhibitor of breast cancer cell lines that had transitioned through 
EMT (Bollong et al., 2017). In the past decade, evidence has emerged alluding to 
important regulatory functions of intermediate filaments (Battaglia et al., 2018; Gregor et 
al., 2014; Ivaska et al., 2007). Although the vimentin knock out mouse is viable without 
obvious phenotypes at a first look (Colucci-Guyon et al., 1994), vimentin has been found 
to be involved in numerous processes, including differentiation, proliferation, migration 
and invasion (Boraas and Ahsan, 2016; Cheng et al., 2016; Nieminen et al., 2006; 
Richardson et al., 2018). Vimentin knock out mice have defects in wound healing in 
various different tissues (Bargagna-Mohan et al., 2012; Cheng et al., 2016; dos Santos et 
al., 2015). Other defects related to VimKO mice are varied and include: mammary gland 
development (Peuhu et al., 2017), glia development (Colucci-Guyon et al., 1999), 
inflammation (dos Santos et al., 2015), steroidogenesis (Shen et al., 2012) and myelination 
of peripheral nerves (Triolo et al., 2012). Astrocytes from GFAP and vimentin double 
knock out mice have been previously reported to have an effect on Notch signaling 
through Jagged1 (Wilhelmsson et al., 2012). Vimentin is also linked to vascular processes, 
including endothelial sprouting, vascular tuning and arterial remodeling (Dave and 
Bayless, 2014; van Engeland et al., 2019). The wide expression profile, extensive 
interaction network and involvement in EMT suggest that the role of vimentin is important 
in highly dynamic processes and may be especially important during various forms of cell 
stress.  
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OUTLINE AND KEY AIMS OF THESIS 
The communication of neighboring cells via the Notch signaling pathway is crucial during 
development and homeostasis in all multicellular organisms that have been studied to this 
day. The key aim of this thesis is to study the regulation and activation of the Notch 
signaling pathway with a special focus on endocytosis and trafficking of Notch receptors 
and ligands. Endocytosis is a key regulator of Notch signaling activation. Endocytosis of 
Notch ligands can generate the force to activate the cleavage of the receptor on the cell 
membrane. During receptor activation the intracellular domain (ICD) of the receptor also 
undergoes endocytosis, which ultimately leads to the relocation of Notch ICD to the 
nucleus and activation of target genes. The studies in the thesis include regulation of 
Notch ligands during angiogenesis and Notch receptors during differentiation. A dual 
label screening approach is also developed and optimized to identify further regulators of 
Notch ligand endocytosis. 
 
Key aims of this thesis: 
 
 Determine how the intermediate filament vimentin regulates Notch ligand-receptor 
interactions in the context of angiogenesis  
 
 Set up a method for visualization and measurement of Notch ligand endocytosis to 
enable identification of new regulators of Jagged1 
 
 Study the effects of Notch receptor phosphorylation by PKCζ on the trafficking and 
activity of Notch receptors. 
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EXPERIMENTAL PROCEDURES 
More detailed information on materials and methods can be found in the original articles 
and the manuscript. 
Table 2. Methods used in the studies of this thesis. 
Method       Study 
Aortic ring assay       I 
Biotinylation assay       I, II, III 
CAM-model       I 
Cell culture       I, II, III 
Cell spot microarray       II 
Cyclohexamide chase experiment     I, III 
Fingerprint assay       I 
Fluorescence activated cell sorting (FACS)   I, III 
High throughput fluorescence plate reading   II 
Image analysis       I, II, III 
Immunocytochemistry & immunohistochemistry I, II, III 
Immunoprecipitation       I, II, III 
In vitro phosphorylation     III 
In vivo transfection       III 
Ligand trans-endocytosis     I, II 
Live cell imaging       I 
Luciferase reporter assay     I, III 
Mass spectrometry       III 
Microscopy       I, II, III 
Proximity ligation assay     I 
Quantitative reverse transcription PCR   I, III 
Recycling assay       I 
SDS-PAGE and western blotting      I, II, III 
siRNA interference       I, II 
Spheroid angiogenesis assay     I 
Statistical analysis       I, II, III 
Transfection       I, II, III 
Ubiquitination assay       III 
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Table 3. Cell lines used in the studies of this thesis. 
Cell line Type     Study 
SW-13 Human adrenal carcinoma   I 
HEK293 Human embryonic kidney   II, III 
HEK293 FLN Human embryonic kidney stable FLN1 overexpression I, III 
HEK293 JAG Human embryonic kidney stable JAG1 overexpression II 
HeLa Human cervical cancer cells   III 
HUVEC Human umbilical vein endothelial cells I 
C2C12 Mouse myoblasts   III 
3T3 JAG Mouse fibroblasts stable JAG1 overexpression I 
MEF VimWT Mouse embryonic fibroblast   I 
MEF VimKO Mouse embryonic fibroblast from Vim knock out mice I 
 
 
Table 4. Primary antibodies used in the studies of this thesis and their applications. 
Antibody   Company Application Study 
β-actin   Cell Signaling WB I, II, III 
β-tubulin   Cell Signaling ICC II 
CD31 PECAM-1   BD Pharmingen IHC I 
Cleaved Notch1 Val1744 Cell Signaling IP, WB I, III 
Delta C20   Santa Cruz Biotechnology WB I, II 
Anti-Dll4   Sigma-Aldrich ICC, IP, PLA, WB I 
GFP   Clontech WB III 
α-GFP   Invitrogen WB III 
HA1.1   Covance IP III 
Hsc70   StressGen WB III 
Jagged1 28H8   Cell Signaling ICC, IP, PLA, WB I, II 
Jagged1 H-66   Santa Cruz Biotechnology PLA I 
Lamp1   Abcam WB III 
Myosin hc   Santa Cruz Biotechnology IF, WB III 
Manic Fringe   Abcam WB I 
Notch1   Sigma-Aldrich WB III 
Notch C20   Santa Cruz Biotechnology ICC, IP, WB I, III 
PECAM-1 C20   Santa Cruz Biotechnology ICC I 
PKCζ   Santa Cruz Biotechnology ICC, IP, WB III 
VE-Cadherin   Enzo Life Sciences ICC I 
Vimentin D21H3   Cell Signaling ICC, IP, WB I 
Vimentin V9   Sigma-Aldrich ICC, PLA I, II 
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RESULTS AND DISCUSSION 
1. Regulation of the Notch ligand Jagged1 by vimentin (I) 
1.1 Vimentin regulates angiogenesis and correlates with Jagged1 
During the last few decades intermediate filaments (IF) have been established as signaling 
modulators, in addition to their structural functions (Battaglia et al., 2018; Pallari and 
Eriksson, 2006). Vimentin is an IF found primarily in mesenchymal cells and is abundant 
in endothelial cells lining the blood vessels (Dave and Bayless, 2014). During 
angiogenesis, endothelial cells in the pre-existing blood vessel initiate the process by 
migrating out a tip cell, which is then followed by stalk cells to form a new vessel sprout 
(Figure 4). Tip and stalk cell identity has been shown to be regulated by Notch signaling 
downstream of VEGF (Benedito and Hellström, 2013; Gerhardt et al., 2003).  
In study I, we used the vimentin knock out mouse (VimKO) to study if and how vimentin 
regulates Notch signaling. VimKO embryos show delayed angiogenesis during embryonal 
day 12.5 (E12.5) of mouse development (I, Fig 4D) and placental tissue from VimKO 
mice at E11.5 also showed a disturbed or delayed surface vascularisation pattern 
compared to VimWT (I, Fig 4C). As previously described, the main Notch ligands 
regulating angiogenesis are Jagged1 and Dll4 (Benedito and Hellström, 2013). Moreover, 
mice lacking Jagged1 display disrupted remodeling of the vasculature in the embryo and 
the yolk sack, which leads to lethality around E10 (Xue et al., 1999). In our study, meta-
analysis of human gene transcripts from the GeneSapiens database showed that Jagged1 
and vimentin correlate strongly in several tissues, which include the heart and blood 
vessels (I, Fig S1A). This analysis also showed a correlation between Jagged1 and 
vimentin in several cancers (I, Fig S1B). Co-expression in several tissues pointed to a 
possibility of a functional link between Jagged1 and vimentin. 
1.2 Vimentin interacts with Jagged1 
Proximity ligation assay (PLA) uses two primary antibodies of distinct species, to target 
two unique proteins, combined with oligonucleotide-labeled secondary antibodies (PLA 
probes). Hybridizing connector oligos can then join the probes only if the two proteins are 
in close proximity. Joining the PLA probes to form a loop, is required for rolling circle 
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amplification and finally a detectable PLA signal (Alam, 2018). Using mouse embryonal 
fibroblast (MEF) cells from VimWT mice in PLAs with primary antibodies against 
vimentin, Jag1 and Dll4, we demonstrated that the PLA signal between Jagged1 and 
vimentin was higher than between Dll4 and vimentin (I, Fig 1A-B). Complementary to 
this, immunoprecipitation (IP) of vimentin consistently showed interactions with Jagged1 
in MEF WT cells (I, Fig 1C). No interaction with Dll4 could be detected (not shown). 
VimKO MEF cells were used as negative controls (I, Fig 1C). It is important to emphasize 
that the targeting of Jagged1 in these PLAs and IPs was done with an antibody that binds 
to the intracellular domain of Jagged1 (Jagged1 28H8, Cell Signaling Technology). 
The observed lack of interaction with Dll4 could in theory have been due to differences in 
affinity between the Jagged1 and Dll4 antibodies. The PLA assay in particular, could give 
misleading results if the Dll4 antibody is significantly weaker in its ability to bind its 
target or if the amount of Dll4 is significantly lower than Jagged1 in these cells. However, 
Dll4 has been readily detected with the same antibody previously in our lab and in human 
umbilical vein endothelial cells (HUVECs) in this study (I, Fig 6B). There is also a 
possibility that the PLA signal could be lower from Dll4 if vimentin covers the epitope for 
the Dll4 antibody, if the distance between the antibodies is different, or if the Dll4 
antibody would be in the wrong orientation. 
In order to provide more convincing evidence for the specific interaction of vimentin with 
Jagged1, and to elucidate if the interaction with vimentin is mediated through the 
intracellular domain of Jagged1, we decided to generate hybrid ligands of Jagged1 and 
Dll4, where we swapped the intracellular domain of the two ligands. By comparing 
Jagged1 ligands, with chimeric ligands consisting of the extracellular domain of Jagged1 
and the intracellular domain of Dll4 (Jagged1ECD-Dll4ICD), we were able to evaluate the 
impact of the ICDs of these two ligands. Importantly, by using an antibody that binds to 
the extracellular domain of Jagged1 (Jagged1 H-66, Santa Cruz Biotechnology) and 
thereby using the same antibody for both types of ligands, we removed the uncertainty of 
potential differences in antibody affinity (I, Fig 1D). The expression levels of the Jagged1 
and the hybrid ligand constructs were controlled by detection of an incorporated turboGFP 
tag and live-cell imaging showed similar localization patterns in transfected cells (not 
shown). Swapping the ICD of Jagged1 to the ICD of Dll4, led to a near complete loss of 
PLA signal (I, Fig 1D). Furthermore, the use of the Jagged1-ECD antibody in this 
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experiment, gave significantly increased amounts of PLA signal compared to the 
intracellular antibody used in I, Fig 1A. Although it is possible that the Jagged1 H-66 
ECD-antibody is simply better at detecting Jagged1 than the Jagged1 28H8 ICD-antibody, 
our previous experiences do not support this, and in this case, it is more likely that the 
extracellular Jagged1 H-66 antibody and the vimentin V9 antibody are more optimally 
spaced to generate consistently robust PLA signals. PLA interactions occurring between 
0-10 nm can be detected only if the two primary antibodies are not sterically hindered 
from binding to their respective sites (Sigma-Aldrich, 2019). If the interaction occurs 
directly between the intracellular domain of Jagged1 and vimentin, as our results indicate, 
it is possible that the antibody binding to the extracellular domain of Jagged1 provides less 
hindrance with the vimentin antibody, compared to the intracellular Jagged1 antibody that 
may be binding close to the interaction site. Antibody epitopes near the protein-protein 
interaction site may also lead to similar results. Although we did not pursue any 
experiments to determine the actual binding region of these proteins, it is attractive to 
speculate that the binding of vimentin to Jagged1 could occur near Glu1140, which is the 
epitope that the Jagged 28H8 antibody recognizes in the intracellular domain of Jagged1. 
As a reference, the PDZ-motif of Jagged1, which has previously been shown to make 
indirect interactions with the cytoskeleton, is at the C-terminus between residues 1213-
1218 (Popovic et al., 2011). The protein MPDZ has later been shown to interact with the 
intracellular domains of Dll1 and Dll4 through their PDZ-binding motif and influence 
Dll4 localization and activity to regulate sprouting angiogenesis (Tetzlaff and Fischer, 
2018). PDZ-domain proteins may therefore function as a link also between intermediate 
filaments and Notch-ligands, although this remains to be seen in the future.  
For potential interaction studies on the vimentin side, the hyaluronan receptor CD44 has 
previously been shown to interact with the head domain of vimentin at the cell membrane 
of endothelial cells (Päll et al., 2011). More interestingly, integrins have been shown to 
bind directly to the vimentin head region, specifically between amino acids 21-45 (Kim et 
al., 2016). Vimentin is composed of 466 amino acids and the head domain includes 
residues 1-77 (Tomiyama et al., 2017). This region of vimentin could also serve as a 
starting point for any future studies detailing the interaction between Jagged1 and 
vimentin. Taken together, our results as demonstrated by PLA and IP provide evidence of 
a novel interaction between the intracellular domain of Jagged1 and the intermediate 
filament vimentin. This interaction is interesting, as both vimentin and Jagged1 have 
RESULTS AND DISCUSSION 
 42 
strong links to tumor progression and metastasis (Bednarz-Knoll et al., 2016; Kidd et al., 
2014; Satelli and Li, 2011; Sethi et al., 2011; Wang et al., 2018; Zhang et al., 2019; Zhu et 
al., 2013). 
1.3 Vimentin affects Jagged1 endocytosis 
As endocytosis of Notch ligands is important for Notch activation through trans-
endocytosis, and since inactive ligands are constantly recycled, we wanted to explore how 
Notch ligands behave in VimWT and VimKO cells. Alexa Fluor 488-conjugated 
recombinant extracellular Notch1 peptides (N1ECDF) that bind to Notch ligands on the 
cell surface and internalize through endocytosis, were differently distributed in VimWT 
and VimKO cells (I, Fig 2C). Moreover, the amount of endocytosed N1ECDF into 
VimKO MEFs was increased (I, Fig 2B). In these MEFs, the total amount of Jagged1 was 
similar in WT and KO cells (I, Fig 2A). N1ECDF-uptake in MEFs transfected with 
Jagged1, followed by live cell imaging for 1 minute further revealed that the loss of 
vimentin increases directional mobility of endocytosed N1ECDF-vesicles (I, Fig 2D-F). 
Surface biotinylation assays and immunocytochemistry also showed increased amounts of 
Jagged1 on the surface of MEF KO cells compared to WT (I, Fig 3B-C). Subsequently we 
used a fingerprint assay to determine if the increased amounts of Jagged1 on the surface of 
these cells could still bind Notch effectively. WT and KO MEFs were cultured on 
coverslips coated with N1ECDF, or FC-control (not shown). A crosslinking agent was 
used to preserve any N1ECDF-Jagged1 interactions, followed by an extraction of the cells. 
Crosslinked Jagged1 was then immunolabelled and the results showed more Jagged1 
bound to the VimKO coverslips (I, Fig 3D). The increased binding is in line with the 
higher accumulation on the surface, which indicates that Jagged1 on the surface of 
VimKO cells is able to bind Notch receptors.  
To measure Notch activity, we used a luciferase reporter assay based on multimerized 
CSL binding sites in a co-culture system using WT or KO MEFs cultured with HEK-293 
cells expressing the 12xCSL-luciferase reporter constructs. Surprisingly, the Notch 
activity was not enhanced in the Notch reporter cells when activated by VimKO cells, and 
when related to the amount of Jagged1 on the surface of these cells, the activation 
potential was significantly lower (I, Fig 3E). Reintroducing vimentin in VimKO cells, 
increased the Notch signaling activity in the reporter cells to correspond closely with 
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Jagged1 ligand levels on the surface of VimKO cells (I, Fig 3E). Previous work from the 
Weinmaster group indicates that constant endocytosis of Notch ligands is distinct from the 
endocytosis required for trans-activation of Notch by pulling force (Meloty-Kapella et al., 
2012; Musse et al., 2012). Pulling NECD-peptides from non-covalently bound agarose 
beads, required different endocytic proteins, such as EPS1/2 and actin, in comparison to 
uptake of free NECD-peptides (Meloty-Kapella et al., 2012). Using a similar setup, with 
N1ECDF bound to protein A agarose beads, we show that the uptake of N1ECDF from 
beads was significantly lowered in VimKO cells (I, Fig 3F), which also supports the lower 
activity in the Notch reporter assay in I, Fig 3E. 
Vimentin may influence endocytosis of Jagged1 directly, but it could also be through 
interactions between vimentin and actin. Actin has been well established as a regulator of 
endocytosis and identified as necessary for Dll1-mediated Notch trans-activation 
(Ferguson et al., 2017; Meloty-Kapella et al., 2012). Looking at the endocytic mechanisms 
of other cell membrane receptors may also provide a clue to endocytosis of Notch 
receptors and ligands. Ligand-induced activation of GPCRs lead to clustering in clathrin-
coated pits. In these pits, the cytoplasmic tail of the receptor can bind to the actin network 
through their PDZ-domains, which slows down endocytosis (Puthenveedu and von 
Zastrow, 2006). Actin may therefore influnce Notch endocytosis independently of 
vimentin as well. We decided not to pursue potential actin dynamics in our system, 
although we did look for an interaction with the actin-related protein-2/3 (ARP2/3) 
complex in our IPs of Jagged1, which could not be detected (not shown, Figure S2A). 
Nevertheless, looking at actin polymerization and its role in potential force generation 
would be highly interesting in the future as actomyosin contractility has recently been 
shown to contribute to the mechanichal tension during Notch activation (Hunter et al., 
2019). 
In conclusion, our data indicate that VimKO MEF cells express similar amounts of total 
Jagged1 protein compared to WT, but display higher Jagged1 levels at the cell membrane, 
resulting in higher uptake of free NECD-peptides. Despite this, VimKO MEFs are not 
stronger activators of Notch signaling in co-culture or more effective at endocytosing 
NECD bound to beads, which mimics the physical strain during Notch activation by trans-
endocytosis. This suggests that vimentin promotes Jagged1-mediated trans-activation 
potential and pulling force strength and without vimentin, signaling incompetent Jagged1 
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ligands are accumulated at the cell membrane. The recent elucidation of the crystal 
structure of the binding interface between Jagged1 and Notch1, indicated that Notch 
ligands and receptors form so called catch bonds, where the binding strength increases 
with increased pulling force, and that Jagged1 requires a higher tension treshold compared 
to Dll4 (Luca et al., 2017). Vimentin may therefore, through such a mechanism, influence 
and tune the Notch activation process by improving the force generation of Jagged1. This 
influence may be further increased during shear stress, such as blood flow. 
1.4 Loss of vimentin disrupts angiogenesis but can be rescued by 
external Jagged1 
In addition to data from mouse embryos showing delayed angiogenesis (I, Fig 4C-D), we 
decided to implement in vitro and ex-vivo angiogenesis assays to see if vimentin also 
affects angiogenesis in more controlled settings. We used human umbilical vein 
endothelial cells (HUVECs) in an in vitro spheroid assay, where round bottom wells (96 
well plates) were coated with agarose to prevent cells from attaching to the well and 
instead promote spheroid formation of the endothelial cells. Spheroids were then mixed 
with fibrinogen, which was allowed to polymerize. Endothelial sprouts were imaged 
during the next 4 days (I, Fig 6H). Knock down of vimentin, through short hairpin-
mediated RNA interference (shVim) (I, Fig 6I), significantly inhibited sprout formation in 
this assay (I, Fig 6H). Jagged1 and Dll4 have been previously shown to regulate 
angiogenic sprouting, where Dll4 has been described as anti-angiogenic and Jagged1 as 
pro-angiogenic (Benedito et al., 2009; Pedrosa et al., 2015; Suchting et al., 2007; Xue et 
al., 1999). Interestingly, mixing in immobilized Jagged1-FC-beads with the spheroids in 
the fibrinogen gel was able to rescue the sprouting defect of shVim treated HUVECs (I, 
Fig 6H). Immobilized FC and Dll4-FC had no observable effect on endothelial sprouting 
from shVim spheroids (not shown). 
To analyze endothelial sprouting directly from VimKO and WT mice, we used a three-
dimensional ex vivo angiogenesis assay (Baker et al., 2012), where a slice of the mouse 
aorta was excised and embedded in collagen. Addition of VEGF allow for the endothelial 
cells lining the inside of the aortic ring to form sprouts (I, Fig 5A). This method has 
several advantages, which include the generation of many aortic rings from one mouse 
aorta to help facilitate quantification, and the simplicity of the assay. More importantly, 
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the assay is more physiologically relevant than in vitro assays, as the vessels form a proper 
lumen and also recruit supporting cells such as vascular smooth muscle cells and pericytes 
to associate with the developing endothelial tube, following a timeline that is similar to 
angiogenesis in vivo. These experiments revealed that aortic rings from VimKO mice have 
fewer sprouts per ring and a reduction in sprout length compared to WT (I, Fig 5A-B). 
Aortic rings from Vim heterozygote mice displayed an intermediate sprouting phenotype, 
indicating that the amount of vimentin can tune this process (I, Fig 5A-B). The sprouting 
endothelial cell tubes were confirmed by immunofluorescence of VE-Cad and PECAM-1 
(I, Fig 5C). In line with the results from the in vitro angiogenesis assay, the addition of 
immobilized Jagged1, but not Dll4 peptides, in the collagen gel, rescued the amount of 
endothelial sprouts initiated from VimKO aortic rings, although in this case the sprout 
length was not significantly affected (I, Fig 6E-G). 
These results challenge the argument that the proangiogenic role of Jagged1 in 
angiogenesis and in stalk cells is merely a result of inhibiting more potent Dll4 signaling 
in tip cells through competitive inhibition (Benedito et al., 2009). Unless Jagged1 
inhibited endothelial Dll4 cis-activation in our assays, it is hard to envision how the 
addition of external Jagged1 peptides would be competing with other ligands, when they 
are interacting with endothelial cells in the aortic rings and spheroids from the outside. I 
hypothesize that a more probable explanation would be that Jagged1 can regulate 
endothelial sprouting differently than Dll4, perhaps in a similar manner as the ligand 
discrimination recently described between Dll1 generating pulsatile and Dll4 sustained 
Notch activation, leading to distinct gene responses (Nandagopal et al., 2018). Distinct 
responses are substantiated by the fact that Dll4 has been unable to replace the function of 
Dll1 in other systems and Dll4 cannot compensate for Dll1 function when knocked into 
the Dll1 locus in mice (Preuße et al., 2015). Nandagopal and colleagues argue that the 
discrete pulsatile effect from Dll1 stem from assembly of ligand-receptor clusters that 
release a burst of NICD when the cluster reaches a critical size, while Dll4 does not 
require clustering and thereby generates a more sustained signaling response (Nandagopal 
et al., 2018). It was further shown that pulsatile bursts favor Hes1 activation while 
sustained Notch activated predominantly Hey1/L. If the closely related Dll1 and Dll4 can 
generate such distinct responses, it is easy to visualize that Jagged1 could also generate 
distinct responses from Dll4 in a similar way. In view of this, the Jagged1 peptides used in 
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our angiogenesis assays would have already been pre-clustered by virtue of being 
immobilized to agarose beads.    
The effects of vimentin on Notch signaling may be further modified and balanced by 
Fringe glycosyltransferases, as immunoblotting of VimKO primary endothelial cells and 
shVim HUVECs both showed increased levels of MFNG compared to wild type (I, Fig 
6B-C). qPCR of VimKO cells also showed an increase in Lfng (I, Fig 6D). Lfng and Mfng 
were previously implicated in balancing Dll4 and Jagged1 during sprouting of retinal 
vasculature (Benedito et al., 2009). Both Lfng and Mfng promote Dll-mediated activation 
of Notch in vitro at the expense of Jagged signaling (Kakuda and Haltiwanger, 2017). We 
did not analyze Fringe-mediated effects any further, nor look at Rfng. As Rfng has been 
shown to promote Jagged1-Notch1 activation in addition to Dll-mediated activation, it is 
still unclear if downregulation of vimentin upregulates all Fringes, or only Dll-Notch 
promoting Mfng and Lfng. If only Lfng and Mfng are upregulated, the data would suggest 
that Jagged1 signaling from VimKO cells is impaired due to loss of trans-endocytosis of 
Jagged1, while Dll signaling to VimKO is further increased due to sugar modifications by 
Fringes that promote Dll activation at the expense of Jagged1 signaling. 
Endothelial specific knock down of Jagged1 imply that Jagged1-mediated vascular defects 
stem from both disrupted angiogenesis and vascular smooth muscle cell differentiation 
(High et al., 2008). We have recently continued our work on vimentin and Jagged1 to 
determine their effects on vascular smooth muscle cell differentiation. We showed that 
vimentin regulates Notch signaling and VSMC differentiation in response to 
hemodynamic force (van Engeland et al., 2019). During conditions of shear stress, 
vimentin phosphorylation of serine 38 was augmented. Notch signaling activity was also 
increased under these conditions, and the use of a phospho-mimicking mutant of VimS38 
increased Notch activation in signaling assays (van Engeland et al., 2019). These results 
imply that site-specific modifications of vimentin under hemodynamic forces may 
influence the effects of vimentin on Notch ligands and Notch signaling activity. The 
increase in Jagged1 activity during shear stress is likely a factor in the regulation of 
angiogenesis as well. 
Taken together, we show that vimentin affects the signal sending potential of Jagged1-
mediated Notch activation by interacting with the intracellular domain of Jagged1. The 
lack of angiogenesis from vimentin null endothelial cells can be rescued by Jagged1-
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mediated Notch signaling. Jagged1 and Dll4 have distinct roles during angiogenesis and 
the use of hybrid Jagged1-Dll4 ligands demonstrate a selective regulation of Notch ligands 
by vimentin. The effects on Notch signaling by a lack of vimentin may be increased by 
downstream effectors that upregulate Fringe glycosyltransferases to further potentiate Dll-
mediated activation of Notch. These results have implications not only in angiogenesis 
and vascular homeostasis, but also in tumorigenesis as both vimentin and Jagged1 are 
linked to tumor progression and metastasis. 
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2. Screening for regulators of Jagged1 endocytosis (II) 
2.1 Dual labeled N1ECD peptides can be used to track and quantify 
endocytosed Jagged1 
We expect that there are other proteins in addition to vimentin that can selectively regulate 
Notch ligands. Previous studies on Notch ligand endocytosis have been focused primarily 
on endocytosis of Delta and Delta-like ligands (Couturier and Schweisguth, 2014; Meloty-
Kapella et al., 2012; Overstreet et al., 2004; Windler and Bilder, 2010). To facilitate 
identification of new regulators of Jagged endocytosis we wanted to design a method 
where we can track Notch ligand endocytosis and then use this setup to track Jagged1 
specifically. We adapted a dual label setup of N1ECD peptides by first introducing 
primary amine NHS labels (555) and combining the pre-labeled N1ECD-555 peptides 
with Alexa Fluor 488 secondary antibody labeling as used previously (Study I). By 
quenching one label (488) at the surface after endocytosis, we now had a screening setup 
that could be used to quantify endocytosis by high-throughput plate readers and by 
confocal microscopy (II, Fig 2A) (Arjonen et al., 2012). Dual label N1ECD peptides 
(N1ECDD) were incubated on ice with HEK-293 cells stably overexpressing Jagged1 
(hereafter, 293-JAG). As expected, Jagged1 expression is drastically higher in these cells 
than other Notch ligands (II, Fig S1). A one hour incubation of N1ECDD peptides on ice 
followed by fixation shows N1ECDD bound to the surface of the cells and a strong overlap 
of 488 and 555 fluorophores (II, Fig 2B). Incubating the cells in 37 °C after attaching 
N1ECDD to cells on ice, allowed for endocytosis to resume in the cells. A 30 min 
incubation in 37 °C, followed by quenching of the Alexa Fluor 488 antibody at the cell 
membrane by an anti-Alexa 488 blocking antibody, effectively quenched green 
fluorescence while leaving red fluorescence unaffected at the cell membrane. This 
facilitated the distinction between endocytosed N1ECDD, and N1ECD555 on the cell 
membrane (II, Fig 2C, 3C). Omitting the endocytosis step with subsequent quenching of 
488 at the cell membrane showed the effectiveness of the surface quenching (II, Fig 2D). 
As another control, the use of dynasore to block dynamin, completely abolished the 
endocytosis of N1ECDD peptides (II, Fig 2E). Dynamin is used in both clathrin dependent 
and clathrin independent endocytosis to pinch of vesicles at the cell membrane. In our 
imaging based proof of concept, the amount of endocytosis was quantified by automated 
image analysis using a ComDet 4.2 plugin in ImageJ (II, Fig 3B-C). Analysis of different 
RESULTS AND DISCUSSION 
 49 
time points (0, 15, 30, 60 min) of endocytosis indicated that the amount of endocytosed 
N1ECDD peptides peak at 15 or 30 minutes before decreasing or becoming harder to 
detect (II, Fig 3A-C). Comparison of this assay with an endocytosis assay based on 
biotinylated cell surface proteins that were immunoprecipitated by streptavidin and blotted 
for Jagged1 displayed similar kinetics as the image based assay, but with a slightly lower 
end point rate at 60 min (II, Fig 3B, D).   
2.2 A cell spot microarray to identify new regulators of Jagged1 
We then employed our N1ECDD-based endocytosis assay in a cell spot microarray 
(CSMA) based on a Qiagen druggable genome library v1.0 (Arjonen et al., 2012; Pellinen 
et al., 2012; Rantala et al., 2011). This library includes siRNAs against genes that are 
considered targets for druggable treatment and include GPCRs, kinases, phosphatases and 
calcium channel receptors. The CSMA technique is based on reverse transfection, where 
the lipid-based transfection reagent and the siRNA are mixed with Matrigel and 
subsequently printed on array plates. CSMAs have several advantages for high-throughput 
screening (HTS) purposes compared to traditional plates. These include no well-to-well 
variation and less reagents needed (50 pg/spot siRNA vs 10 ng/well for 384 well plate). 
The arrays allow for multiparametric analysis and readouts through high-content imaging 
and microarray scanners (II, Fig 4A-B). Using a restricted cell adhesion time of 15 min 
allowed for adherence of 293-JAG cells to the array spots (II, Fig S2). After 48 hours of 
reverse transfection the cell arrays were incubated with N1ECDD on ice, allowed to 
endocytose for 30 min, followed by quenching of Alexa Fluor 488 at the cell surface as 
described previously. Cells were then fixed and analyzed by laser microarray scanning 
(Tecan LS400). The CSMA technology was available through a collaboration with 
Professor Johanna Ivaskas group, where the same library and CSMA design had been used 
previously to identify regulators of β1 integrins (Pellinen et al., 2012; Rantala et al., 2011). 
This was our first application of the N1ECDD-based assay in a high-throughput setting. As 
a consequence of the array being predesigned, it lacked some of the relevant positive 
controls for Notch endocytosis, including dynamin that we used earlier as our proof of 
concept. Nevertheless, we reasoned that this setup can give an interesting set of potential 
effector targets that can serve as a starting point for hits to be included and verified in 
smaller secondary screens in the future. Validation with individual siRNAs is crucial also 
when using all the appropriate controls. In a previous screen for active β1 integrin, with an 
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identical CSMA design, the secondary validation confirmed 23 out of 50 top hits, and 5 
genes turned out to have the opposite effect on integrin activity compared to what was 
shown in the primary screen (Pellinen et al., 2012).  
From our preliminary data we present 20 targets (individual siRNAs) that had the highest 
increase in N1ECDD endocytosis and 20 targets that had the highest decrease in N1ECDD 
endocytosis when knocked down (II, Fig 4C). Gene ontology (GO) analysis of clusters 
including a minimum of three genes from the same biological process (BP), molecular 
function (MF) or cellular component (CC) identified kinase activity (MF) as the most 
significant cluster of hits (II, Fig 4D). Other overrepresented clusters of targets that led to 
a reduction of N1ECDD internalization when knocked down included targets previously 
linked to endocytosis and intracellular signaling pathways (II, Fig 4D). These three 
clusters of genes with roles as positive regulators of endocytosis, receptor-mediated 
endocytosis and intracellular receptor signaling pathways indicate the validity of many of 
our top hits. This is promising, as the risk of false positives is high within a single screen. 
Targets that increased endocytosis in this assay formed less significant clusters with the 
most notable one being related to cell junction assembly (BP). This is not an unreasonable 
finding as Notch is often found in various cell junctions and has also been shown to be 
involved in their remodeling (Batchuluun et al., 2017; Benhra et al., 2011; Grammont, 
2007; Hatakeyama et al., 2014; Sasaki et al., 2007). This cluster contains CDC-42, which 
is also important for clathrin-independent endocytosis (Ferreira and Boucrot, 2018). The 
highest individual hit upregulating endocytosis of N1ECD in our screen was PDZD2 
(PDZ domain-containing intracellular PDZ protein 2). On the other hand, MAGI2, another 
PDZ domain-containing protein was a hit with a negative effect on endocytosis. MAGI2 
has also been shown previously to interact with other Notch ligands (Pfister et al., 2003). 
In Study I, we speculate that the differential regulation of Jagged1 from Dll4 could be due 
to PDZ binding motif interactions with vimentin, as vimentin has previously found to 
interact to SCRBBL through its PDZ domain (Phua et al., 2009). This group of proteins 
require further validation as it may point to a player in Notch ligand regulation in both 
study I and within these preliminary hits in study II. With over 300 proteins containing a 
PDZ-domain, there are plenty of potential interaction studies in the future (Pintar et al., 
2007). Within our research group we have recently generated Jagged1 constructs lacking 
the intracellular PDZ-binding motif to further study potential differences in interaction 
between Jagged1 and other proteins. Targets from the screen in study II that have been 
RESULTS AND DISCUSSION 
 51 
shown to be related to Notch signaling activity or ligand endocytosis include at least the 
following: LRRK (Imai et al., 2015), HIPK4 (Lee et al., 2009), PAK4 (Santiago-Gómez et 
al., 2019), MAGI2 (Pfister et al., 2003), SNAI1 (Morel et al., 2003; Saad et al., 2010), 
MAML2 (Lin et al., 2002), PLG (Shimizu et al., 2011) and CDC-42 (Balklava et al., 
2007). Further analysis is best performed on hits that are validated with more stringent 
requirements in upcoming secondary screens. During these screens and during validation 
with individual siRNAs we could also incorporate the agarose beads from study I to 
mimic the strain required for trans-endocytosis of Notch. This would then allow for 
identification of potential differences between constant endocytosis of ligands and Notch-
activating trans-endocytosis. 
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3. Phosphorylation by PKCζ regulates Notch trafficking (III) 
3.1 PKCζ interacts with and phosphorylates Notch1 
Post-translational modifications such as phosphorylation increase the functional diversity 
of proteins. Phosphorylation is a reversible modification and can thereby function to 
deliver rapid control of protein and cellular function. Although technological advances 
have allowed for global profiling of the proteome and many Notch phosphorylation sites 
have been identified, only a number of sites have been linked to specific functional 
outcomes and kinases (Antfolk et al., 2019).  
In study III, we investigated the role of atypical protein kinase C zeta (PKCζ). PKCζ has 
previously been shown to regulate differentiation in mammals (McCaffrey and Macara, 
2009). We first used C2C12 mouse myoblasts to determine PKCζ-mediated effects on 
Notch. C2C12 cells are able to proliferate at a high rate under conditions of high serum 
but undergo differentiation to myoblasts under low serum conditions. We found that PKCζ 
interacts with endogenous Notch1 in both differentiated and undifferentiated C2C12 cells 
(III, Fig 2A). PKCζ also interacted with transfected Full Length Notch1 (FLN1) in C2C12 
cells and a membrane-tethered active form of Notch1 (Notch1ΔE) in HeLa cells (III, Fig 
2B-C). Moreover, blocking Notch S3 cleavage by a γ-secretase inhibitor (GSI) led to a 
slight increase in interaction (III, Fig 2B-C). We did not detect an interaction by IP when 
using an antibody that recognizes only cleaved NICD (III, Fig 2D) nor when transfecting 
NICD and using an antibody that recognizes both full length and cleaved forms of Notch 
(III, Fig 2D right and bottom). These data suggest that Notch interacts with PKCζ when 
Notch is tethered to the cell membrane, as GSI treatment results in more Notch1ΔE stuck 
at the membrane, hence more interaction, while transfected NICD is never localized to the 
cell membrane, resulting in no visible interaction. These findings are supported by specific 
features of atypical PKCs. Atypical PKCs (PKCζ and PKCι/λ) have a mutation in their C1 
domain rendering them insensitive to DAG. The same mutation also changes the electric 
potential of the C1 domain leading to an increased interaction with the negatively charged 
plasma membrane (Pu et al., 2006).   
3.1.1 S1791 is identified as a PKCζ phosphorylation site on Notch1 
We found that immunoprecipitated Notch1 is phosphorylated in vitro by recombinant 
PKCζ, as shown by autoradiography of radioactive phosphorus-32-ATP (III, Fig 2E). To 
RESULTS AND DISCUSSION 
 53 
identify PKCζ-mediated phosphorylation sites on Notch1, we performed mass 
spectrometry analysis of immunoprecipitated Notch1 that was phosphorylated in vitro by 
PKCζ (III, Fig S3A). Serine 1791 was identified as the predominant phosphorylation site 
on mouse Notch1 (III, Fig S3A) (Figure 11). Further analysis with atypical PKCι showed 
that both atypical PKC isoforms are capable of phosphorylating mNotch1 on S1791 (III, 
Fig S3B). The identified serine is conserved in many species including Homo sapiens, 
Rattus norvegicus, Mus musculus, Xenopus laevis and Danio rerio, but not in Drosophila 
melanogaster or Caenorhabditis elegans (III, Fig S4).  
 
Figure 11. S1791 is phosphorylated on Notch1. Mass spectrometry identified S1791 in the 
intracellular domain of mNotch1 as the predominant phosphorylation site of atypical PKCζ (zeta) 
and ι (iota). S1791 on mouse Notch1 corresponds to S1801 on human NOTCH1.   
3.2 PKCζ increases Notch activation 
Transfection of a constitutively active form of PKCζ (caPKCζ) led to an increase in Notch 
activation in Notch reporter assays based on 12xCSL-Luc constructs, where Full Length 
Notch (FLN) overexpressing cells were activated by immobilized ligands (III, Fig 3A). 
Similarly, caPKCζ increased the reporter signal from transfected Notch1ΔE (III, Fig 3B). 
In contrast, caPKCζ had no effect on transfected NICD in these cells (III, Fig 3C). These 
results are in agreement with the lack of interaction between PKCζ and NICD (III, Fig 2D). 
Moreover, caPKCζ did not enhance the low reporter activity measured from mutant 
Notch1ΔEK1749R (III, Fig 3D). The point mutation of K1749R has previously been shown 
to generate highly unstable forms of NICD, which are rapidly degraded before any 
activation of transcription can occur (Tagami et al., 2008). Our results are consistent with 
this model. Transfecting caPKCζ or caPKCι in different concentrations together with 
Notch1ΔE also led to a dose dependent increase in NICD levels (III, Fig 3E).  
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3.2.1 Site directed mutagenesis of S1791  
To determine the specific role of the identified aPKC phosporylation site S1791, we 
employed site directed mutagenesis to generate phosphorylation-deficient and 
phosporylation-mimicking forms of Notch1ΔE. In the phospho-deficient form, the serine 
at 1791 was substituted for alanine (Notch1ΔES1791A), and in the mimicking form for 
glutamic acid (Notch1ΔES1791E) (III, Fig 4A) (Figure 12). We also generated a phospho-
mimicking form of full-length Notch, Notch1FLNS1791E (III, Fig 4A).  
 
Figure 12. Mutations of S1791. Substituting the serine 1791 for an alanine residue, renders the 
S1791 site unavailable for phosphorylation resulting in a phospho-deficient or phospho-dead 
mutant. Glutamic acid (E) has a negatively charged side group, which can mimic some of the 
functions of a phosphorylated serine in the cell.  
Transfecting WT, 1791A and 1791E mutant versions of Notch1ΔE and blocking S3 
cleavage by GSI show equal amounts of Notch1ΔE from the different constructs, and low 
levels of NICD as expected when inhibiting S3 cleavage (III, Fig 4B upper). Without GSI, 
expression of Notch1ΔES1791E resulted in increased levels of NICD compared to WT, 
while expression of Notch1ΔES1791A resulted in lower NICD levels than WT (III, Fig 4B 
lower). 12xCSL-Luc reporter assays support these findings and show enhanced signaling 
from Notch1ΔES1791E and decreased signaling from Notch1ΔES1791A (III, Fig 4C). Lower 
reporter activation from Notch1ΔES1791A could not be compensated or increased by 
caPKCζ (III, Fig 4D). On the contrary, we found that expression of caPKCζ resulted in 
even lower activity from Notch1ΔES1791A (III, Fig 4D). This could be due to 
downregulation of endogenous Notch upon transfection with Notch1ΔE forms, or direct or 
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indirect repressive effects of PKCζ on Notch when S1791 is not available for 
phosphorylation. Expression of the Notch1FLNS1791E mutant produced higher reporter 
activity when activated by immobilized ligands, which is in agreement with the 
Notch1ΔES1791E results (III, Fig 4E-F). The increase in NICD levels were not due to 
different degradation rates of NICD as determined by cyclohexamide chase experiments, 
where we compared NICD levels at 0, 3 and 7 hours of cyclohexamide treatment (III, Fig 
S8A). 
3.3 PKCζ affects trafficking of Notch1 
3.3.1 Internalization of activated Notch receptors 
Immunostaining of Notch1ΔE, Notch1ΔES1791A and Notch1ΔES1791E indicated that 
Notch1ΔES1791E and Notch1ΔE localize more to the nucleus compared to the phospho-
deficient Notch1ΔES1791A (III, Fig 5A). Western blotting of nuclear extracts also pointed 
to increased levels of NICD from Notch1ΔES1791E, and lower levels from Notch1ΔES1791A, 
compared to Notch1ΔE (III, Fig 5B). Our experiments further showed increased nuclear 
staining of Notch in different cell lines when caPKCζ was expressed together with 
Notch1ΔE (III, Fig 3H-I). The use of a dominant negative PKCζ mutant (dnPKCζ), with a 
defective catalytic domain showed an opposite effect on Notch, with less nuclear Notch 
reactivity and no increase in NICD production (III, Fig 3F, 3H-I). This result indicates that 
the kinase activity of PKCζ is important for the observed effects on Notch signaling.  
All three forms of Notch1ΔE interacted with Rab5 and Rab7, representing early and late 
endosomal localizations, respectively. The interaction between the phospho-mimetic 
Notch1ΔES1791E and Rab7 was slightly decreased, indicating that this form of Notch1ΔE 
may be released from the late endosomes or from early endosomes during its transition to 
late endosomes. This implies that less Notch/NICD is being transferred to lysosomes (III, 
Fig 5D-E). Moreover, downregulation of PKCζ by siRNA increased the interaction 
between Notch and lysosomal associated protein LAMP-1 (III, Fig 5G). A similar result 
was obtained when PKCζ was inhibited by a pseudosubstrate, which instead led to strong 
co-localization between Notch1 and LAMP-1 (III, Fig 5H). 
In conclusion, these results suggest that when PKCζ is active or a phospho-mimicking 
mutation of S1791 is used, the amount of NICD generated is increased (III, Fig 3E, 4B 
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lower) and more active Notch is translocated to the nucleus (III, Fig 3H-I, 5A-B) leading 
to higher Notch activity (III, Fig 4C, E-F). Conversely, when PKCζ is inhibited more 
Notch is shifted through late endosomes to lysosomes, leading to a degradation of Notch, 
resulting in lower observed levels of NICD (III, Fig 3E-F, I, 4B lower, 5B) and decreased 
Notch signaling activity (III, Fig 4C-D).  
3.3.2 Recycling of inactive Notch receptors 
The results from previous sections describe the impact of PKCζ on activated Notch 
receptors. Although our study focused on activated receptors, we made some interesting 
observations on the effects of PKCζ on non-active receptors. When Notch receptors are 
inactive by the lack of cell-cell interactions in sparsely cultured cells without immobilized 
ligand activation, PKCζ does not promote higher levels of NICD or signaling activity. In 
these cells, caPKCζ expression results in an initial shift of Notch from the cell membrane 
to intracellular vesicles (III, Fig 7A-C). In contrast to activated receptors, this transfer did 
not lead to a higher NICD production (III, Fig 7D). Instead we observed an increase in the 
ubiquitination of Notch (III, Fig 7E) and an accompanied increase in interaction between 
Notch1 and the ubiquitin binding protein Hrs, which functions as an endosomal sorting 
protein (III, Fig 7F). The internalization, ubiquitination, and endosomal sorting was not 
linked to an increased degradation of Notch (III, Fig 7G). Our best explanation is that non-
activated receptors are recycled back to the cell membrane supported by other reports 
describing constant recycling to and from the cell membrane (Johnson et al., 2016; McGill 
et al., 2009; Yamamoto et al., 2010). 
3.4 S1791 regulates myogenic differentiation in vitro and PKCζ regulates 
neuronal differentiation in vivo  
We then decided to examine if PKCζ inhibition can affect the differentiation in our C2C12 
mouse myoblast cell line and in primary myoblasts, as myogenic differentiation has been 
previously shown to be regulated by Notch signaling (Buas and Kadesch, 2010; Nofziger 
et al., 1999). We used the myosin heavy chain (MHC) as a marker for myogenic 
differentiation. Primary mouse myoblasts treated with pseudosubstrate show significantly 
higher differentiation rates compared to cells treated with scrambled control (III, Fig 6 A-
B). Similarly, down regulation of PKCζ by siRNA also resulted in earlier differentiation 
of C2C12 cells and conversely, expression of caPKCζ resulted in a delayed differentiation 
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(III, Fig 6C-D). Expression of Notch1ΔES1791A further showed that 71% of cells 
expressing the phospho-deficient S1791A were positive for MHC compared to only 14% 
for Notch1ΔE after 72 h of differentiation (III, Fig 6E).  
Finally we employed a previously used model to study differentiation of the developing 
chick central nervous system (CNS) (Holmberg et al., 2008). We used an engineered 
Notch1ΔE construct with an incorporated myc-tag, and an IRES-EGFP to track expression 
of nuclear Notch. We first tested the CAG-Notch1ΔE-Myc-IRES-EGFP construct by 
expressing it together with a 12xCSL-dsRED reporter construct and confirmed strong 
activation of Notch signaling (III, Fig 1A-C). We then co-expressed CAG-Notch1ΔE-
Myc-IRES-EGFP with a myristylated pseudosubstrate to inhibit PKCζ in stage 10 chick 
embryos (Hamburger Hamilton stage 10). We looked at the amount of Tuj-1 (neuronal 
lineage marker) positive neuronal cells. Expressing the Notch construct on one side of the 
neural tube led to a significant reduction in Tuj-1 positive cells as compared to the other 
side of the neural tube without the active Notch construct (III, Fig 1D, F). This is in 
accordance with the established function of Notch as an inhibitor of differentiation in the 
CNS (Borghese et al., 2010; Holmberg et al., 2008; Louvi and Artavanis-Tsakonas, 2006; 
Yoon and Gaiano, 2005). When we then used the pseudosubstrate inhibitor of PKCζ 
together with the Notch construct, we identified more Notch1 positive cells (tracked by 
EGFP) in the marginal zone of the neural tube, with cells being positive for both Notch1 
and Tuj-1 (III, Fig 1E). This suggests that the cells were able to undergo differentiation 
despite the high Notch1 expression from the active construct. Our analysis also revealed 
differences in intracellular localization of Notch1 when we examined Notch 
immunoreactivity through the incorporated myc-tag. Notch expression without the PKCζ 
inhibitor produced both nuclear and cytoplasmic Notch-myc reactivity, but addition of the 
PKCζ inhibitor reduced the nuclear staining (III, Fig S1A-B). We also quantified the ratio 
of nuclear to cytoplasmic myc reactivity, which indicated that approximately half as many 
cells show nuclear reactivity during PKCζ inhibition (III, Fig 1G-I).  
Our results on PKCζ-mediated effects on differentiation are in agreement with a previous 
study, which also identified PKCζ as a suppressor of neuronal differentiation (Ossipova et 
al., 2009). Ossipova and colleagues proposed that PKCζ excerts its effects on 
neurogenesis through Notch by linking PKCζ-mediated regulation of PAR-1 to critical 
regulation of the E3 ligase Mib. This is another possible function of PKCζ-mediated 
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regulation. However, studies with PAR-1 knock out mice show no Notch-related 
phenotypes (Hurov et al., 2001). We suggest a more direct regulation of Notch by PKCζ, 
which is most likely determining the outcome of Notch in combination with other effects 
of PKCζ phosphorylation, such as general regulation of endocytosis or the aforementioned 
regulation of Mib. It is likely that PKCζ can regulate endocytosis in other ways to 
internalize Notch receptors independently of S1791 when caPKCζ is expressed, but 
perhaps phosphorylation of S1791 further specifies the Notch signaling outcome. This 
would explain why Notch1ΔES1791A in some settings could be downregulated by caPKCζ 
(III, Fig 2D) if some parts of the general PKCζ-mediated internalized endosomes are 
targeted for degradation. Again, actin or vimentin may be involved in the mechanisms of 
influencing the general endocytosis through PKCs. At least one novel PKC isoform has 
been shown to influence the generation of a large actin-based lamellum allowing for 
efficient Notch cleavage by ADAM10 (Britton et al., 2017). Regulation of vimentin by 
PKCs has been previously documented to affect integrin recycling (Ivaska et al., 2005) 
and more recently, both atypical isoforms PKCζ and PKCι have been shown to influence 
vimentin assembly (Ratnayake et al., 2018).  
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CONCLUDING REMARKS 
During the last few decades many key aspects of Notch signaling have been described in 
both development and disease. Still researchers struggle to understand the context-
dependent output of Notch. The aim of this thesis has been to provide new insights into 
the regulation of the Notch signaling pathway. These aims involve phosphorylation of 
Notch and endocytosis of Jagged ligands. In our first study, Jagged1 ligands accumulated 
at the surface of cells lacking vimentin, but with a compromised signal sending ability. 
Vimentin interacts with the intracellular domain of Jagged1, but not with Dll4 as 
demonstrated by swapping the intracellular domain of Jagged1 to Dll4-ICD, where the 
interaction was lost. We then studied the vimentin-Jagged1 axis in the context of 
angiogenesis. A lack of vimentin negatively affected the ability of endothelial cells to 
form angiogenic sprouts. Addition of external Jagged1 ligands rescued the angiogenic 
defects of vimentin ablation, which also challenges the prevailing argument that the main 
role of Jagged1 in angiogenesis is to inhibit more potent Dll4-Notch signaling. Recent 
studies on tip cell dynamics combined with our study highlight a more complex role for 
Jagged1 during angiogenesis, where it might not be low Notch that drives initial tip cell 
sprouting but that Jagged1 and Dll4 may activate Notch in distinct ways. Our findings 
further add to the important roles of intermediate filaments as signaling modulators and 
the interplay between vimentin and Jagged1 may also be amenable to therapeutic 
intervention in areas such as tumor angiogenesis and metastasis. Future studies will likely 
determine how and which Notch ligands can be regulated by IFs. With keratin IFs recently 
shown to interact with Notch receptors (Lähdeniemi et al., 2017), these studies can easily 
be extended to Notch receptors as well.   
Accumulating evidence point to deregulated Jagged1 in several different cancers, with an 
overexpression of JAGGED1 associated with increased metastasis and poor survival in 
women with breast cancer (Bednarz-Knoll et al., 2016; Sethi et al., 2011). Similarly, 
higher expression of JAGGED1 has been identified in prostate cancer patients with 
especially aggressive tumors (Zhu et al., 2013). Our dual label approach to track 
endocytosis of Notch ligands in study II should allow us to identify and validate other new 
Jagged1 modulators in the future. In addition, the hits from the cell spot microarray pilot 
screen have given us a short list of targets to include in our upcoming efforts to detail 
Notch ligand endocytosis.  
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Finally, we identify atypical protein kinase C zeta (PKCζ) as a regulator of Notch 
trafficking and activation. PKCζ interacts with membrane-tethered Notch1 receptors and 
phosphorylates S1791 in the intracellular domain of the receptor. The signaling from 
active Notch receptors is further enhanced by PKCζ, leading to relocation of more NICD 
to the nucleus and higher activation in reporter assays. When PKCζ was blocked, we 
found that the opposite was true, and observed less Notch signaling activity, less NICD in 
the nucleus, and a relocation of Notch to late endosomes. We then generated phospho-
deficient (S1791A) and phospho-mimicking (S1791E) mutants of active Notch1ΔE. In 
agreement with our previous findings, expression of the phospho-mimicking 
Notch1ΔE1791E led to increased signaling and NICD with more Notch localized to the 
nucleus, while the phospho-deficient Notch1ΔE1791A led to lower signaling, less NICD and 
more Notch localized in intracellular vesicles. We also report that blockage of PKCζ leads 
to more neuronal differentiation in vivo in the developing chicken spinal cord. 
Corroborating these results we found that C2C12 cells expressing phospho-deficient 
Notch1ΔE1791A consistently differentiated to myotubes. These results suggest that 
phosphorylation by PKCζ can influence differentiation through Notch1. 
Taken together, this thesis shows for the first time an interaction between the intermediate 
filament vimentin and Jagged1 in the signal sending cell as well as PKCζ and Notch1 in 
the signal receiving cell (summarized in figure 13). These results also provide insight into 
the regulation of Notch during angiogenesis and differentiation. Combining the data from 
these studies paint a picture of a potential network between PKCζ, vimentin, Jagged and 
Notch. Determining the interplay between these components should provide for plenty of 
research opportunities in the future.  
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Figure 13. Schematic of the Notch signaling pathway and the main findings in this thesis. 
Vimentin promotes force generation and trans-activation potential of Jagged1 in the signal-
sending cell (Notch ligand cell). In the signal-receiving cell, PKCζ interacts with membrane-bound 
Notch1 and phosphorylates S1791 in the intracellular domain of Notch1, which further enhances 
active Notch signaling. When Notch is inactive, PKCζ leads to an initial internalization of Notch 
receptors but without an increase in either signaling or degradation. The majority of these 
receptors may be recycled back to the cell membrane. 
  
        Jagged1
trans-endocytosis
      promoted
Notch ligand cell
Notch receptor cell
Jagged1
MAMLCoAct
CSL
Target genes
ON
NICD
Notch1
       
(S3)
 (S2)
Ligand-
interaction
Increased
activation = Vimentin
Recycling of
 non-active
  receptors?
PKCζ
PKCζ
PKCζ
ACKNOWLEDGEMENTS 
 62 
ACKNOWLEDGEMENTS 
The work presented in this thesis was conducted at the Faculty of Science and Engineering, 
Cell Biology, Åbo Akademi University (ÅAU) and Turku Bioscience, University of Turku 
and ÅAU. My studies were supported by the Turku Doctoral Network in Molecular 
Biosciences (MolBio) at ÅAU and I would like to thank all the group leaders involved, 
especially Annika Meinander for her contributions to the programme. John Eriksson, 
Cecilia Sahlgren and Annika Meinander are acknowledged for their work as head of the 
Cell Biology department. I am also grateful to Riitta Lahesmaa and John Eriksson for 
providing excellent facilities and atmosphere at the Turku Bioscience. 
I wish to express my deepest gratitude to my supervisor Cecilia Sahlgren for the chance to 
conduct my work in her laboratory. Your enthusiasm for science is awesome, your ability 
to conceptualize projects borders on genius, and I thank you sincerely for the opportunity 
to learn from you. You have been the perfect supervisor for me, pushing projects further 
as needed but also allowing me to work on projects independently. I highly appreciate 
your generosity in so many matters as well as your speedy responses to any science-
related questions. Thank you for all the support and guidance!  
I want to thank Penny Handford and Jeroen Pouwels for reviewing my thesis. I greatly 
appreciate the encouraging comments and for taking the time to examine my thesis. I 
would also like to thank Vincent Luca for accepting the invitation to be my opponent, with 
the long travel it entails. I really appreciate the chance to discuss my research with you. 
Johanna Ivaska and Noora Kotaja are acknowledged for their advice and suggestions as 
part of my thesis advisory committee. Especially in the beginning of my studies it was 
comforting to know that your great expertise was available when needed. Thank you also 
Johanna for our collaboration. 
I wish to thank all the technical and secretarial staff at ÅAU and Turku Bioscience for 
their assistance throughout the years. A special mention to Markku Saari and Jouko 
Sandholm for all their help with microscopy related issues, Helena Saarento during the 
early days, as well as Gunilla Henriksson, Barbro Lindholm and Thomas Bymark for their 
help with ordering, travel and IT-related issues. I also wish to thank Fredrik Karlsson and 
Anne-Leena Gröning for help with the official details regarding the dissertation.    
ACKNOWLEDGEMENTS 
 63 
Great science in our field is not possible without great collaborators. I would like to 
sincerely thank all the co-authors in the studies conducted during this thesis work: Marika 
Sjöqvist, Kimmo Isoniemi, Saima Ferraris, Marjaana Parikainen, Antti Arjonen, Fang 
Cheng, Adolfo Rivero-Müller, Susumu Imanishi, Sebastian Landor, Rasmus Niemi, 
Christian Antila, Cecilia Haga, Camille Duran, Vilma Rraklli, Anders Mutvei, Shaobo Jin, 
Carlijn Bouten, Kayla Bayless, Johan Holmberg, Urban Lendahl, Johanna Ivaska, John 
Eriksson, and Cecilia Sahlgren. I would also like to take the opportunity to acknowledge 
all the co-authors in the publications outside of the thesis and Kalen Lin for help with the 
figures. I want to pay my special regards to my closest collaborator Marika for all the 
work we did together and for all your help after our main projects ended, both in science 
and on the outside. I hope we will have more projects together in the future.  
I would like to thank the group leaders John Eriksson, Diana Toivola, Lea Sistonen, Kid 
Törnqvist, Jessica Rosenholm and Annika Meinander for their support at ÅAU. Thank 
you also Diana for joint events, encouragement, conferences and other travel experiences. 
I also want to thank John as kustos and collaborator, including all help and comments on 
our manuscripts. I would like to extend my gratitude also to the past and present members 
of all these labs, all colleagues at Turku Bioscience and the ÅAU Biochemistry department 
for a good atmosphere in the corridors and facilities. Special thanks to Josef for all the 
good times and great discussions during lunches, travels and otherwise. A big thank you to 
Erik and Iris for being such good friends. Thank you Iris, Jonas, Terhi, Calle, Laura and 
Joel for your good company during IF conferences. 
I want to thank all previous and current members of the Sahlgren group for all the good 
times, trips and your help during this work. Special thanks to Marika, Rasmus, Sebastian, 
Johanna and Martina for all the lunches, fun trips, restaurant visits, wine evenings and 
more. Sebastian also for your company in frisbee golf, poker, gaming and snooker. Thank 
you Rasmus for your cooking treats, shared wine bottles and funny puns. Thank you 
Martina for all the funny comments, your help with my last project and good times. Thank 
you Johanna for commenting on my thesis and for your listening. Thanks to Christian for 
fun times during poker, parties and traveling since our early studies, Kati for organizing 
Friday beers and for always telling me stories, Marjaana for cakes, parties and 
collaboration, Ezgi and Valeriy for good times since (almost) the beginning, and to the 
ACKNOWLEDGEMENTS 
 64 
late Veronika for all the fun times, interesting discussions and advice. Thank you also to 
everyone else. I feel honored to have been part of the Sahlgren group. 
I want to thank the Biosense group of Lina, Sussi, Cissi, Inkku, Stina for everything 
during our studies and after. Thank you also to the significant others of this group for 
summer meetups and more. Thank you Cissi for bringing life to the PKC project during 
your master’s thesis that later led to the real start of my PhD. Thank you Lina, especially 
your support during my master’s thesis and during the earlier days of my doctoral studies. 
I also want to thank all my other friends outside of science. Thanks to Jocke and Johan for 
keeping contact even when I have been swamped in research. Thank you Ilja for fun 
discussions, gaming, and sports. I miss all the restaurant visits with you and Nora.  
I am very grateful to my family and relatives for supporting me during my studies and in 
life. I would like to mention especially my mother Ann-Christin, father Berndt, brother 
Tobias, sister Hanna, grandmother Marita, as well as Mikael and Ulla for their 
encouragement. 
I am grateful for the financial support, which truly made this work possible, including all 
the travel grants to present my work abroad: The Turku Doctoral Network in Molecular 
Biosciences (MolBio), Åbo Akademi foundation, Finnish cultural foundation, K. Albin 
Johansson, Swedish cultural foundation of Finland, Instrumentariumin tiedesäätiö, Maud 
Kuistila, Ida Montini, Svensk Österbottniska samfundet, Liv och Hälsa r.f., Magnus 
Ehrnrooth’s foundation, Victoriastiftelsen, Oskar Öflund, Aarne ja Aili Turusen säätiö, 
Waldemar von Frenckell’s foundation, Finsk-Norska medicinska stiftelsen, Aarne 
Koskelo foundation, Einar och Karin Stroem, Otto Malm, Sydäntutkimussäätiö, TOP-
säätiö, Lounais-Suomen syöpäsäätiö and Syöpäjärjestöt. 
 
Daniel  
REFERENCES 
 65 
REFERENCES 
Acosta, H., López, S.L., Revinski, D.R., Carrasco, A.E., 2011. Notch destabilises maternal beta-
catenin and restricts dorsal-anterior development in Xenopus. Development 138, 2567–79. 
https://doi.org/10.1242/dev.061143 
Alam, M.S., 2018. Proximity Ligation Assay (PLA). Curr. Protoc. Immunol. 123, e58. 
https://doi.org/10.1002/cpim.58 
Alanko, J., Mai, A., Jacquemet, G., Schauer, K., Kaukonen, R., Saari, M., Goud, B., Ivaska, J., 
2015. Integrin endosomal signalling suppresses anoikis. Nat. Cell Biol. 17, 1412–1421. 
https://doi.org/10.1038/ncb3250 
Ali, S.A., Justilien, V., Jamieson, L., Murray, N.R., Fields, A.P., 2016. Protein Kinase Cι Drives a 
NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer 
Cell 29, 367–378. https://doi.org/10.1016/j.ccell.2016.02.012 
Andersen, P., Uosaki, H., Shenje, L.T., Kwon, C., 2012. Non-canonical Notch signaling: emerging 
role and mechanism. Trends Cell Biol. 22, 257–265. https://doi.org/10.1016/ 
j.tcb.2012.02.003 
Andersson, E.R., Lendahl, U., 2014. Therapeutic modulation of Notch signalling--are we there 
yet? Nat. Rev. Drug Discov. 13, 357–78. https://doi.org/10.1038/nrd4252 
Andersson, E.R., Sandberg, R., Lendahl, U., 2011. Notch signaling: simplicity in design, 
versatility in function. Development 138, 3593–612. https://doi.org/10.1242/dev.063610 
Antal, C.E., Hudson, A.M., Kang, E., Zanca, C., Wirth, C., Stephenson, N.L., Trotter, E.W., 
Gallegos, L.L., Miller, C.J., Furnari, F.B., Hunter, T., Brognard, J., Newton, A.C., 2015. 
Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor. 
Cell 160, 489–502. https://doi.org/10.1016/j.cell.2015.01.001 
Antfolk, D., Antila, C., Kemppainen, K., Landor, S.K.-J., Sahlgren, C., 2019. Decoding the PTM-
switchboard of Notch. Biochim. Biophys. Acta - Mol. Cell Res. 118507. 
https://doi.org/10.1016/j.bbamcr.2019.07.002 
Aquila, G., Kostina, A., Vieceli Dalla Sega, F., Shlyakhto, E., Kostareva, A., Marracino, L., 
Ferrari, R., Rizzo, P., Malaschicheva, A., 2019. The Notch pathway: a novel therapeutic 
target for cardiovascular diseases? Expert Opin. Ther. Targets 23, 695–710. 
https://doi.org/10.1080/14728222.2019.1641198 
Arjonen, A., Alanko, J., Veltel, S., Ivaska, J., 2012. Distinct recycling of active and inactive β1 
integrins. Traffic 13, 610–25. https://doi.org/10.1111/j.1600-0854.2012.01327.x 
Arroyo, A.G., Iruela-Arispe, M.L., 2010. Extracellular matrix, inflammation, and the angiogenic 
response. Cardiovasc. Res. 86, 226–235. https://doi.org/10.1093/cvr/cvq049 
Artavanis-Tsakonas, S., Muskavitch, M.A., Yedvobnick, B., 1983. Molecular cloning of Notch, a 
locus affecting neurogenesis in Drosophila melanogaster. Proc. Natl. Acad. Sci. 80, 1977–
1981. https://doi.org/10.1073/pnas.80.7.1977 
Artavanis-Tsakonas, S., Muskavitch, M.A.T., 2010. Notch: The Past, the Present, and the Future. 
pp. 1–29. https://doi.org/10.1016/S0070-2153(10)92001-2 
Aster, J.C., Pear, W.S., Blacklow, S.C., 2017. The Varied Roles of Notch in Cancer. Annu. Rev. 
Pathol. Mech. Dis. 12, 245–275. https://doi.org/10.1146/annurev-pathol-052016-100127 
Avila, J.L., Kissil, J.L., 2013. Notch signaling in pancreatic cancer: oncogene or tumor 
suppressor? Trends Mol. Med. 19, 320–327. https://doi.org/10.1016/j.molmed.2013.03.003 
Ayaz, F., Osborne, B.A., 2014. Non-Canonical Notch Signaling in Cancer and Immunity. Front. 
Oncol. 4. https://doi.org/10.3389/fonc.2014.00345 
REFERENCES 
 66
Aydin, I.T., Melamed, R.D., Adams, S.J., Castillo-Martin, M., Demir, A., Bryk, D., Brunner, G., 
Cordon-Cardo, C., Osman, I., Rabadan, R., Celebi, J.T., 2014. FBXW7 Mutations in 
Melanoma and a New Therapeutic Paradigm. JNCI J. Natl. Cancer Inst. 106, dju107. 
https://doi.org/10.1093/jnci/dju107 
Baker, M., Robinson, S.D., Lechertier, T., Barber, P.R., Tavora, B., D’Amico, G., Jones, D.T., 
Vojnovic, B., Hodivala-Dilke, K., 2012. Use of the mouse aortic ring assay to study 
angiogenesis. Nat. Protoc. 7, 89–104. https://doi.org/10.1038/nprot.2011.435 
Balklava, Z., Pant, S., Fares, H., Grant, B.D., 2007. Genome-wide analysis identifies a general 
requirement for polarity proteins in endocytic traffic. Nat. Cell Biol. 9, 1066–1073. 
https://doi.org/10.1038/ncb1627 
Bargagna-Mohan, P., Paranthan, R.R., Hamza, A., Zhan, C.-G., Lee, D.-M., Kim, K.B., Lau, D.L., 
Srinivasan, C., Nakayama, K., Nakayama, K.I., Herrmann, H., Mohan, R., 2012. Corneal 
Antifibrotic Switch Identified in Genetic and Pharmacological Deficiency of Vimentin. J. 
Biol. Chem. 287, 989–1006. https://doi.org/10.1074/jbc.M111.297150 
Barsi, J.C., Rajendra, R., Wu, J.I., Artzt, K., 2005. Mind bomb1 is a ubiquitin ligase essential for 
mouse embryonic development and Notch signaling. Mech. Dev. 122, 1106–1117. 
https://doi.org/10.1016/j.mod.2005.06.005 
Basmanav, F.B., Oprisoreanu, A.M., Pasternack, S.M., Thiele, H., Fritz, G., Wenzel, J., Größer, L., 
Wehner, M., Wolf, S., Fagerberg, C., Bygum, A., Altmüller, J., Rütten, A., Parmentier, L., El 
Shabrawi-Caelen, L., Hafner, C., Nürnberg, P., Kruse, R., Schoch, S., Hanneken, S., Betz, 
R.C., 2014. Mutations in POGLUT1, encoding protein o-glucosyltransferase 1, cause 
autosomal-dominant dowling-degos disease. Am. J. Hum. Genet. 94, 135–143. 
https://doi.org/10.1016/j.ajhg.2013.12.003 
Batchuluun, K., Azuma, M., Yashiro, T., Kikuchi, M., 2017. Notch signaling-mediated cell-to-cell 
interaction is dependent on E-cadherin adhesion in adult rat anterior pituitary. Cell Tissue 
Res. https://doi.org/10.1007/s00441-016-2540-5 
Battaglia, R.A., Delic, S., Herrmann, H., Snider, N.T., 2018. Vimentin on the move: new 
developments in cell migration. F1000Research 7, 1796. https://doi.org/10.12688/ 
f1000research.15967.1 
Becam, I., Fiuza, U.-M., Arias, A.M., Milán, M., 2010. A role of receptor Notch in ligand cis-
inhibition in Drosophila. Curr. Biol. 20, 554–60. https://doi.org/10.1016/j.cub.2010.01.058 
Bednarz-Knoll, N., Efstathiou, A., Gotzhein, F., Wikman, H., Mueller, V., Kang, Y., Pantel, K., 
2016. Potential Involvement of Jagged1 in Metastatic Progression of Human Breast 
Carcinomas. Clin. Chem. 62, 378–386. https://doi.org/10.1373/clinchem.2015.246686 
Benedito, R., Hellström, M., 2013. Notch as a hub for signaling in angiogenesis. Exp. Cell Res. 
319, 1281–1288. https://doi.org/10.1016/j.yexcr.2013.01.010 
Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M., Adams, R.H., 2009. 
The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis. Cell 137, 
1124–1135. https://doi.org/10.1016/j.cell.2009.03.025 
Benedito, R., Rocha, S.F., Woeste, M., Zamykal, M., Radtke, F., Casanovas, O., Duarte, A., 
Pytowski, B., Adams, R.H., 2012. Notch-dependent VEGFR3 upregulation allows 
angiogenesis without VEGF–VEGFR2 signalling. Nature 484, 110–114. https://doi.org/ 
10.1038/nature10908 
Benhra, N., Lallet, S., Cotton, M., Le Bras, S., Dussert, A., Le Borgne, R., 2011. AP-1 controls the 
trafficking of notch and sanpodo toward E-cadherin junctions in sensory organ precursors. 
Curr. Biol. https://doi.org/10.1016/j.cub.2010.12.010 
REFERENCES 
 67 
Benhra, N., Vignaux, F., Dussert, A., Schweisguth, F., Le Borgne, R., 2010. Neuralized Promotes 
Basal to Apical Transcytosis of Delta in Epithelial Cells. Mol. Biol. Cell 21, 2078–2086. 
https://doi.org/10.1091/mbc.e09-11-0926 
Beres, T.M., Masui, T., Swift, G.H., Shi, L., Henke, R.M., MacDonald, R.J., 2006. PTF1 is an 
organ-specific and Notch-independent basic helix-loop-helix complex containing the 
mammalian Suppressor of Hairless (RBP-J) or its paralogue, RBP-L. Mol. Cell. Biol. 26, 
117–30. https://doi.org/10.1128/MCB.26.1.117-130.2006 
Bezanilla, M., Gladfelter, A.S., Kovar, D.R., Lee, W.-L., 2015. Cytoskeletal dynamics: A view 
from the membrane. J. Cell Biol. 209, 329–337. https://doi.org/10.1083/JCB.201502062 
Blanco, R., Gerhardt, H., 2013. VEGF and Notch in Tip and Stalk Cell Selection. Cold Spring 
Harb. Perspect. Med. 3, a006569–a006569. https://doi.org/10.1101/cshperspect.a006569 
Blaumueller, C.M., Qi, H., Zagouras, P., Artavanis-Tsakonas, S., 1997. Intracellular cleavage of 
Notch leads to a heterodimeric receptor on the plasma membrane. Cell 90, 281–91. 
Boareto, M., Jolly, M.K., Ben-Jacob, E., Onuchic, J.N., 2015. Jagged mediates differences in 
normal and tumor angiogenesis by affecting tip-stalk fate decision. Proc. Natl. Acad. Sci. U. 
S. A. 112, E3836-44. https://doi.org/10.1073/pnas.1511814112 
Bollong, M.J., Pietilä, M., Pearson, A.D., Sarkar, T.R., Ahmad, I., Soundararajan, R., Lyssiotis, 
C.A., Mani, S.A., Schultz, P.G., Lairson, L.L., 2017. A vimentin binding small molecule 
leads to mitotic disruption in mesenchymal cancers. Proc. Natl. Acad. Sci. U. S. A. 114, 
E9903–E9912. https://doi.org/10.1073/pnas.1716009114 
Boraas, L.C., Ahsan, T., 2016. Lack of vimentin impairs endothelial differentiation of embryonic 
stem cells. Sci. Rep. 6, 30814. https://doi.org/10.1038/srep30814 
Borggrefe, T., Lauth, M., Zwijsen, A., Huylebroeck, D., Oswald, F., Giaimo, B.D., 2016. The 
Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia 
pathways. Biochim. Biophys. Acta - Mol. Cell Res. 1863, 303–313. 
https://doi.org/10.1016/j.bbamcr.2015.11.020 
Borggrefe, T., Oswald, F., 2009. The Notch signaling pathway: transcriptional regulation at Notch 
target genes. Cell. Mol. Life Sci. 66, 1631–46. https://doi.org/10.1007/s00018-009-8668-7 
Borghese, L., Dolezalova, D., Opitz, T., Haupt, S., Leinhaas, A., Steinfarz, B., Koch, P., 
Edenhofer, F., Hampl, A., Brüstle, O., 2010. Inhibition of Notch Signaling in Human 
Embryonic Stem Cell-Derived Neural Stem Cells Delays G1/S Phase Transition and 
Accelerates Neuronal Differentiation In Vitro and In Vivo. Stem Cells 28, 955–964. 
https://doi.org/10.1002/stem.408 
Bozkulak, E.C., Weinmaster, G., 2009. Selective use of ADAM10 and ADAM17 in activation of 
Notch1 signaling. Mol. Cell. Biol. 29, 5679–95. https://doi.org/10.1128/MCB.00406-09 
Bray, S., Bernard, F., 2010. Notch Targets and Their Regulation, in: Current Topics in 
Developmental Biology. pp. 253–275. https://doi.org/10.1016/S0070-2153(10)92008-5 
Bray, S.J., 2016. Notch signalling in context. Nat. Rev. Mol. Cell Biol. 17, 722–735. 
https://doi.org/10.1038/nrm.2016.94 
Bray, S.J., 2006. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 
7, 678–689. https://doi.org/10.1038/nrm2009 
Britannica, E., 2019. Giant cell | Britannica.com [WWW Document]. URL 
https://www.britannica.com/science/giant-cell (accessed 12.31.19). 
Britton, G.J., Ambler, R., Clark, D.J., Hill, E. V, Tunbridge, H.M., McNally, K.E., Burton, B.R., 
Butterweck, P., Sabatos-Peyton, C., Hampton-O’Neil, L.A., Verkade, P., Wülfing, C., Wraith, 
D.C., 2017. PKCθ links proximal T cell and Notch signaling through localized regulation of 
the actin cytoskeleton. Elife 6. https://doi.org/10.7554/eLife.20003 
REFERENCES 
 68
Brückner, K., Perez, L., Clausen, H., Cohen, S., 2000. Glycosyltransferase activity of Fringe 
modulates Notch-Delta interactions. Nature 406, 411–5. https://doi.org/10.1038/35019075 
Buas, M.F., Kadesch, T., 2010. Regulation of skeletal myogenesis by Notch. Exp. Cell Res. 316, 
3028–33. https://doi.org/10.1016/j.yexcr.2010.05.002 
Buehler, M.J., 2013. Mechanical players-The role of intermediate filaments in cell mechanics and 
organization. Biophys. J. 105, 1733–4. https://doi.org/10.1016/j.bpj.2013.08.050 
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., 
Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., 
Risau, W., Nagy, A., 1996. Abnormal blood vessel development and lethality in embryos 
lacking a single VEGF allele. Nature 380, 435–439. https://doi.org/10.1038/380435a0 
Carrieri, F.A., Murray, P.J., Ditsova, D., Ferris, M.A., Davies, P., Dale, J.K., 2019. CDK1 and 
CDK2 regulate NICD1 turnover and the periodicity of the segmentation clock. EMBO Rep. 
20, e46436. https://doi.org/10.15252/embr.201846436 
Castel, D., Mourikis, P., Bartels, S.J.J., Brinkman, A.B., Tajbakhsh, S., Stunnenberg, H.G., 2013. 
Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev. 27, 1059–71. 
https://doi.org/10.1101/gad.211912.112 
Chapman, G., Sparrow, D.B., Kremmer, E., Dunwoodie, S.L., 2011. Notch inhibition by the ligand 
Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal 
dysostosis. Hum. Mol. Genet. 20, 905–916. https://doi.org/10.1093/hmg/ddq529 
Chastagner, P., Israël, A., Brou, C., 2008. AIP4/Itch Regulates Notch Receptor Degradation in the 
Absence of Ligand. PLoS One 3, e2735. https://doi.org/10.1371/journal.pone.0002735 
Chen, H., Fre, S., Slepnev, V.I., Capua, M.R., Takei, K., Butler, M.H., Di Fiore, P.P., De Camilli, 
P., 1998. Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis. 
Nature 394, 793–797. https://doi.org/10.1038/29555 
Chen, H., Ko, G., Zatti, A., Di Giacomo, G., Liu, L., Raiteri, E., Perucco, E., Collesi, C., Min, W., 
Zeiss, C., De Camilli, P., Cremona, O., 2009. Embryonic arrest at midgestation and 
disruption of Notch signaling produced by the absence of both epsin 1 and epsin 2 in mice. 
Proc. Natl. Acad. Sci. U. S. A. 106, 13838–43. https://doi.org/10.1073/pnas.0907008106 
Chen, J., Zhang, M., 2013. The Par3/Par6/aPKC complex and epithelial cell polarity. Exp. Cell 
Res. 319, 1357–1364. https://doi.org/10.1016/j.yexcr.2013.03.021 
Cheng, F., Shen, Y., Mohanasundaram, P., Lindström, M., Ivaska, J., Ny, T., Eriksson, J.E., 2016. 
Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound 
healing via TGF-β–Slug signaling. Proc. Natl. Acad. Sci. 113, E4320–E4327. https://doi.org/ 
10.1073/pnas.1519197113 
Chillakuri, C.R., Sheppard, D., Lea, S.M., Handford, P.A., 2012. Notch receptor–ligand binding 
and activation: Insights from molecular studies. Semin. Cell Dev. Biol. 23, 421–428. 
https://doi.org/10.1016/j.semcdb.2012.01.009 
Chitnis, A., 2009. Notch Pathway: Lateral Inhibition. Encycl. Neurosci. 1249–1257. 
https://doi.org/10.1016/B978-008045046-9.01027-5 
Chowdhury, F., Li, I.T.S., Ngo, T.T.M., Leslie, B.J., Kim, B.C., Sokoloski, J.E., Weiland, E., 
Wang, X., Chemla, Y.R., Lohman, T.M., Ha, T., 2016. Defining Single Molecular Forces 
Required for Notch Activation Using Nano Yoyo. Nano Lett. 16, 3892–7. 
https://doi.org/10.1021/acs.nanolett.6b01403 
Cohen, I., Silberstein, E., Perez, Y., Landau, D., Elbedour, K., Langer, Y., Kadir, R., Volodarsky, 
M., Sivan, S., Narkis, G., Birk, O.S., 2014. Autosomal recessive Adams-Oliver syndrome 
caused by homozygous mutation in EOGT, encoding an EGF domain-specific O-GlcNAc 
transferase. Eur. J. Hum. Genet. 22, 374–378. https://doi.org/10.1038/ejhg.2013.159 
REFERENCES 
 69 
Colucci-Guyon, E., Giménez Y Ribotta, M., Maurice, T., Babinet, C., Privat, A., 1999. Cerebellar 
defect and impaired motor coordination in mice lacking vimentin. Glia 25, 33–43. 
Colucci-Guyon, E., Portier, M.-M., Dunia, I., Paulin, D., Pournin, S., Babinet, C., 1994. Mice 
lacking vimentin develop and reproduce without an obvious phenotype. Cell 79, 679–694. 
https://doi.org/10.1016/0092-8674(94)90553-3 
Conner, S.D., 2016. Regulation of Notch Signaling Through Intracellular Transport. Int. Rev. Cell 
Mol. Biol. 323, 107–127. https://doi.org/10.1016/BS.IRCMB.2015.12.002 
Couturier, L., Schweisguth, F., 2014. Antibody Uptake Assay and In Vivo Imaging to Study 
Intracellular Trafficking of Notch and Delta in Drosophila, in: Methods in Molecular Biology 
(Clifton, N.J.). pp. 79–86. https://doi.org/10.1007/978-1-4939-1139-4_6 
Cui, D., Dai, J., Keller, J.M., Mizokami, A., Xia, S., Keller, E.T., 2015. Notch Pathway Inhibition 
Using PF-03084014, a  -Secretase Inhibitor (GSI), Enhances the Antitumor Effect of 
Docetaxel in Prostate Cancer. Clin. Cancer Res. 21, 4619–4629. https://doi.org/10.1158/ 
1078-0432.CCR-15-0242 
D’Souza, B., Miyamoto, A., Weinmaster, G., 2008. The many facets of Notch ligands. Oncogene 
27, 5148–5167. https://doi.org/10.1038/onc.2008.229 
Dave, J.M., Bayless, K.J., 2014. Vimentin as an Integral Regulator of Cell Adhesion and 
Endothelial Sprouting. Microcirculation 21, 333–344. https://doi.org/10.1111/micc.12111 
del Álamo, D., Rouault, H., Schweisguth, F., 2011. Mechanism and Significance of cis-Inhibition 
in Notch Signalling. Curr. Biol. 21, R40–R47. https://doi.org/10.1016/j.cub.2010.10.034 
Dexter, J.S., 1914. The Analysis of a Case of Continuous Variation in Drosophila by a Study of Its 
Linkage Relations. Am. Nat. https://doi.org/10.2307/2455888 
Dhanasekaran, S.M., Dash, A., Yu, J., Maine, I.P., Laxman, B., Tomlins, S.A., Creighton, C.J., 
Menon, A., Rubin, M.A., Chinnaiyan, A.M., 2005. Molecular profiling of human prostate 
tissues: Insights into gene expression patterns of prostate development during puberty. 
FASEB J. 19, 243–245. https://doi.org/10.1096/fj.04-2415fje 
Di Fiore, P.P., von Zastrow, M., 2014. Endocytosis, signaling, and beyond. Cold Spring Harb. 
Perspect. Biol. 6. https://doi.org/10.1101/cshperspect.a016865 
Diefenbacher, M.E., Chakraborty, A., Blake, S.M., Mitter, R., Popov, N., Eilers, M., Behrens, A., 
2015. Usp28 counteracts Fbw7 in intestinal homeostasis and cancer. Cancer Res. 75, 1181–6. 
https://doi.org/10.1158/0008-5472.CAN-14-1726 
Doherty, G.J., McMahon, H.T., 2009. Mechanisms of Endocytosis. Annu. Rev. Biochem. 78, 857–
902. https://doi.org/10.1146/annurev.biochem.78.081307.110540 
dos Santos, G., Rogel, M.R., Baker, M.A., Troken, J.R., Urich, D., Morales-Nebreda, L., Sennello, 
J.A., Kutuzov, M.A., Sitikov, A., Davis, J.M., Lam, A.P., Cheresh, P., Kamp, D., Shumaker, 
D.K., Budinger, G.R.S., Ridge, K.M., 2015. Vimentin regulates activation of the NLRP3 
inflammasome. Nat. Commun. 6, 6574. https://doi.org/10.1038/ncomms7574 
Dowling, C.M., Phelan, J., Callender, J.A., Cathcart, M.C., Mehigan, B., McCormick, P., Dalton, 
T., Coffey, J.C., Newton, A.C., O’Sullivan, J., Kiely, P.A., 2016. Protein kinase C beta II 
suppresses colorectal cancer by regulating IGF-1 mediated cell survival. Oncotarget 7, 
20919–33. https://doi.org/10.18632/oncotarget.8062 
Duarte, A., Hirashima, M., Benedito, R., Trindade, A., Diniz, P., Bekman, E., Costa, L., Henrique, 
D., Rossant, J., 2004. Dosage-sensitive requirement for mouse Dll4 in artery development. 
Genes Dev. 18, 2474–2478. https://doi.org/10.1101/gad.1239004 
Dumont, D.J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., Breitman, M., 
Alitalo, K., 1998. Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3. 
Science (80-. ). 282, 946–949. https://doi.org/10.1126/science.282.5390.946 
REFERENCES 
 70
Dunleavy, J.E.M., O’Bryan, M.K., Stanton, P.G., O’Donnell, L., 2019. The cytoskeleton in 
spermatogenesis. Reproduction. https://doi.org/10.1530/REP-18-0457 
Eiraku, M., Hirata, Y., Takeshima, H., Hirano, T., Kengaku, M., 2002. Delta/notch-like epidermal 
growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to 
dendrites of developing and adult central nervous system neurons. J. Biol. Chem. 277, 
25400–7. https://doi.org/10.1074/jbc.M110793200 
Eisenberg, E., Greene, L.E., 2007. Multiple Roles of Auxilin and Hsc70 in Clathrin-Mediated 
Endocytosis. Traffic 8, 640–646. https://doi.org/10.1111/j.1600-0854.2007.00568.x 
Ellisen, L.W., Bird, J., West, D.C., Soreng, A.L., Reynolds, T.C., Smith, S.D., Sklar, J., 1991. 
TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal 
translocations in T lymphoblastic neoplasms. Cell 66, 649–61. 
Emery, G., Hutterer, A., Berdnik, D., Mayer, B., Wirtz-Peitz, F., Gaitan, M.G., Knoblich, J.A., 
2005. Asymmetric Rab 11 endosomes regulate delta recycling and specify cell fate in the 
Drosophila nervous system. Cell 122, 763–73. https://doi.org/10.1016/j.cell.2005.08.017 
Eriksson, J.E., He, T., Trejo-Skalli, A. V, Härmälä-Braskén, A.-S., Hellman, J., Chou, Y.-H., 
Goldman, R.D., 2004. Specific in vivo phosphorylation sites determine the assembly 
dynamics of vimentin intermediate filaments. J. Cell Sci. 117, 919–932. https://doi.org/ 
10.1242/jcs.00906 
Espinosa, L., Inglés-Esteve, J., Aguilera, C., Bigas, A., 2003. Phosphorylation by Glycogen 
Synthase Kinase-3β Down-regulates Notch Activity, a Link for Notch and Wnt Pathways. J. 
Biol. Chem. 278, 32227–32235. https://doi.org/10.1074/jbc.M304001200 
Estève, P.O., Chicoine, E., Robledo, O., Aoudjit, F., Descoteaux, A., Potworowski, E.F., St-Pierre, 
Y., 2002. Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene 
induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. J. Biol. Chem. 277, 35150–
5. https://doi.org/10.1074/jbc.M108600200 
Etienne-Manneville, S., Hall, A., 2001. Integrin-mediated activation of Cdc42 controls cell 
polarity in migrating astrocytes through PKCζ. Cell 106, 489–498. https://doi.org/10.1016/ 
S0092-8674(01)00471-8 
Evrard, Y.A., Lun, Y., Aulehla, A., Gan, L., Johnson, R.L., 1998. lunatic fringe is an essential 
mediator of somite segmentation and patterning. Nature 394, 377–381. https://doi.org/ 
10.1038/28632 
Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, 
A.C., Mao, Y., Miao, R.Q., Sessa, W.C., Qin, J., Zhang, P., Su, B., Jacinto, E., 2008. The 
mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein 
kinase C. EMBO J. 27, 1932–43. https://doi.org/10.1038/emboj.2008.120 
Falo-Sanjuan, J., Lammers, N.C., Garcia, H.G., Bray, S.J., 2019. Enhancer Priming Enables Fast 
and Sustained Transcriptional Responses to Notch Signaling. Dev. Cell 50, 411-425.e8. 
https://doi.org/10.1016/j.devcel.2019.07.002 
Ferguson, J.P., Huber, S.D., Willy, N.M., Aygün, E., Goker, S., Atabey, T., Kural, C., 2017. 
Mechanoregulation of clathrin-mediated endocytosis. J. Cell Sci. 130, 3631–3636. 
https://doi.org/10.1242/jcs.205930 
Fernandez-Valdivia, R., Takeuchi, H., Samarghandi, A., Lopez, M., Leonardi, J., Haltiwanger, 
R.S., Jafar-Nejad, H., 2011. Regulation of mammalian Notch signaling and embryonic 
development by the protein O-glucosyltransferase Rumi. Development 138, 1925–1934. 
https://doi.org/10.1242/dev.060020 
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K.S., Powell-Braxton, L., 
Hillan, K.J., Moore, M.W., 1996. Heterozygous embryonic lethality induced by targeted 
inactivation of the VEGF gene. Nature 380, 439–442. https://doi.org/10.1038/380439a0 
REFERENCES 
 71 
Ferreira, A.P.A., Boucrot, E., 2018. Mechanisms of Carrier Formation during Clathrin-
Independent Endocytosis. Trends Cell Biol. https://doi.org/10.1016/j.tcb.2017.11.004 
Fischer, A., Schumacher, N., Maier, M., Sendtner, M., Gessler, M., 2004. The Notch target genes 
Hey1 and Hey2 are required for embryonic vascular development. Genes Dev. 18, 901–911. 
https://doi.org/10.1101/gad.291004 
Fleming, R.J., Scottgale, T.N., Diederich, R.J., Artavanis-Tsakonas, S., 1990. The gene Serrate 
encodes a putative EGF-like transmembrane protein essential for proper ectodermal 
development in Drosophila melanogaster. Genes Dev. 4, 2188–2201. 
https://doi.org/10.1101/gad.4.12a.2188 
Foltz, D.R., Santiago, M.C., Berechid, B.E., Nye, J.S., 2002. Glycogen synthase kinase-3beta 
modulates notch signaling and stability. Curr. Biol. 12, 1006–11. 
Fortini, M.E., Bilder, D., 2009. Endocytic regulation of Notch signaling. Curr. Opin. Genet. Dev. 
19, 323–8. https://doi.org/10.1016/j.gde.2009.04.005 
Franke, T.F., Tartof, K.D., Tsichlis, P.N., 1994. The SH2-like Akt homology (AH) domain of c-
akt is present in multiple copies in the genome of vertebrate and invertebrate eucaryotes. 
Cloning and characterization of the Drosophila melanogaster c-akt homolog Dakt1. 
Oncogene 9, 141–8. 
Frederick, L.A., Matthews, J.A., Jamieson, L., Justilien, V., Thompson, E.A., Radisky, D.C., 
Fields, A.P., 2008. Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-
Par6alpha-mediated lung cancer. Oncogene 27, 4841–53. https://doi.org/10.1038/ 
onc.2008.119 
Fryer, C.J., White, J.B., Jones, K.A., 2004. Mastermind recruits CycC:CDK8 to phosphorylate the 
Notch ICD and coordinate activation with turnover. Mol. Cell 16, 509–20. 
https://doi.org/10.1016/j.molcel.2004.10.014 
Gale, N.W., Dominguez, M.G., Noguera, I., Pan, L., Hughes, V., Valenzuela, D.M., Murphy, A.J., 
Adams, N.C., Lin, H.C., Holash, J., Thurston, G., Yancopoulos, G.D., 2004. 
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects 
in arterial and vascular development. Proc. Natl. Acad. Sci. U. S. A. 101, 15949–54. 
https://doi.org/10.1073/pnas.0407290101 
Galvez, A.S., Duran, A., Linares, J.F., Pathrose, P., Castilla, E.A., Abu-Baker, S., Leitges, M., 
Diaz-Meco, M.T., Moscat, J., 2009. Protein kinase Czeta represses the interleukin-6 
promoter and impairs tumorigenesis in vivo. Mol. Cell. Biol. 29, 104–15. 
https://doi.org/10.1128/MCB.01294-08 
Garcia, A., Kandel, J.J., 2012. Notch: a key regulator of tumor angiogenesis and metastasis. Histol. 
Histopathol. 27, 151–6. https://doi.org/10.14670/HH-27.151 
Garg, R., Benedetti, L.G., Abera, M.B., Wang, H., Abba, M., Kazanietz, M.G., 2014. Protein 
kinase C and cancer: What we know and what we do not. Oncogene. 
https://doi.org/10.1038/onc.2013.524 
Garg, V., Muth, A.N., Ransom, J.F., Schluterman, M.K., Barnes, R., King, I.N., Grossfeld, P.D., 
Srivastava, D., 2005. Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270–274. 
https://doi.org/10.1038/nature03940 
George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-
Cuesta, L., Bosco, G., Müller, C., Dahmen, I., Jahchan, N.S., Park, K.-S., Yang, D., Karnezis, 
A.N., Vaka, D., Torres, A., Wang, M.S., Korbel, J.O., Menon, R., Chun, S.-M., Kim, D., 
Wilkerson, M., Hayes, N., Engelmann, D., Pützer, B., Bos, M., Michels, S., Vlasic, I., Seidel, 
D., Pinther, B., Schaub, P., Becker, C., Altmüller, J., Yokota, J., Kohno, T., Iwakawa, R., 
Tsuta, K., Noguchi, M., Muley, T., Hoffmann, H., Schnabel, P.A., Petersen, I., Chen, Y., 
Soltermann, A., Tischler, V., Choi, C., Kim, Y.-H., Massion, P.P., Zou, Y., Jovanovic, D., 
Kontic, M., Wright, G.M., Russell, P.A., Solomon, B., Koch, I., Lindner, M., Muscarella, 
REFERENCES 
 72
L.A., la Torre, A., Field, J.K., Jakopovic, M., Knezevic, J., Castaños-Vélez, E., Roz, L., 
Pastorino, U., Brustugun, O.-T., Lund-Iversen, M., Thunnissen, E., Köhler, J., Schuler, M., 
Botling, J., Sandelin, M., Sanchez-Cespedes, M., Salvesen, H.B., Achter, V., Lang, U., 
Bogus, M., Schneider, P.M., Zander, T., Ansén, S., Hallek, M., Wolf, J., Vingron, M., 
Yatabe, Y., Travis, W.D., Nürnberg, P., Reinhardt, C., Perner, S., Heukamp, L., Büttner, R., 
Haas, S.A., Brambilla, E., Peifer, M., Sage, J., Thomas, R.K., 2015. Comprehensive genomic 
profiles of small cell lung cancer. Nature 524, 47–53. https://doi.org/10.1038/nature14664 
Georgiou, M., Marinari, E., Burden, J., Baum, B., 2008. Cdc42, Par6, and aPKC Regulate Arp2/3-
Mediated Endocytosis to Control Local Adherens Junction Stability. Curr. Biol. 18, 1631–
1638. https://doi.org/10.1016/j.cub.2008.09.029 
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., 
Mitchell, C., Alitalo, K., Shima, D., Betsholtz, C., 2003. VEGF guides angiogenic sprouting 
utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163–1177. https://doi.org/10.1083/ 
jcb.200302047 
Gilbert, C.A., Daou, M.-C., Moser, R.P., Ross, A.H., 2010. Gamma-secretase inhibitors enhance 
temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and 
xenograft recurrence. Cancer Res. 70, 6870–9. https://doi.org/10.1158/0008-5472.CAN-10-
1378 
Glomski, K., Monette, S., Manova, K., De Strooper, B., Saftig, P., Blobel, C.P., 2011. Deletion of 
Adam10 in endothelial cells leads to defects in organ-specific vascular structures. Blood 118, 
1163–74. https://doi.org/10.1182/blood-2011-04-348557 
Gomez-Lamarca, M.J., Falo-Sanjuan, J., Stojnic, R., Abdul Rehman, S., Muresan, L., Jones, M.L., 
Pillidge, Z., Cerda-Moya, G., Yuan, Z., Baloul, S., Valenti, P., Bystricky, K., Payre, F., 
O’Holleran, K., Kovall, R., Bray, S.J., 2018. Activation of the Notch Signaling Pathway 
In Vivo Elicits Changes in CSL Nuclear Dynamics. Dev. Cell 44, 611-623.e7. 
https://doi.org/10.1016/j.devcel.2018.01.020 
Gordon, W.R., Arnett, K.L., Blacklow, S.C., 2008. The molecular logic of Notch signaling - a 
structural and biochemical perspective. J. Cell Sci. 121, 3109–3119. https://doi.org/10.1242/ 
jcs.035683 
Gordon, W.R., Vardar-Ulu, D., Histen, G., Sanchez-Irizarry, C., Aster, J.C., Blacklow, S.C., 2007. 
Structural basis for autoinhibition of Notch. Nat. Struct. Mol. Biol. 14, 295–300. 
https://doi.org/10.1038/nsmb1227 
Gordon, W.R., Vardar-Ulu, D., L’Heureux, S., Ashworth, T., Malecki, M.J., Sanchez-Irizarry, C., 
McArthur, D.G., Histen, G., Mitchell, J.L., Aster, J.C., Blacklow, S.C., 2009. Effects of S1 
Cleavage on the Structure, Surface Export, and Signaling Activity of Human Notch1 and 
Notch2. PLoS One 4, e6613. https://doi.org/10.1371/journal.pone.0006613 
Gordon, W.R., Zimmerman, B., He, L., Miles, L.J., Huang, J., Tiyanont, K., McArthur, D.G., 
Aster, J.C., Perrimon, N., Loparo, J.J., Blacklow, S.C., 2015. Mechanical Allostery: 
Evidence for a Force Requirement in the Proteolytic Activation of Notch. Dev. Cell 33, 729–
36. https://doi.org/10.1016/j.devcel.2015.05.004 
Grammont, M., 2007. Adherens junction remodeling by the Notch pathway in Drosophila 
melanogaster oogenesis. J. Cell Biol. 177, 139–150. https://doi.org/10.1083/jcb.200609079 
Grant, B.D., Donaldson, J.G., 2009. Pathways and mechanisms of endocytic recycling. Nat. Rev. 
Mol. Cell Biol. 10, 597–608. https://doi.org/10.1038/nrm2755 
Greene, M., Lai, Y., Pajcini, K., Bailis, W., Pear, W.S., Lancaster, E., 2016. Delta/Notch-Like 
EGF-Related Receptor (DNER) Is Not a Notch Ligand. PLoS One 11, e0161157. 
https://doi.org/10.1371/journal.pone.0161157 
Gregor, M., Osmanagic-Myers, S., Burgstaller, G., Wolfram, M., Fischer, I., Walko, G., Resch, 
G.P., Jörgl, A., Herrmann, H., Wiche, G., 2014. Mechanosensing through focal adhesion-
REFERENCES 
 73 
anchored intermediate filaments. FASEB J. 28, 715–729. https://doi.org/10.1096/fj.13-
231829 
Gridley, T., 2010. Notch signaling in the vasculature. Curr. Top. Dev. Biol. 92, 277–309. 
https://doi.org/10.1016/S0070-2153(10)92009-7 
Grosberg, R.K., Strathmann, R.R., 2007. The Evolution of Multicellularity: A Minor Major 
Transition? Annu. Rev. Ecol. Evol. Syst. 38, 621–654. https://doi.org/10.1146/ 
annurev.ecolsys.36.102403.114735 
Gruenbaum, Y., Aebi, U., 2014. Intermediate filaments: a dynamic network that controls cell 
mechanics. F1000Prime Rep. 6, 54. https://doi.org/10.12703/P6-54 
Gupta-Rossi, N., Six, E., LeBail, O., Logeat, F., Chastagner, P., Olry, A., Israël, A., Brou, C., 2004. 
Monoubiquitination and endocytosis direct gamma-secretase cleavage of activated Notch 
receptor. J. Cell Biol. 166, 73–83. https://doi.org/10.1083/jcb.200310098 
Hanlon, L., Avila, J.L., Demarest, R.M., Troutman, S., Allen, M., Ratti, F., Rustgi, A.K., Stanger, 
B.Z., Radtke, F., Adsay, V., Long, F., Capobianco, A.J., Kissil, J.L., 2010. Notch1 functions 
as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer 
Res. 70, 4280–6. https://doi.org/10.1158/0008-5472.CAN-09-4645 
Hansra, G., Garcia-Paramio, P., Prevostel, C., Whelan, R.D., Bornancin, F., Parker, P.J., 1999. 
Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes. 
Biochem. J. 342 ( Pt 2), 337–44. 
Hansson, E.M., Lanner, F., Das, D., Mutvei, A., Marklund, U., Ericson, J., Farnebo, F., Stumm, G., 
Stenmark, H., Andersson, E.R., Lendahl, U., 2010. Control of Notch-ligand endocytosis by 
ligand-receptor interaction. J. Cell Sci. 123, 2931–2942. https://doi.org/10.1242/jcs.073239 
Hapak, S.M., Rothlin, C. V, Ghosh, S., 2018. PAR3-PAR6-atypical PKC polarity complex 
proteins in neuronal polarization. Cell. Mol. Life Sci. 75, 2735–2761. 
https://doi.org/10.1007/s00018-018-2828-6 
Harvey, B.M., Haltiwanger, R.S., 2018. Regulation of Notch Function by O-Glycosylation, in: 
Advances in Experimental Medicine and Biology. pp. 59–78. https://doi.org/10.1007/978-3-
319-89512-3_4 
Hasan, S.S., Tsaryk, R., Lange, M., Wisniewski, L., Moore, J.C., Lawson, N.D., Wojciechowska, 
K., Schnittler, H., Siekmann, A.F., 2017. Endothelial Notch signalling limits angiogenesis 
via control of artery formation. Nat. Cell Biol. 19, 928–940. https://doi.org/10.1038/ncb3574 
Hatakeyama, J., Wakamatsu, Y., Nagafuchi, A., Kageyama, R., Shigemoto, R., Shimamura, K., 
2014. Cadherin-based adhesions in the apical endfoot are required for active Notch signaling 
to control neurogenesis in vertebrates. Development 141, 1671–1682. 
https://doi.org/10.1242/dev.102988 
Hellström, M., Phng, L.-K., Hofmann, J.J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., 
Nilsson, A.-K., Karlsson, L., Gaiano, N., Yoon, K., Rossant, J., Iruela-Arispe, M.L., Kalén, 
M., Gerhardt, H., Betsholtz, C., 2007. Dll4 signalling through Notch1 regulates formation of 
tip cells during angiogenesis. Nature 445, 776–780. https://doi.org/10.1038/nature05571 
Henkel, T., Ling, P.D., Hayward, S.D., Peterson, M.G., 1994. Mediation of Epstein-Barr virus 
EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265, 92–5. 
Henrique, D., Schweisguth, F., 2019. Mechanisms of Notch signaling: a simple logic deployed in 
time and space. Development 146, dev172148. https://doi.org/10.1242/dev.172148 
Herreman, A., Hartmann, D., Annaert, W., Saftig, P., Craessaerts, K., Serneels, L., Umans, L., 
Schrijvers, V., Checler, F., Vanderstichele, H., Baekelandt, V., Dressel, R., Cupers, P., 
Huylebroeck, D., Zwijsen, A., Leuven, F. Van, Strooper, B. De, 1999. Presenilin 2 
deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein 
REFERENCES 
 74
processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc. 
Natl. Acad. Sci. U. S. A. 96, 11872. https://doi.org/10.1073/PNAS.96.21.11872 
Herrmann, H., Aebi, U., 2016. Intermediate Filaments: Structure and Assembly. Cold Spring Harb. 
Perspect. Biol. 8, a018242. https://doi.org/10.1101/cshperspect.a018242 
Heuss, S.F., Ndiaye-Lobry, D., Six, E.M., Israël, A., Logeat, F., 2008. The intracellular region of 
Notch ligands Dll1 and Dll3 regulates their trafficking and signaling activity. Proc. Natl. 
Acad. Sci. U. S. A. 105, 11212–7. https://doi.org/10.1073/pnas.0800695105 
High, F.A., Lu, M.M., Pear, W.S., Loomes, K.M., Kaestner, K.H., Epstein, J.A., 2008. Endothelial 
expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. 
Proc. Natl. Acad. Sci. U. S. A. 105, 1955–9. https://doi.org/10.1073/pnas.0709663105 
Hofmann, J.J., Iruela-Arispe, M.L., 2007. Notch Signaling in Blood Vessels. Circ. Res. 100, 1556–
1568. https://doi.org/10.1161/01.RES.0000266408.42939.e4 
Hoglund, V.J., Majesky, M.W., 2012. Patterning the Artery Wall by Lateral Induction of Notch 
Signaling. Circulation 125, 212–215. https://doi.org/10.1161/CIRCULATION-
AHA.111.075937 
Holmberg, J., Hansson, E., Malewicz, M., Sandberg, M., Perlmann, T., Lendahl, U., Muhr, J., 
2008. SoxB1 transcription factors and Notch signaling use distinct mechanisms to regulate 
proneural gene function and neural progenitor differentiation. Development 135, 1843–1851. 
https://doi.org/10.1242/dev.020180 
Hori, K., Cholewa-Waclaw, J., Nakada, Y., Glasgow, S.M., Masui, T., Henke, R.M., Wildner, H., 
Martarelli, B., Beres, T.M., Epstein, J.A., Magnuson, M.A., Macdonald, R.J., Birchmeier, C., 
Johnson, J.E., 2008. A nonclassical bHLH Rbpj transcription factor complex is required for 
specification of GABAergic neurons independent of Notch signaling. Genes Dev. 22, 166–78. 
https://doi.org/10.1101/gad.1628008 
Hori, K., Sen, A., Kirchhausen, T., Artavanis-Tsakonas, S., 2011. Synergy between the ESCRT-III 
complex and Deltex defines a ligand-independent Notch signal. J. Cell Biol. 195, 1005–1015. 
https://doi.org/10.1083/jcb.201104146 
Horvath, C.A.J., Vanden Broeck, D., Boulet, G.A.V., Bogers, J., De Wolf, M.J.S., 2007. Epsin: 
Inducing membrane curvature. Int. J. Biochem. Cell Biol. 39, 1765–1770. 
https://doi.org/10.1016/j.biocel.2006.12.004 
Hukriede, N.A., Gu, Y., Fleming, R.J., 1997. A dominant-negative form of Serrate acts as a 
general antagonist of Notch activation. Development 124, 3427–37. 
Hunter, G.L., He, L., Perrimon, N., Charras, G., Giniger, E., Baum, B., 2019. A role for 
actomyosin contractility in Notch signaling. BMC Biol. 17, 12. https://doi.org/10.1186/ 
s12915-019-0625-9 
Hurov, J.B., Stappenbeck, T.S., Zmasek, C.M., White, L.S., Ranganath, S.H., Russell, J.H., Chan, 
A.C., Murphy, K.M., Piwnica-Worms, H., 2001. Immune system dysfunction and 
autoimmune disease in mice lacking Emk (Par-1) protein kinase. Mol. Cell. Biol. 21, 3206–
19. https://doi.org/10.1128/MCB.21.9.3206-3219.2001 
Imai, Y., Kobayashi, Y., Inoshita, T., Meng, H., Arano, T., Uemura, K., Asano, T., Yoshimi, K., 
Zhang, C.L., Matsumoto, G., Ohtsuka, T., Kageyama, R., Kiyonari, H., Shioi, G., Nukina, N., 
Hattori, N., Takahashi, R., 2015. The Parkinson’s Disease-Associated Protein Kinase 
LRRK2 Modulates Notch Signaling through the Endosomal Pathway. PLoS Genet. 
https://doi.org/10.1371/journal.pgen.1005503 
Irvine, K.D., Wieschaus, E., 1994. Cell intercalation during Drosophila germband extension and 
its regulation by pair-rule segmentation genes. Development 120, 827–41. 
Ishitani, T., Hirao, T., Suzuki, M., Isoda, M., Ishitani, S., Harigaya, K., Kitagawa, M., Matsumoto, 
K., Itoh, M., 2010. Nemo-like kinase suppresses Notch signalling by interfering with 
REFERENCES 
 75 
formation of the Notch active transcriptional complex. Nat. Cell Biol. 12, 278–285. 
https://doi.org/10.1038/ncb2028 
Itoh, M., Kim, C.-H., Palardy, G., Oda, T., Jiang, Y.-J., Maust, D., Yeo, S.-Y., Lorick, K., Wright, 
G.J., Ariza-McNaughton, L., Weissman, A.M., Lewis, J., Chandrasekharappa, S.C., Chitnis, 
A.B., 2003. Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch 
signaling by Delta. Dev. Cell 4, 67–82. 
Ivaska, J., 2011. Vimentin: Central hub in EMT induction? Small GTPases 2, 51–53. 
https://doi.org/10.4161/sgtp.2.1.15114 
Ivaska, J., Pallari, H.-M., Nevo, J., Eriksson, J.E., 2007. Novel functions of vimentin in cell 
adhesion, migration, and signaling. Exp. Cell Res. 313, 2050–2062. 
https://doi.org/10.1016/j.yexcr.2007.03.040 
Ivaska, J., Vuoriluoto, K., Huovinen, T., Izawa, I., Inagaki, M., Parker, P.J., 2005. PKCɛ-mediated 
phosphorylation of vimentin controls integrin recycling and motility. EMBO J. 24, 3834–
3845. https://doi.org/10.1038/sj.emboj.7600847 
Jacob, J.T., Coulombe, P.A., Kwan, R., Omary, M.B., 2018. Types I and II Keratin Intermediate 
Filaments. Cold Spring Harb. Perspect. Biol. 10, a018275. https://doi.org/10.1101/ 
cshperspect.a018275 
Jacobsen, T.L., Brennan, K., Arias, A.M., Muskavitch, M.A., 1998. Cis-interactions between Delta 
and Notch modulate neurogenic signalling in Drosophila. Development 125, 4531–40. 
Jafar-Nejad, H., Andrews, H.K., Acar, M., Bayat, V., Wirtz-Peitz, F., Mehta, S.Q., Knoblich, J.A., 
Bellen, H.J., 2005. Sec15, a component of the exocyst, promotes notch signaling during the 
asymmetric division of Drosophila sensory organ precursors. Dev. Cell 9, 351–63. 
https://doi.org/10.1016/j.devcel.2005.06.010 
Jaken, S., Tashjian, A.H., Blumberg, P.M., 1981. Characterization of phorbol ester receptors and 
their down-modulation in GH4C1 rat pituitary cells. Cancer Res. 41, 2175–81. 
Jehn, B.M., Dittert, I., Beyer, S., von der Mark, K., Bielke, W., 2002. c-Cbl binding and ubiquitin-
dependent lysosomal degradation of membrane-associated Notch1. J. Biol. Chem. 277, 
8033–40. https://doi.org/10.1074/jbc.M108552200 
Jin, S., Mutvei, A.P., Chivukula, I. V, Andersson, E.R., Ramsköld, D., Sandberg, R., Lee, K.L., 
Kronqvist, P., Mamaeva, V., Ostling, P., Mpindi, J.-P., Kallioniemi, O., Screpanti, I., 
Poellinger, L., Sahlgren, C., Lendahl, U., 2013. Non-canonical Notch signaling activates IL-
6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ. 
Oncogene 32, 4892–902. https://doi.org/10.1038/onc.2012.517 
Jin, Y.H., Kim, H., Oh, M., Ki, H., Kim, K., 2009. Regulation of Notch1/NICD and Hes1 
expressions by GSK-3α/β. Mol. Cells 27, 15–19. https://doi.org/10.1007/s10059-009-0001-7 
Johnson, S.A., Zitserman, D., Roegiers, F., 2016. Numb regulates the balance between Notch 
recycling and late-endosome targeting in Drosophila neural progenitor cells. Mol. Biol. Cell 
27, 2857. https://doi.org/10.1091/MBC.E15-11-0751 
Jovic, M., Sharma, M., Rahajeng, J., Caplan, S., 2010. The early endosome: a busy sorting station 
for proteins at the crossroads. Histol. Histopathol. 25, 99–112. https://doi.org/10.14670/HH-
25.99 
Justilien, V., Walsh, M.P., Ali, S.A., Thompson, E.A., Murray, N.R., Fields, A.P., 2014. The 
PRKCI and SOX2 Oncogenes Are Coamplified and Cooperate to Activate Hedgehog 
Signaling in Lung Squamous Cell Carcinoma. Cancer Cell 25, 139–151. 
https://doi.org/10.1016/j.ccr.2014.01.008 
Kakuda, S., Haltiwanger, R.S., 2017. Deciphering the Fringe-Mediated Notch Code: Identification 
of Activating and Inhibiting Sites Allowing Discrimination between Ligands. Dev. Cell 40, 
193–201. https://doi.org/10.1016/j.devcel.2016.12.013 
REFERENCES 
 76
Kamstrup, M.R., Biskup, E., Manfè, V., Savorani, C., Liszewski, W., Wirèn, J., Specht, L., 
Gniadecki, R., 2017. Chemotherapeutic treatment is associated with Notch1 induction in 
cutaneous T-cell lymphoma. Leuk. Lymphoma 58, 171–178. https://doi.org/10.1080/ 
10428194.2016.1180681 
Kangsamaksin, T., Murtomaki, A., Kofler, N.M., Cuervo, H., Chaudhri, R.A., Tattersall, I.W., 
Rosenstiel, P.E., Shawber, C.J., Kitajewski, J., 2015. NOTCH Decoys That Selectively Block 
DLL/NOTCH or JAG/NOTCH Disrupt Angiogenesis by Unique Mechanisms to Inhibit 
Tumor Growth. Cancer Discov. 5, 182–197. https://doi.org/10.1158/2159-8290.CD-14-0650 
Kershaw, N.J., Church, N.L., Griffin, M.D.W., Luo, C.S., Adams, T.E., Burgess, A.W., 2015. 
Notch ligand delta-like1: X-ray crystal structure and binding affinity. Biochem. J. 468, 159–
166. https://doi.org/10.1042/BJ20150010 
Kerstjens-Frederikse, W.S., van de Laar, I.M.B.H., Vos, Y.J., Verhagen, J.M.A., Berger, R.M.F., 
Lichtenbelt, K.D., Klein Wassink-Ruiter, J.S., van der Zwaag, P.A., du Marchie Sarvaas, G.J., 
Bergman, K.A., Bilardo, C.M., Roos-Hesselink, J.W., Janssen, J.H.P., Frohn-Mulder, I.M., 
van Spaendonck-Zwarts, K.Y., van Melle, J.P., Hofstra, R.M.W., Wessels, M.W., 2016. 
Cardiovascular malformations caused by NOTCH1 mutations do not keep left: data on 428 
probands with left-sided CHD and their families. Genet. Med. 18, 914–923. 
https://doi.org/10.1038/gim.2015.193 
Kidd, M.E., Shumaker, D.K., Ridge, K.M., 2014. The role of Vimentin intermediate filaments in 
the progression of lung cancer. Am. J. Respir. Cell Mol. Biol. https://doi.org/ 
10.1165/rcmb.2013-0314TR 
Kidd, S., Baylies, M.K., Gasic, G.P., Young, M.W., 1989. Structure and distribution of the Notch 
protein in developing Drosophila. Genes Dev. 3, 1113–29. https://doi.org/ 
10.1101/GAD.3.8.1113 
Kidd, S., Lockett, T.J., Young, M.W., 1983. The Notch locus of Drosophila melanogaster. Cell 34, 
421–433. https://doi.org/10.1016/0092-8674(83)90376-8 
Kiernan, A.E., 2013. Notch signaling during cell fate determination in the inner ear. Semin. Cell 
Dev. Biol. 24, 470–479. https://doi.org/10.1016/J.SEMCDB.2013.04.002 
Kim, B., Stephen, S.L., Hanby, A.M., Horgan, K., Perry, S.L., Richardson, J., Roundhill, E.A., 
Valleley, E.M.A., Verghese, E.T., Williams, B.J., Thorne, J.L., Hughes, T.A., 2015. 
Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which 
sensitizes breast cancer cells to chemotherapy. BMC Cancer 15, 634. 
https://doi.org/10.1186/s12885-015-1625-y 
Kim, J., Yang, C., Kim, E.J., Jang, J., Kim, S.-J., Kang, S.M., Kim, M.G., Jung, H., Park, D., Kim, 
C., 2016. Vimentin filaments regulate integrin–ligand interactions by binding to the 
cytoplasmic tail of integrin β3. J. Cell Sci. 129, 2030–2042. https://doi.org/10.1242/ 
jcs.180315 
Kim, S., Coulombe, P.A., 2007. Intermediate filament scaffolds fulfill mechanical, organizational, 
and signaling functions in the cytoplasm. Genes Dev. 21, 1581–97. https://doi.org/ 
10.1101/gad.1552107 
Koenig, S.N., LaHaye, S., Feller, J.D., Rowland, P., Hor, K.N., Trask, A.J., Janssen, P.M.L., 
Radtke, F., Lilly, B., Garg, V., 2017. Notch1 haploinsufficiency causes ascending aortic 
aneurysms in mice. JCI Insight 2. https://doi.org/10.1172/jci.insight.91353 
Kofler, N.M., Shawber, C.J., Kangsamaksin, T., Reed, H.O., Galatioto, J., Kitajewski, J., 2011. 
Notch signaling in developmental and tumor angiogenesis. Genes Cancer 2, 1106–16. 
https://doi.org/10.1177/1947601911423030 
Kolte, D., 2016. Vasculogenesis and Angiogenesis. Transl. Res. Coron. Artery Dis. 49–65. 
https://doi.org/10.1016/B978-0-12-802385-3.00006-1 
REFERENCES 
 77 
Komander, D., Rape, M., 2012. The Ubiquitin Code. Annu. Rev. Biochem. 81, 203–229. 
https://doi.org/10.1146/annurev-biochem-060310-170328 
Koo, B.-K., Lim, H.-S., Song, R., Yoon, M.-J., Yoon, K.-J., Moon, J.-S., Kim, Y.-W., Kwon, M.-
C., Yoo, K.-W., Kong, M.-P., Lee, J., Chitnis, A.B., Kim, C.-H., Kong, Y.-Y., 2005. Mind 
bomb 1 is essential for generating functional Notch ligands to activate Notch. Development 
132, 3459–3470. https://doi.org/10.1242/dev.01922 
Koo, Bon-Kyoung, Yoon, K.-J., Yoo, K.-W., Lim, H.-S., Song, R., So, J.-H., Kim, C.-H., Kong, 
Y.-Y., 2005. Mind Bomb-2 Is an E3 Ligase for Notch Ligand. J. Biol. Chem. 280, 22335–
22342. https://doi.org/10.1074/jbc.M501631200 
Koo, B.-K., Yoon, M.-J., Yoon, K.-J., Im, S.-K., Kim, Y.-Y., Kim, C.-H., Suh, P.-G., Jan, Y.N., 
Kong, Y.-Y., 2007. An obligatory role of mind bomb-1 in notch signaling of mammalian 
development. PLoS One 2, e1221. https://doi.org/10.1371/journal.pone.0001221 
Kooh, P.J., Fehon, R.G., Muskavitch, M.A., 1993. Implications of dynamic patterns of Delta and 
Notch expression for cellular interactions during Drosophila development. Development 117, 
493–507. 
Kopan, R., Ilagan, M.X.G., 2009. The Canonical Notch Signaling Pathway: Unfolding the 
Activation Mechanism. Cell 137, 216–233. https://doi.org/10.1016/j.cell.2009.03.045 
Koutelou, E., Sato, S., Tomomori-Sato, C., Florens, L., Swanson, S.K., Washburn, M.P., 
Kokkinaki, M., Conaway, R.C., Conaway, J.W., Moschonas, N.K., 2008. Neuralized-like 1 
(Neurl1) Targeted to the Plasma Membrane by N -Myristoylation Regulates the Notch 
Ligand Jagged1. J. Biol. Chem. 283, 3846–3853. https://doi.org/10.1074/jbc.M706974200 
Kovall, R.A., Gebelein, B., Sprinzak, D., Kopan, R., 2017. The Canonical Notch Signaling 
Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force. Dev. Cell 41, 
228–241. https://doi.org/10.1016/j.devcel.2017.04.001 
Krebs, L.T., Shutter, J.R., Tanigaki, K., Honjo, T., Stark, K.L., Gridley, T., 2004. 
Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway 
mutants. Genes Dev. 18, 2469–2473. https://doi.org/10.1101/gad.1239204 
Krebs, L.T., Starling, C., Chervonsky, A. V., Gridley, T., 2010. Notch1 activation in mice causes 
arteriovenous malformations phenocopied by ephrinB2 and EphB4 mutants. genesis 48, NA-
NA. https://doi.org/10.1002/dvg.20599 
Krebs, L.T., Xue, Y., Norton, C.R., Shutter, J.R., Maguire, M., Sundberg, J.P., Gallahan, D., 
Closson, V., Kitajewski, J., Callahan, R., Smith, G.H., Stark, K.L., Gridley, T., 2000. Notch 
signaling is essential for vascular morphogenesis in mice. Genes Dev. 14, 1343–52. 
Krejcí, A., Bray, S., 2007. Notch activation stimulates transient and selective binding of 
Su(H)/CSL to target enhancers. Genes Dev. 21, 1322–7. https://doi.org/10.1101/gad.424607 
Kwon, C., Cheng, P., King, I.N., Andersen, P., Shenje, L., Nigam, V., Srivastava, D., 2011. Notch 
post-translationally regulates β-catenin protein in stem and progenitor cells. Nat. Cell Biol. 
13, 1244–51. https://doi.org/10.1038/ncb2313 
Ladi, E., Nichols, J.T., Ge, W., Miyamoto, A., Yao, C., Yang, L.-T., Boulter, J., Sun, Y.E., 
Kintner, C., Weinmaster, G., 2005. The divergent DSL ligand Dll3 does not activate Notch 
signaling but cell autonomously attenuates signaling induced by other DSL ligands. J. Cell 
Biol. 170, 983–92. https://doi.org/10.1083/jcb.200503113 
LaFoya, B., Munroe, J.A., Pu, X., Albig, A.R., 2018. Src kinase phosphorylates Notch1 to inhibit 
MAML binding. Sci. Rep. 8, 15515. https://doi.org/10.1038/s41598-018-33920-y 
Lähdeniemi, I.A.K., Misiorek, J.O., Antila, C.J.M., Landor, S.K.-J., Stenvall, C.-G.A., Fortelius, 
L.E., Bergström, L.K., Sahlgren, C., Toivola, D.M., 2017. Keratins regulate colonic 
epithelial cell differentiation through the Notch1 signalling pathway. Cell Death Differ. 24, 
984–996. https://doi.org/10.1038/cdd.2017.28 
REFERENCES 
 78
Lai, E.C., Deblandre, G.A., Kintner, C., Rubin, G.M., 2001. Drosophila neuralized is a ubiquitin 
ligase that promotes the internalization and degradation of delta. Dev. Cell 1, 783–94. 
Lai, E.C., Roegiers, F., Qin, X., Jan, Y.N., Rubin, G.M., 2005. The ubiquitin ligase Drosophila 
Mind bomb promotes Notch signaling by regulating the localization and activity of Serrate 
and Delta. Development 132, 2319–2332. https://doi.org/10.1242/dev.01825 
Langridge, P.D., Struhl, G., 2017. Epsin-Dependent Ligand Endocytosis Activates Notch by Force. 
Cell 171, 1383-1396.e12. https://doi.org/10.1016/j.cell.2017.10.048 
Larson Gedman, A., Chen, Q., Kugel Desmoulin, S., Ge, Y., LaFiura, K., Haska, C.L., Cherian, C., 
Devidas, M., Linda, S.B., Taub, J.W., Matherly, L.H., 2009. The impact of NOTCH1, FBW7 
and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute 
lymphoblastic leukemia: a report from the Children’s Oncology Group. Leukemia 23, 1417–
1425. https://doi.org/10.1038/leu.2009.64 
Le Borgne, R., Remaud, S., Hamel, S., Schweisguth, F., 2005. Two distinct E3 ubiquitin ligases 
have complementary functions in the regulation of delta and serrate signaling in Drosophila. 
PLoS Biol. 3, e96. https://doi.org/10.1371/journal.pbio.0030096 
Le Borgne, R., Schweisguth, F., 2003. Unequal segregation of Neuralized biases Notch activation 
during asymmetric cell division. Dev. Cell 5, 139–48. https://doi.org/10.1016/s1534-
5807(03)00187-4 
Le Bras, S., Loyer, N., Le Borgne, R., 2011. The Multiple Facets of Ubiquitination in the 
Regulation of Notch Signaling Pathway. Traffic 12, 149–161. https://doi.org/10.1111/j.1600-
0854.2010.01126.x 
Lee, C., Shin, H., Kimble, J., 2019. Dynamics of Notch-Dependent Transcriptional Bursting in Its 
Native Context. Dev. Cell 50, 426-435.e4. https://doi.org/10.1016/j.devcel.2019.07.001 
Lee, H.J., Kim, M.Y., Park, H.S., 2015. Phosphorylation-dependent regulation of Notch1 
signaling: The fulcrum of Notch1 signaling. BMB Rep. 48, 431–437. https://doi.org/ 
10.5483/BMBRep.2015.48.8.107 
Lee, K.-S., Wu, Z., Song, Y., Mitra, S.S., Feroze, A.H., Cheshier, S.H., Lu, B., 2013. Roles of 
PINK1, mTORC2, and mitochondria in preserving brain tumor-forming stem cells in a 
noncanonical Notch signaling pathway. Genes Dev. 27, 2642–7. https://doi.org/10.1101/ 
gad.225169.113 
Lee, W., Andrews, B.C., Faust, M., Walldorf, U., Verheyen, E.M., 2009. Hipk is an essential 
protein that promotes Notch signal transduction in the Drosophila eye by inhibition of the 
global co-repressor Groucho. Dev. Biol. 325, 263–272. https://doi.org/10.1016/ 
j.ydbio.2008.10.029 
Lehmann, R., Jiménez, F., Dietrich, U., Campos-Ortega, J.A., 1983. On the phenotype and 
development of mutants of early neurogenesis inDrosophila melanogaster. Wilhelm Roux’s 
Arch. Dev. Biol. 192, 62–74. https://doi.org/10.1007/BF00848482 
Leibfried, A., Fricke, R., Morgan, M.J., Bogdan, S., Bellaiche, Y., 2008. Drosophila Cip4 and 
WASp Define a Branch of the Cdc42-Par6-aPKC Pathway Regulating E-Cadherin 
Endocytosis. Curr. Biol. 18, 1639–1648. https://doi.org/10.1016/j.cub.2008.09.063 
Lenburg, M.E., Liou, L.S., Gerry, N.P., Frampton, G.M., Cohen, H.T., Christman, M.F., 2003. 
Previously unidentified changes in renal cell carcinoma gene expression identified by 
parametric analysis of microarray data. BMC Cancer 3. https://doi.org/10.1186/1471-2407-3-
31 
Li, J.-L., Sainson, R.C.A., Shi, W., Leek, R., Harrington, L.S., Preusser, M., Biswas, S., Turley, H., 
Heikamp, E., Hainfellner, J.A., Harris, A.L., 2007. Delta-like 4 Notch Ligand Regulates 
Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth In 
vivo. Cancer Res. 67, 11244–11253. https://doi.org/10.1158/0008-5472.CAN-07-0969 
REFERENCES 
 79 
Li, J., Fici, G.J., Mao, C.-A., Myers, R.L., Shuang, R., Donoho, G.P., Pauley, A.M., Himes, C.S., 
Qin, W., Kola, I., Merchant, K.M., Nye, J.S., 2003. Positive and Negative Regulation of the 
γ-Secretase Activity by Nicastrin in a Murine Model. J. Biol. Chem. 278, 33445–33449. 
https://doi.org/10.1074/jbc.M301288200 
Li, M., Cheng, R., Liang, J., Yan, H., Zhang, H., Yang, L., Li, Chengrang, Jiao, Q., Lu, Z., He, J., 
Ji, J., Shen, Z., Li, Chunqi, Hao, F., Yu, H., Yao, Z., 2013. Mutations in POFUT1, encoding 
protein O-fucosyltransferase 1, cause generalized Dowling-Degos disease. Am. J. Hum. 
Genet. 92, 895–903. https://doi.org/10.1016/j.ajhg.2013.04.022 
Li, N., Fassl, A., Chick, J., Inuzuka, H., Li, X., Mansour, M.R., Liu, L., Wang, H., King, B., Shaik, 
S., Gutierrez, A., Ordureau, A., Otto, T., Kreslavsky, T., Baitsch, L., Bury, L., Meyer, C.A., 
Ke, N., Mulry, K.A., Kluk, M.J., Roy, M., Kim, S., Zhang, X., Geng, Y., Zagozdzon, A., 
Jenkinson, S., Gale, R.E., Linch, D.C., Zhao, J.J., Mullighan, C.G., Harper, J.W., Aster, J.C., 
Aifantis, I., von Boehmer, H., Gygi, S.P., Wei, W., Look, A.T., Sicinski, P., 2014. Cyclin C 
is a haploinsufficient tumour suppressor. Nat. Cell Biol. 16, 1080–1091. 
https://doi.org/10.1038/ncb3046 
Li, Z.-L., Chen, C., Yang, Y., Wang, C., Yang, T., Yang, X., Liu, S.-C., 2015. Gamma secretase 
inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells. Int. J. Clin. Exp. Pathol. 
8, 4378–87. 
Lim, R., Sugino, T., Nolte, H., Andrade, J., Zimmermann, B., Shi, C., Doddaballapur, A., Ong, 
Y.T., Wilhelm, K., Fasse, J.W.D., Ernst, A., Kaulich, M., Husnjak, K., Boettger, T., 
Guenther, S., Braun, T., Krüger, M., Benedito, R., Dikic, I., Potente, M., 2019. 
Deubiquitinase USP10 regulates Notch signaling in the endothelium. Science 364, 188–193. 
https://doi.org/10.1126/science.aat0778 
Limbourg, F.P., Takeshita, K., Radtke, F., Bronson, R.T., Chin, M.T., Liao, J.K., 2005. Essential 
role of endothelial Notch1 in angiogenesis. Circulation 111, 1826–32. 
https://doi.org/10.1161/01.CIR.0000160870.93058.DD 
Lin, S.E., Oyama, T., Nagase, T., Harigaya, K., Kitagawa, M., 2002. Identification of new human 
mastermind proteins defines a family that consists of positive regulators for notch signaling. 
J. Biol. Chem. https://doi.org/10.1074/jbc.M209529200 
Lobov, I.B., Renard, R.A., Papadopoulos, N., Gale, N.W., Thurston, G., Yancopoulos, G.D., 
Wiegand, S.J., 2007. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator 
of angiogenic sprouting. Proc. Natl. Acad. Sci. 104, 3219–3224. 
https://doi.org/10.1073/pnas.0611206104 
Louvi, A., Artavanis-Tsakonas, S., 2012. Notch and disease: A growing field. Semin. Cell Dev. 
Biol. 23, 473–480. https://doi.org/10.1016/j.semcdb.2012.02.005 
Louvi, A., Artavanis-Tsakonas, S., 2006. Notch signalling in vertebrate neural development. Nat. 
Rev. Neurosci. 7, 93–102. https://doi.org/10.1038/nrn1847 
Luca, V.C., Jude, K.M., Pierce, N.W., Nachury, M. V., Fischer, S., Garcia, K.C., 2015. Structural 
basis for Notch1 engagement of Delta-like 4. Science (80-. ). 347, 847–853. 
https://doi.org/10.1126/science.1261093 
Luca, V.C., Kim, B.C., Ge, C., Kakuda, S., Wu, D., Roein-Peikar, M., Haltiwanger, R.S., Zhu, C., 
Ha, T., Garcia, K.C., 2017. Notch-Jagged complex structure implicates a catch bond in 
tuning ligand sensitivity. Science (80-. ). 355, 1320–1324. https://doi.org/10.1126/ 
science.aaf9739 
Malecki, M.J., Sanchez-Irizarry, C., Mitchell, J.L., Histen, G., Xu, M.L., Aster, J.C., Blacklow, 
S.C., 2006. Leukemia-associated mutations within the NOTCH1 heterodimerization domain 
fall into at least two distinct mechanistic classes. Mol. Cell. Biol. 26, 4642–51. 
https://doi.org/10.1128/MCB.01655-05 
REFERENCES 
 80
Malyukova, A., Dohda, T., von der Lehr, N., Akhoondi, S., Akhondi, S., Corcoran, M., Heyman, 
M., Spruck, C., Grandér, D., Lendahl, U., Sangfelt, O., 2007. The tumor suppressor gene 
hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional 
consequences for Notch signaling. Cancer Res. 67, 5611–6. https://doi.org/10.1158/0008-
5472.CAN-06-4381 
Manderfield, L.J., High, F.A., Engleka, K.A., Liu, F., Li, L., Rentschler, S., Epstein, J.A., 2012. 
Notch activation of Jagged1 contributes to the assembly of the arterial wall. Circulation 125, 
314–23. https://doi.org/10.1161/CIRCULATIONAHA.111.047159 
Mansour, M.R., Sulis, M.L., Duke, V., Foroni, L., Jenkinson, S., Koo, K., Allen, C.G., Gale, R.E., 
Buck, G., Richards, S., Paietta, E., Rowe, J.M., Tallman, M.S., Goldstone, A.H., Ferrando, 
A.A., Linch, D.C., 2009. Prognostic implications of NOTCH1 and FBXW7 mutations in 
adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG 
E2993 protocol. J. Clin. Oncol. 27, 4352–6. https://doi.org/10.1200/JCO.2009.22.0996 
Martincorena, I., Fowler, J.C., Wabik, A., Lawson, A.R.J., Abascal, F., Hall, M.W.J., Cagan, A., 
Murai, K., Mahbubani, K., Stratton, M.R., Fitzgerald, R.C., Handford, P.A., Campbell, P.J., 
Saeb-Parsy, K., Jones, P.H., 2018. Somatic mutant clones colonize the human esophagus 
with age. Science (80-. ). 362, 911–917. https://doi.org/10.1126/science.aau3879 
Masui, T., Long, Q., Beres, T.M., Magnuson, M.A., MacDonald, R.J., 2007. Early pancreatic 
development requires the vertebrate Suppressor of Hairless (RBPJ) in the PTF1 bHLH 
complex. Genes Dev. 21, 2629–43. https://doi.org/10.1101/gad.1575207 
Matsuno, K., Diederich, R.J., Go, M.J., Blaumueller, C.M., Artavanis-Tsakonas, S., 1995. Deltex 
acts as a positive regulator of Notch signaling through interactions with the Notch ankyrin 
repeats. Development 121, 2633–44. 
McCaffrey, L.M., Macara, I.G., 2009. The Par3/aPKC interaction is essential for end bud 
remodeling and progenitor differentiation during mammary gland morphogenesis. Genes 
Dev. 23, 1450–1460. https://doi.org/10.1101/gad.1795909 
McGill, M.A., Dho, S.E., Weinmaster, G., McGlade, C.J., 2009. Numb Regulates Post-endocytic 
Trafficking and Degradation of Notch1. J. Biol. Chem. 284, 26427–26438. 
https://doi.org/10.1074/jbc.M109.014845 
McMahon, H.T., Boucrot, E., 2011. Molecular mechanism and physiological functions of clathrin-
mediated endocytosis. Nat. Rev. Mol. Cell Biol. 12, 517–533. https://doi.org/10.1038/ 
nrm3151 
Meloty-Kapella, L., Shergill, B., Kuon, J., Botvinick, E., Weinmaster, G., 2012. Notch Ligand 
Endocytosis Generates Mechanical Pulling Force Dependent on Dynamin, Epsins, and Actin. 
Dev. Cell 22, 1299–1312. https://doi.org/10.1016/j.devcel.2012.04.005 
Mendez, M.G., Kojima, S.-I., Goldman, R.D., 2010. Vimentin induces changes in cell shape, 
motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 24, 1838–
1851. https://doi.org/10.1096/fj.09-151639 
Meyer, R.D., Mohammadi, M., Rahimi, N., 2006. A Single Amino Acid Substitution in the 
Activation Loop Defines the Decoy Characteristic of VEGFR-1/FLT-1. J. Biol. Chem. 281, 
867–875. https://doi.org/10.1074/jbc.M506454200 
Miele, L., Golde, T., Osborne, B., 2006. Notch Signaling in Cancer. Curr. Mol. Med. 6, 905–918. 
https://doi.org/10.2174/156652406779010830 
Mo, J.-S., Kim, M.-Y., Han, S.-O., Kim, I.-S., Ann, E.-J., Lee, K.S., Seo, M.-S., Kim, J.-Y., Lee, 
S.-C., Park, J.-W., Choi, E.-J., Seong, J.Y., Joe, C.O., Faessler, R., Park, H.-S., 2007. 
Integrin-Linked Kinase Controls Notch1 Signaling by Down-Regulation of Protein Stability 
through Fbw7 Ubiquitin Ligase. Mol. Cell. Biol. 27, 5565–5574. https://doi.org/ 
10.1128/MCB.02372-06 
REFERENCES 
 81 
Mohr, O.L., 1919. Character Changes Caused by Mutation of an Entire Region of a Chromosome 
in Drosophila. Genetics 4, 275–82. 
Moloney, D.J., Panin, V.M., Johnston, S.H., Chen, J., Shao, L., Wilson, R., Wang, Y., Stanley, P., 
Irvine, K.D., Haltiwanger, R.S., Vogt, T.F., 2000. Fringe is a glycosyltransferase that 
modifies Notch. Nature 406, 369–75. https://doi.org/10.1038/35019000 
Moran, J.L., Levorse, J.M., Vogt, T.F., 1999. Limbs move beyond the Radical fringe. Nature 399, 
742–743. https://doi.org/10.1038/21560 
Moran, J.L., Shifley, E.T., Levorse, J.M., Mani, S., Ostmann, K., Perez-Balaguer, A., Walker, 
D.M., Vogt, T.F., Cole, S.E., 2009. Manic fringe is not required for embryonic development, 
and fringe family members do not exhibit redundant functions in the axial skeleton, limb, or 
hindbrain. Dev. Dyn. 238, 1803–1812. https://doi.org/10.1002/dvdy.21982 
Morel, V., Le Borgne, R., Schweisguth, F., 2003. Snail is required for Delta endocytosis and 
Notch-dependent activation of single-minded expression. Dev. Genes Evol. 213, 65–72. 
https://doi.org/10.1007/s00427-003-0296-x 
Morgan, T.H., 1917. The theory of the gene. Am. Nat. https://doi.org/10.2307/2455888 
Mukherjee, A., Veraksa, A., Bauer, A., Rosse, C., Camonis, J., Artavanis-Tsakonas, S., 2005. 
Regulation of Notch signalling by non-visual β-arrestin. Nat. Cell Biol. 7, 1191–1201. 
https://doi.org/10.1038/ncb1327 
Musse, A.A., Meloty-Kapella, L., Weinmaster, G., 2012. Notch ligand endocytosis: Mechanistic 
basis of signaling activity. Semin. Cell Dev. Biol. 23, 429–436. 
https://doi.org/10.1016/j.semcdb.2012.01.011 
Nandagopal, N., Santat, L.A., Elowitz, M.B., 2019. Cis-activation in the Notch signaling pathway. 
Elife 8. https://doi.org/10.7554/eLife.37880 
Nandagopal, N., Santat, L.A., LeBon, L., Sprinzak, D., Bronner, M.E., Elowitz, M.B., 2018. 
Dynamic Ligand Discrimination in the Notch Signaling Pathway. Cell 172, 869-880.e19. 
https://doi.org/10.1016/j.cell.2018.01.002 
Newton, A.C., 2018. Protein kinase C: perfectly balanced. Crit. Rev. Biochem. Mol. Biol. 53, 
208–230. https://doi.org/10.1080/10409238.2018.1442408 
Nguyen, H.T., Voza, F., Ezzeddine, N., Frasch, M., 2007. Drosophila mind bomb2 is required for 
maintaining muscle integrity and survival. J. Cell Biol. 179, 219–227. 
https://doi.org/10.1083/jcb.200708135 
Nichols, J.T., Miyamoto, A., Olsen, S.L., D’Souza, B., Yao, C., Weinmaster, G., 2007. DSL 
ligand endocytosis physically dissociates Notch1 heterodimers before activating proteolysis 
can occur. J. Cell Biol. 176, 445–458. https://doi.org/10.1083/jcb.200609014 
Nieminen, M., Henttinen, T., Merinen, M., Marttila–Ichihara, F., Eriksson, J.E., Jalkanen, S., 2006. 
Vimentin function in lymphocyte adhesion and transcellular migration. Nat. Cell Biol. 8, 
156–162. https://doi.org/10.1038/ncb1355 
Nishizuka, Y., 1992. Intracellular signaling by hydrolysis of phospholipids and activation of 
protein kinase C. Science 258, 607–14. 
Nofziger, D., Miyamoto, A., Lyons, K.M., Weinmaster, G., 1999. Notch signaling imposes two 
distinct blocks in the differentiation of C2C12 myoblasts. Development 126, 1689–702. 
O’Neil, J., Grim, J., Strack, P., Rao, S., Tibbitts, D., Winter, C., Hardwick, J., Welcker, M., 
Meijerink, J.P., Pieters, R., Draetta, G., Sears, R., Clurman, B.E., Look, A.T., 2007. FBW7 
mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase 
inhibitors. J. Exp. Med. 204, 1813–1824. https://doi.org/10.1084/jem.20070876 
REFERENCES 
 82
Obata, J., Yano, M., Mimura, H., Goto, T., Nakayama, R., Mibu, Y., Oka, C., Kawaichi, M., 2001. 
p48 subunit of mouse PTF1 binds to RBP-Jkappa/CBF-1, the intracellular mediator of Notch 
signalling, and is expressed in the neural tube of early stage embryos. Genes Cells 6, 345–60. 
Okochi, M., Steiner, H., Fukumori, A., Tanii, H., Tomita, T., Tanaka, T., Iwatsubo, T., Kudo, T., 
Takeda, M., Haass, C., 2002. Presenilins mediate a dual intramembranous gamma-secretase 
cleavage of Notch-1. EMBO J. 21, 5408–16. 
Oon, C.E., Bridges, E., Sheldon, H., Sainson, R.C.A., Jubb, A., Turley, H., Leek, R., Buffa, F., 
Harris, A.L., Li, J.-L., Oon, C.E., Bridges, E., Sheldon, H., Sainson, R.C.A., Jubb, A., Turley, 
H., Leek, R., Buffa, F., Harris, A.L., Li, J.-L., 2017. Role of Delta-like 4 in Jagged1-induced 
tumour angiogenesis and tumour growth. Oncotarget 8, 40115–40131. https://doi.org/ 
10.18632/oncotarget.16969 
Osipo, C., Patel, P., Rizzo, P., Clementz, A.G., Hao, L., Golde, T.E., Miele, L., 2008. ErbB-2 
inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. 
Oncogene 27, 5019–32. https://doi.org/10.1038/onc.2008.149 
Ossipova, O., Ezan, J., Sokol, S.Y., 2009. PAR-1 phosphorylates Mind bomb to promote 
vertebrate neurogenesis. Dev. Cell 17, 222–33. https://doi.org/10.1016/j.devcel.2009.06.010 
Overstreet, E., Fitch, E., Fischer, J.A., 2004. Fat facets and Liquid facets promote Delta 
endocytosis and Delta signaling in the signaling cells. Development 131, 5355–66. 
https://doi.org/10.1242/dev.01434 
Päll, T., Pink, A., Kasak, L., Turkina, M., Anderson, W., Valkna, A., Kogerman, P., 2011. Soluble 
CD44 Interacts with Intermediate Filament Protein Vimentin on Endothelial Cell Surface. 
PLoS One 6, e29305. https://doi.org/10.1371/journal.pone.0029305 
Pallari, H.-M., Eriksson, J.E., 2006. Intermediate Filaments as Signaling Platforms. Sci. STKE 
2006, pe53–pe53. https://doi.org/10.1126/stke.3662006pe53 
Palmer, W.H., Jia, D., Deng, W.-M., 2014. Cis-interactions between Notch and its ligands block 
ligand-independent Notch activity. Elife 3. https://doi.org/10.7554/eLife.04415 
Panin, V.M., Papayannopoulos, V., Wilson, R., Irvine, K.D., 1997. Fringe modulates Notch–
ligand interactions. Nature 387, 908–912. https://doi.org/10.1038/43191 
Parker, P.J., Justilien, V., Riou, P., Linch, M., Fields, A.P., 2014. Atypical Protein Kinase Cι as a 
human oncogene and therapeutic target. Biochem. Pharmacol. 88, 1–11. 
https://doi.org/10.1016/j.bcp.2013.10.023 
Parks, A.L., Klueg, K.M., Stout, J.R., Muskavitch, M.A., 2000. Ligand endocytosis drives receptor 
dissociation and activation in the Notch pathway. Development 127, 1373–85. 
Pasternak, S.H., Bagshaw, R.D., Guiral, M., Zhang, S., Ackerley, C.A., Pak, B.J., Callahan, J.W., 
Mahuran, D.J., 2003. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase 
activity are co-localized in the lysosomal membrane. J. Biol. Chem. 278, 26687–94. 
https://doi.org/10.1074/jbc.m304009200 
Pedrosa, A.-R., Trindade, A., Carvalho, C., Graça, J., Carvalho, S., Peleteiro, M.C., Adams, R.H., 
Duarte, A., 2015. Endothelial Jagged1 promotes solid tumor growth through both pro-
angiogenic and angiocrine functions. Oncotarget 6, 24404–23. https://doi.org/10.18632/ 
oncotarget.4380 
Pellinen, T., Rantala, J.K., Arjonen, A., Mpindi, J.-P., Kallioniemi, O., Ivaska, J., 2012. A 
functional genetic screen reveals new regulators of β1-integrin activity. J. Cell Sci. 125, 649–
61. https://doi.org/10.1242/jcs.090704 
Penton, A.L., Leonard, L.D., Spinner, N.B., 2012. Notch signaling in human development and 
disease. Semin. Cell Dev. Biol. 23, 450–457. https://doi.org/10.1016/j.semcdb.2012.01.010 
Perumalsamy, L.R., Nagala, M., Banerjee, P., Sarin, A., 2009. A hierarchical cascade activated by 
non-canonical Notch signaling and the mTOR-Rictor complex regulates neglect-induced 
REFERENCES 
 83 
death in mammalian cells. Cell Death Differ. 16, 879–89. https://doi.org/10.1038/ 
cdd.2009.20 
Petrovic, J., Formosa-Jordan, P., Luna-Escalante, J.C., Abello, G., Ibanes, M., Neves, J., Giraldez, 
F., 2014. Ligand-dependent Notch signaling strength orchestrates lateral induction and lateral 
inhibition in the developing inner ear. Development 141, 2313–2324. https://doi.org/ 
10.1242/dev.108100 
Peuhu, E., Virtakoivu, R., Mai, A., Wärri, A., Ivaska, J., 2017. Epithelial vimentin plays a 
functional role in mammary gland development. Development 144, 4103–4113. 
https://doi.org/10.1242/dev.154229 
Pfeffer, I., Brewitz, L., Krojer, T., Jensen, S.A., Kochan, G.T., Kershaw, N.J., Hewitson, K.S., 
McNeill, L.A., Kramer, H., Münzel, M., Hopkinson, R.J., Oppermann, U., Handford, P.A., 
McDonough, M.A., Schofield, C.J., 2019. Aspartate/asparagine-β-hydroxylase crystal 
structures reveal an unexpected epidermal growth factor-like domain substrate disulfide 
pattern. Nat. Commun. 10. https://doi.org/10.1038/s41467-019-12711-7 
Pfister, S., Przemeck, G.K.H., Gerber, J.-K., Beckers, J., Adamski, J., de Angelis, M.H., 2003. 
Interaction of the MAGUK Family Member Acvrinp1 and the Cytoplasmic Domain of the 
Notch Ligand Delta1. J. Mol. Biol. 333, 229–235. https://doi.org/10.1016/ 
J.JMB.2003.08.043 
Phua, D.C.Y., Humbert, P.O., Hunziker, W., 2009. Vimentin regulates scribble activity by 
protecting it from proteasomal degradation. Mol. Biol. Cell 20, 2841–55. https://doi.org/ 
10.1091/mbc.e08-02-0199 
Pintar, A., De Biasio, A., Popovic, M., Ivanova, N., Pongor, S., 2007. The intracellular region of 
Notch ligands: does the tail make the difference? Biol. Direct 2, 19. 
https://doi.org/10.1186/1745-6150-2-19 
Pitulescu, M.E., Schmidt, I., Giaimo, B.D., Antoine, T., Berkenfeld, F., Ferrante, F., Park, H., 
Ehling, M., Biljes, D., Rocha, S.F., Langen, U.H., Stehling, M., Nagasawa, T., Ferrara, N., 
Borggrefe, T., Adams, R.H., 2017. Dll4 and Notch signalling couples sprouting angiogenesis 
and artery formation. Nat. Cell Biol. 19, 915–927. https://doi.org/10.1038/ncb3555 
Plentz, R., Park, J.-S., Rhim, A.D., Abravanel, D., Hezel, A.F., Sharma, S. V, Gurumurthy, S., 
Deshpande, V., Kenific, C., Settleman, J., Majumder, P.K., Stanger, B.Z., Bardeesy, N., 2009. 
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of 
pancreatic ductal adenocarcinoma. Gastroenterology 136, 1741–9.e6. https://doi.org/10.1053/ 
j.gastro.2009.01.008 
Popovic, M., Bella, J., Zlatev, V., Hodnik, V., Anderluh, G., Barlow, P.N., Pintar, A., Pongor, S., 
2011. The interaction of Jagged-1 cytoplasmic tail with afadin PDZ domain is local, folding-
independent, and tuned by phosphorylation. J. Mol. Recognit. 24, 245–253. 
https://doi.org/10.1002/jmr.1042 
Poulson, D.F., 1937. Chromosomal Deficiencies and the Embryonic Development of Drosophila 
Melanogaster. Proc. Natl. Acad. Sci. U. S. A. 23, 133–7. 
Preuss, C., Capredon, M., Wünnemann, F., Chetaille, P., Prince, A., Godard, B., Leclerc, S., 
Sobreira, N., Ling, H., Awadalla, P., Thibeault, M., Khairy, P., Samuels, M.E., Andelfinger, 
G., Andelfinger, G., 2016. Family Based Whole Exome Sequencing Reveals the Multifaceted 
Role of Notch Signaling in Congenital Heart Disease. PLOS Genet. 12, e1006335. 
https://doi.org/10.1371/journal.pgen.1006335 
Preuße, K., Tveriakhina, L., Schuster-Gossler, K., Gaspar, C., Rosa, A.I., Henrique, D., Gossler, 
A., Stauber, M., 2015. Context-Dependent Functional Divergence of the Notch Ligands 
DLL1 and DLL4 In Vivo. PLOS Genet. 11, e1005328. https://doi.org/10.1371/ 
journal.pgen.1005328 
REFERENCES 
 84
Pu, Y., Peach, M.L., Garfield, S.H., Wincovitch, S., Marquez, V.E., Blumberg, P.M., 2006. Effects 
on ligand interaction and membrane translocation of the positively charged arginine residues 
situated along the C1 domain binding cleft in the atypical protein kinase C isoforms. J. Biol. 
Chem. 281, 33773–88. https://doi.org/10.1074/jbc.M606560200 
Puthenveedu, M.A., von Zastrow, M., 2006. Cargo Regulates Clathrin-Coated Pit Dynamics. Cell 
127, 113–124. https://doi.org/10.1016/j.cell.2006.08.035 
Rajan, A., Tien, A.-C., Haueter, C.M., Schulze, K.L., Bellen, H.J., 2009. The Arp2/3 complex and 
WASp are required for apical trafficking of Delta into microvilli during cell fate specification 
of sensory organ precursors. Nat. Cell Biol. 11, 815–824. https://doi.org/10.1038/ncb1888 
Ramakrishnan, G., Davaakhuu, G., Chung, W.C., Zhu, H., Rana, A., Filipovic, A., Green, A.R., 
Atfi, A., Pannuti, A., Miele, L., Tzivion, G., 2015. AKT and 14-3-3 regulate Notch4 nuclear 
localization. Sci. Rep. 5, 8782. https://doi.org/10.1038/srep08782 
Rampal, R., Li, A.S.Y., Moloney, D.J., Georgiou, S.A., Luther, K.B., Nita-Lazar, A., Haltiwanger, 
R.S., 2005. Lunatic fringe, manic fringe, and radical fringe recognize similar specificity 
determinants in O-fucosylated epidermal growth factor-like repeats. J. Biol. Chem. 280, 
42454–63. https://doi.org/10.1074/jbc.M509552200 
Rana, N.A., Nita-Lazar, A., Takeuchi, H., Kakuda, S., Luther, K.B., Haltiwanger, R.S., 2011. O-
glucose trisaccharide is present at high but variable stoichiometry at multiple sites on mouse 
Notch1. J. Biol. Chem. 286, 31623–31637. https://doi.org/10.1074/jbc.M111.268243 
Ranganathan, P., Vasquez-Del Carpio, R., Kaplan, F.M., Wang, H., Gupta, A., VanWye, J.D., 
Capobianco, A.J., 2011a. Hierarchical Phosphorylation within the Ankyrin Repeat Domain 
Defines a Phosphoregulatory Loop That Regulates Notch Transcriptional Activity. J. Biol. 
Chem. 286, 28844–28857. https://doi.org/10.1074/jbc.M111.243600 
Ranganathan, P., Weaver, K.L., Capobianco, A.J., 2011b. Notch signalling in solid tumours: a 
little bit of everything but not all the time. Nat. Rev. Cancer 11, 338–351. 
https://doi.org/10.1038/nrc3035 
Rantala, J.K., Mäkelä, R., Aaltola, A.-R., Laasola, P., Mpindi, J.-P., Nees, M., Saviranta, P., 
Kallioniemi, O., 2011. A cell spot microarray method for production of high density siRNA 
transfection microarrays. BMC Genomics 12, 162. https://doi.org/10.1186/1471-2164-12-162 
Ratnayake, W.S., Apostolatos, C.A., Apostolatos, A.H., Schutte, R.J., Huynh, M.A., Ostrov, D.A., 
Acevedo-Duncan, M., 2018. Oncogenic PKC-ι activates Vimentin during epithelial-
mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors. 
Cell Adh. Migr. 12, 447–463. https://doi.org/10.1080/19336918.2018.1471323 
Richardson, A.M., Havel, L.S., Koyen, A.E., Konen, J.M., Shupe, J., Wiles, W.G., Martin, W.D., 
Grossniklaus, H.E., Sica, G., Gilbert-Ross, M., Marcus, A.I., 2018. Vimentin Is Required for 
Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast 
Interactions during Collective Invasion. Clin. Cancer Res. 24, 420–432. 
https://doi.org/10.1158/1078-0432.CCR-17-1776 
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, 
R.J., Callahan, C., Kasman, I., Singh, M., Chien, M., Tan, C., Hongo, J.-A.S., de Sauvage, F., 
Plowman, G., Yan, M., 2006. Inhibition of Dll4 signalling inhibits tumour growth by 
deregulating angiogenesis. Nature 444, 1083–1087. https://doi.org/10.1038/nature05313 
Rink, J., Ghigo, E., Kalaidzidis, Y., Zerial, M., 2005. Rab Conversion as a Mechanism of 
Progression from Early to Late Endosomes. Cell 122, 735–749. https://doi.org/10.1016/ 
j.cell.2005.06.043 
Saad, S., Stanners, S.R., Yong, R., Tang, O., Pollock, C.A., 2010. Notch mediated epithelial to 
mesenchymal transformation is associated with increased expression of the Snail 
transcription factor. Int. J. Biochem. Cell Biol. https://doi.org/10.1016/j.biocel.2010.03.016 
REFERENCES 
 85 
Sanchez-Carbayo, M., Socci, N.D., Lozano, J., Saint, F., Cordon-Cardo, C., 2006. Defining 
molecular profiles of poor outcome in patients with invasive bladder cancer using 
oligonucleotide microarrays. J. Clin. Oncol. 24, 778–789. https://doi.org/10.1200/ 
JCO.2005.03.2375 
Santiago-Gómez, A., Kedward, T., Simões, B.M., Dragoni, I., NicAmhlaoibh, R., Trivier, E., 
Sabin, V., Gee, J.M., Sims, A.H., Howell, S.J., Clarke, R.B., 2019. PAK4 regulates stemness 
and progression in endocrine resistant ER-positive metastatic breast cancer. Cancer Lett. 
https://doi.org/10.1016/j.canlet.2019.05.014 
Santio, N.M., Landor, S.K.J., Vahtera, L., Ylä-Pelto, J., Paloniemi, E., Imanishi, S.Y., Corthals, G., 
Varjosalo, M., Manoharan, G.B., Uri, A., Lendahl, U., Sahlgren, C., Koskinen, P.J., 2016. 
Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and 
prostate cancer cells. Oncotarget 7, 43220–43238. https://doi.org/10.18632/oncotarget.9215 
Sanz-Ezquerro, J.J., Münsterberg, A.E., Stricker, S., 2017. Editorial: Signaling Pathways in 
Embryonic Development. Front. cell Dev. Biol. 5, 76. https://doi.org/10.3389/ 
fcell.2017.00076 
Saravanamuthu, S.S., Gao, C.Y., Zelenka, P.S., 2009. Notch signaling is required for lateral 
induction of Jagged1 during FGF-induced lens fiber differentiation. Dev. Biol. 332, 166–176. 
https://doi.org/10.1016/j.ydbio.2009.05.566 
Sasaki, N., Sasamura, T., Ishikawa, H.O., Kanai, M., Ueda, R., Saigo, K., Matsuno, K., 2007. 
Polarized exocytosis and transcytosis of Notch during its apical localization in Drosophila 
epithelial cells. Genes to Cells. https://doi.org/10.1111/j.1365-2443.2007.01037.x 
Satelli, A., Li, S., 2011. Vimentin in cancer and its potential as a molecular target for cancer 
therapy. Cell. Mol. Life Sci. https://doi.org/10.1007/s00018-011-0735-1 
Sato, K., Watanabe, T., Wang, S., Kakeno, M., Matsuzawa, K., Matsui, T., Yokoi, K., Murase, K., 
Sugiyama, I., Ozawa, M., Kaibuchi, K., 2011. Numb controls E-cadherin endocytosis 
through p120 catenin with aPKC. Mol. Biol. Cell 22, 3103–19. 
https://doi.org/10.1091/mbc.E11-03-0274 
Selbie, L.A., Schmitz-Peiffer, C., Sheng, Y., Biden, T.J., 1993. Molecular cloning and 
characterization of PKC iota, an atypical isoform of protein kinase C derived from insulin-
secreting cells. J. Biol. Chem. 268, 24296–302. 
Selkoe, D.J., Wolfe, M.S., 2007. Presenilin: running with scissors in the membrane. Cell 131, 
215–21. https://doi.org/10.1016/j.cell.2007.10.012 
Sen, A., Madhivanan, K., Mukherjee, D., Aguilar, R.C., 2012. The epsin protein family: 
coordinators of endocytosis and signaling. Biomol. Concepts 3, 117–126. 
https://doi.org/10.1515/bmc-2011-0060 
Seo, D., Southard, K.M., Kim, J.-W., Lee, H.J., Farlow, J., Lee, J.-U., Litt, D.B., Haas, T., 
Alivisatos, A.P., Cheon, J., Gartner, Z.J., Jun, Y.-W., 2016. A Mechanogenetic Toolkit for 
Interrogating Cell Signaling in Space and Time. Cell 165, 1507–1518. 
https://doi.org/10.1016/j.cell.2016.04.045 
Sethi, M.K., Buettner, F.F.R., Krylov, V.B., Takeuchi, H., Nifantiev, N.E., Haltiwanger, R.S., 
Gerardy-Schahn, R., Bakker, H., 2010. Identification of Glycosyltransferase 8 Family 
Members as Xylosyltransferases Acting on O -Glucosylated Notch Epidermal Growth Factor 
Repeats. J. Biol. Chem. 285, 1582–1586. https://doi.org/10.1074/jbc.C109.065409 
Sethi, N., Dai, X., Winter, C.G., Kang, Y., 2011. Tumor-Derived Jagged1 Promotes Osteolytic 
Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells. Cancer Cell 
19, 192–205. https://doi.org/10.1016/j.ccr.2010.12.022 
Seugnet, L., Simpson, P., Haenlin, M., 1997. Requirement for dynamin during Notch signaling in 
Drosophila neurogenesis. Dev. Biol. 192, 585–98. https://doi.org/10.1006/dbio.1997.8723 
REFERENCES 
 86
Shen, W.-J., Zaidi, S.K., Patel, S., Cortez, Y., Ueno, M., Azhar, R., Azhar, S., Kraemer, F.B., 2012. 
Ablation of Vimentin Results in Defective Steroidogenesis. Endocrinology 153, 3249–3257. 
https://doi.org/10.1210/en.2012-1048 
Shi, S., Stanley, P., 2003. Protein O-fucosyltransferase 1 is an essential component of Notch 
signaling pathways. Proc. Natl. Acad. Sci. 100, 5234–5239. https://doi.org/10.1073/ 
pnas.0831126100 
Shimizu, M., Cohen, B., Goldvasser, P., Berman, H., Virtanen, C., Reedijk, M., 2011. 
Plasminogen activator uPA is a direct transcriptional target of the JAG1-notch receptor 
signaling pathway in breast cancer. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-10-
2523 
Siekmann, A.F., Affolter, M., Belting, H.-G., 2013. The tip cell concept 10 years after: new 
players tune in for a common theme. Exp. Cell Res. 319, 1255–63. https://doi.org/ 
10.1016/j.yexcr.2013.01.019 
Sigismund, S., Woelk, T., Puri, C., Maspero, E., Tacchetti, C., Transidico, P., Di Fiore, P.P., Polo, 
S., 2005. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. 
102, 2760–2765. https://doi.org/10.1073/pnas.0409817102 
Sigma-Aldrich, 2019. Duolink® PLA Troubleshooting Guide | Sigma-Aldrich [WWW Document]. 
URL https://www.sigmaaldrich.com/technical-documents/protocols/biology/duolink-trouble-
shooting-guide.html (accessed 11.28.19). 
Simons, K., Toomre, D., 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 
31–39. https://doi.org/10.1038/35036052 
Sjöqvist, M., Andersson, E.R., 2019. Do as I say, Not(ch) as I do: Lateral control of cell fate. Dev. 
Biol. 447, 58–70. https://doi.org/10.1016/j.ydbio.2017.09.032 
Skalska, L., Stojnic, R., Li, J., Fischer, B., Cerda‐Moya, G., Sakai, H., Tajbakhsh, S., Russell, S., 
Adryan, B., Bray, S.J., 2015. Chromatin signatures at Notch‐regulated enhancers reveal 
large‐scale changes in H3K56ac upon activation. EMBO J. 34, 1889–1904. 
https://doi.org/10.15252/embj.201489923 
Smith, C.A., Lau, K.M., Rahmani, Z., Dho, S.E., Brothers, G., She, Y.M., Berry, D.M., Bonneil, 
E., Thibault, P., Schweisguth, F., Le Borgne, R., McGlade, C.J., 2007. aPKC-mediated 
phosphorylation regulates asymmetric membrane localization of the cell fate determinant 
Numb. EMBO J. 26, 468–80. https://doi.org/10.1038/sj.emboj.7601495 
Snider, N.T., Omary, M.B., 2014. Post-translational modifications of intermediate filament 
proteins: mechanisms and functions. Nat. Rev. Mol. Cell Biol. 15, 163–177. 
https://doi.org/10.1038/nrm3753 
Song, J., Park, S., Kim, M., Shin, I., 2008. Down-regulation of Notch-dependent transcription by 
Akt in vitro. FEBS Lett. 582, 1693–1699. https://doi.org/10.1016/j.febslet.2008.04.024 
Song, Y., Kumar, V., Wei, H.-X., Qiu, J., Stanley, P., 2016. Lunatic, Manic, and Radical Fringe 
Each Promote T and B Cell Development. J. Immunol. 196, 232–243. https://doi.org/ 
10.4049/jimmunol.1402421 
Sorensen, E.B., Conner, S.D., 2010. γ-secretase-dependent cleavage initiates notch signaling from 
the plasma membrane. Traffic 11, 1234–45. https://doi.org/10.1111/j.1600-0854.2010. 
01090.x 
Spang, A., 2009. On the fate of early endosomes. Biol. Chem. 390, 753–9. https://doi.org/10.1515/ 
BC.2009.056 
Sparrow, D.B., Chapman, G., Wouters, M.A., Whittock, N. V., Ellard, S., Fatkin, D., Turnpenny, 
P.D., Kusumi, K., Sillence, D., Dunwoodie, S.L., 2006. Mutation of the LUNATIC FRINGE 
gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. Am. J. 
Hum. Genet. 78, 28–37. https://doi.org/10.1086/498879 
REFERENCES 
 87 
Sprinzak, D., Lakhanpal, A., LeBon, L., Santat, L.A., Fontes, M.E., Anderson, G.A., Garcia-
Ojalvo, J., Elowitz, M.B., 2010. Cis-interactions between Notch and Delta generate mutually 
exclusive signalling states. Nature 465, 86–90. https://doi.org/10.1038/nature08959 
Spuul, P., Daubon, T., Pitter, B., Alonso, F., Fremaux, I., Kramer, Ij., Montanez, E., Génot, E., 
2016. VEGF-A/Notch-Induced Podosomes Proteolyse Basement Membrane Collagen-IV 
during Retinal Sprouting Angiogenesis. Cell Rep. 17, 484–500. 
https://doi.org/10.1016/j.celrep.2016.09.016 
Suchting, S., Freitas, C., le Noble, F., Benedito, R., Breant, C., Duarte, A., Eichmann, A., 2007. 
The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel 
branching. Proc. Natl. Acad. Sci. 104, 3225–3230. https://doi.org/10.1073/pnas.0611177104 
Suckling, R.J., Korona, B., Whiteman, P., Chillakuri, C., Holt, L., Handford, P.A., Lea, S.M., 
2017. Structural and functional dissection of the interplay between lipid and Notch binding 
by human Notch ligands. EMBO J. 36, 2204–2215. https://doi.org/10.15252/ 
embj.201796632 
Sun, X., Artavanis-Tsakonas, S., 1997. Secreted forms of DELTA and SERRATE define 
antagonists of Notch signaling in Drosophila. Development 124, 3439–48. 
Swatek, K.N., Komander, D., 2016. Ubiquitin modifications. Cell Res. 26, 399–422. 
https://doi.org/10.1038/cr.2016.39 
Tagami, S., Okochi, M., Yanagida, K., Ikuta, A., Fukumori, A., Matsumoto, N., Ishizuka-Katsura, 
Y., Nakayama, T., Itoh, N., Jiang, J., Nishitomi, K., Kamino, K., Morihara, T., Hashimoto, 
R., Tanaka, T., Kudo, T., Chiba, S., Takeda, M., 2008. Regulation of Notch Signaling by 
Dynamic Changes in the Precision of S3 Cleavage of Notch-1. Mol. Cell. Biol. 28, 165–176. 
https://doi.org/10.1128/MCB.00863-07 
Takeuchi, H., Haltiwanger, R.S., 2014. Significance of glycosylation in Notch signaling. Biochem. 
Biophys. Res. Commun. 453, 235–42. https://doi.org/10.1016/j.bbrc.2014.05.115 
Takeuchi, H., Schneider, M., Williamson, D.B., Ito, A., Takeuchi, M., Handford, P.A., 
Haltiwanger, R.S., 2018. Two novel protein O-glucosyltransferases that modify sites distinct 
from POGLUT1 and affect Notch trafficking and signaling. Proc. Natl. Acad. Sci. U. S. A. 
115, E8395–E8402. https://doi.org/10.1073/pnas.1804005115 
Tamagnone, L., Zacchigna, S., Rehman, M., 2018. Taming the Notch Transcriptional Regulator 
for Cancer Therapy. Molecules 23, 431. https://doi.org/10.3390/molecules23020431 
Tammela, T., Zarkada, G., Wallgard, E., Murtomäki, A., Suchting, S., Wirzenius, M., Waltari, M., 
Hellström, M., Schomber, T., Peltonen, R., Freitas, C., Duarte, A., Isoniemi, H., Laakkonen, 
P., Christofori, G., Ylä-Herttuala, S., Shibuya, M., Pytowski, B., Eichmann, A., Betsholtz, C., 
Alitalo, K., 2008. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network 
formation. Nature 454, 656–660. https://doi.org/10.1038/nature07083 
Tanaka, N., Kyuuma, M., Sugamura, K., 2008. Endosomal sorting complex required for transport 
proteins in cancer pathogenesis, vesicular transport, and non-endosomal functions. Cancer 
Sci. 99, 1293–303. https://doi.org/10.1111/j.1349-7006.2008.00825.x 
Taylor, K.L., Henderson, A.M., Hughes, C.C.W., 2002. Notch Activation during Endothelial Cell 
Network Formation in Vitro Targets the Basic HLH Transcription Factor HESR-1 and 
Downregulates VEGFR-2/KDR Expression. Microvasc. Res. 64, 372–383. 
https://doi.org/10.1006/mvre.2002.2443 
Taylor, P., Takeuchi, H., Sheppard, D., Chillakuri, C., Lea, S.M., Haltiwanger, R.S., Handford, 
P.A., 2014. Fringe-mediated extension of O-linked fucose in the ligand-binding region of 
Notch1 increases binding to mammalian Notch ligands. Proc. Natl. Acad. Sci. U. S. A. 111, 
7290–7295. https://doi.org/10.1073/pnas.1319683111 
REFERENCES 
 88
Teider, N., Scott, D.K., Neiss, A., Weeraratne, S.D., Amani, V.M., Wang, Y., Marquez, V.E., Cho, 
Y.-J., Pomeroy, S.L., 2010. Neuralized1 causes apoptosis and downregulates Notch target 
genes in medulloblastoma. Neuro. Oncol. 12, 1244–1256. https://doi.org/10.1093/ 
neuonc/noq091 
Tetzlaff, F., Fischer, A., 2018. Control of Blood Vessel Formation by Notch Signaling, in: 
Advances in Experimental Medicine and Biology. pp. 319–338. https://doi.org/10.1007/978-
3-319-89512-3_16 
Tobias, I.S., Newton, A.C., 2016. Protein Scaffolds Control Localized Protein Kinase Cζ Activity. 
J. Biol. Chem. 291, 13809–13822. https://doi.org/10.1074/jbc.M116.729483 
Toivola, D.M., Strnad, P., Habtezion, A., Omary, M.B., 2010. Intermediate filaments take the heat 
as stress proteins. Trends Cell Biol. 20, 79. https://doi.org/10.1016/J.TCB.2009.11.004 
Tomiyama, L., Kamino, H., Fukamachi, H., Urano, T., 2017. Precise epitope determination of the 
anti-vimentin monoclonal antibody V9. Mol. Med. Rep. 16, 3917–3921. https://doi.org/ 
10.3892/mmr.2017.7102 
Traustadóttir, G.Á., Jensen, C.H., Thomassen, M., Beck, H.C., Mortensen, S.B., Laborda, J., 
Baladrón, V., Sheikh, S.P., Andersen, D.C., 2016. Evidence of non-canonical NOTCH 
signaling: Delta-like 1 homolog (DLK1) directly interacts with the NOTCH1 receptor in 
mammals. Cell. Signal. 28, 246–54. https://doi.org/10.1016/j.cellsig.2016.01.003 
Trindade, A., Kumar, S.R., Scehnet, J.S., Lopes-da-Costa, L., Becker, J., Jiang, W., Liu, R., Gill, 
P.S., Duarte, A., 2008. Overexpression of delta-like 4 induces arterialization and attenuates 
vessel formation in developing mouse embryos. Blood 112, 1720–9. 
https://doi.org/10.1182/blood-2007-09-112748 
Triolo, D., Dina, G., Taveggia, C., Vaccari, I., Porrello, E., Rivellini, C., Domi, T., La Marca, R., 
Cerri, F., Bolino, A., Quattrini, A., Previtali, S.C., 2012. Vimentin regulates peripheral nerve 
myelination. Development 139, 1359–67. https://doi.org/10.1242/dev.072371 
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., 
Liu, Z., Edfors, F., Sanli, K., von Feilitzen, K., Oksvold, P., Lundberg, E., Hober, S., Nilsson, 
P., Mattsson, J., Schwenk, J.M., Brunnström, H., Glimelius, B., Sjöblom, T., Edqvist, P.-H., 
Djureinovic, D., Micke, P., Lindskog, C., Mardinoglu, A., Ponten, F., 2017. A pathology 
atlas of the human cancer transcriptome. Science (80-. ). 357, eaan2507. 
https://doi.org/10.1126/science.aan2507 
Uyttendaele, H., Ho, J., Rossant, J., Kitajewski, J., 2001. Vascular patterning defects associated 
with expression of activated Notch4 in embryonic endothelium. Proc. Natl. Acad. Sci. U. S. 
A. 98, 5643–8. https://doi.org/10.1073/pnas.091584598 
Vaccari, T., Lu, H., Kanwar, R., Fortini, M.E., Bilder, D., 2008. Endosomal entry regulates Notch 
receptor activation in Drosophila melanogaster. J. Cell Biol. 180, 755–62. 
https://doi.org/10.1083/jcb.200708127 
van Engeland, N.C.A., Suarez Rodriguez, F., Rivero-Müller, A., Ristori, T., Duran, C.L., Stassen, 
O.M.J.A., Antfolk, D., Driessen, R.C.H., Ruohonen, S., Ruohonen, S.T., Nuutinen, S., 
Savontaus, E., Loerakker, S., Bayless, K.J., Sjöqvist, M., Bouten, C.V.C., Eriksson, J.E., 
Sahlgren, C.M., 2019. Vimentin regulates Notch signaling strength and arterial remodeling in 
response to hemodynamic stress. Sci. Rep. 9, 12415. https://doi.org/10.1038/s41598-019-
48218-w 
van Tetering, G., van Diest, P., Verlaan, I., van der Wall, E., Kopan, R., Vooijs, M., 2009. 
Metalloprotease ADAM10 Is Required for Notch1 Site 2 Cleavage. J. Biol. Chem. 284, 
31018–31027. https://doi.org/10.1074/jbc.M109.006775 
Varnum-Finney, B., Wu, L., Yu, M., Brashem-Stein, C., Staats, S., Flowers, D., Griffin, J.D., 
Bernstein, I.D., 2000. Immobilization of Notch ligand, Delta-1, is required for induction of 
notch signaling. J. Cell Sci. 113 Pt 23, 4313–8. 
REFERENCES 
 89 
Vässin, H., Bremer, K.A., Knust, E., Campos-Ortega, J.A., 1987. The neurogenic gene Delta of 
Drosophila melanogaster is expressed in neurogenic territories and encodes a putative 
transmembrane protein with EGF-like repeats. EMBO J. 6, 3431–40. 
Veeraraghavalu, K., Subbaiah, V.K., Srivastava, S., Chakrabarti, O., Syal, R., Krishna, S., 2005. 
Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-
phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent 
of CBF1;Su(H);Lag-1 activation. J. Virol. 79, 7889–98. https://doi.org/10.1128/ 
JVI.79.12.7889-7898.2005 
Wandinger-Ness, A., Zerial, M., 2014. Rab proteins and the compartmentalization of the 
endosomal system. Cold Spring Harb. Perspect. Biol. 6, a022616. https://doi.org/10.1101/ 
cshperspect.a022616 
Wang, N.J., Sanborn, Z., Arnett, K.L., Bayston, L.J., Liao, W., Proby, C.M., Leigh, I.M., Collisson, 
E.A., Gordon, P.B., Jakkula, L., Pennypacker, S., Zou, Y., Sharma, M., North, J.P., Vemula, 
S.S., Mauro, T.M., Neuhaus, I.M., LeBoit, P.E., Hur, J.S., Park, K., Huh, N., Kwok, P.-Y., 
Arron, S.T., Massion, P.P., Bale, A.E., Haussler, D., Cleaver, J.E., Gray, J.W., Spellman, 
P.T., South, A.P., Aster, J.C., Blacklow, S.C., Cho, R.J., 2011. Loss-of-function mutations in 
Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. 108, 
17761–17766. https://doi.org/10.1073/pnas.1114669108 
Wang, W., Struhl, G., 2005. Distinct roles for Mind bomb, Neuralized and Epsin in mediating 
DSL endocytosis and signaling in Drosophila. Development 132, 2883–94. 
https://doi.org/10.1242/dev.01860 
Wang, W., Struhl, G., 2004. Drosophila Epsin mediates a select endocytic pathway that DSL 
ligands must enter to activate Notch. Development 131, 5367–80. 
https://doi.org/10.1242/dev.01413 
Wang, W., Yi, M., Zhang, R., Li, J., Chen, S., Cai, J., Zeng, Z., Li, X., Xiong, W., Wang, L., Li, 
G., Xiang, B., 2018. Vimentin is a crucial target for anti-metastasis therapy of 
nasopharyngeal carcinoma. Mol. Cell. Biochem. 438, 47–57. https://doi.org/10.1007/s11010-
017-3112-z 
Weisshuhn, P.C., Handford, P.A., Redfield, C., 2015a. 1H, 13C and 15N assignments of EGF 
domains 4 to 7 of human Notch-1. Biomol. NMR Assign. 9, 275–279. 
https://doi.org/10.1007/s12104-014-9591-x 
Weisshuhn, P.C., Handford, P.A., Redfield, C., 2015b. 1H, 13C and 15N assignments of EGF 
domains 8–11 of human Notch-1. Biomol. NMR Assign. 9, 375–379. 
https://doi.org/10.1007/s12104-015-9613-3 
Weisshuhn, P.C., Sheppard, D., Taylor, P., Whiteman, P., Lea, S.M., Handford, P.A., Redfield, C., 
2016. Non-Linear and Flexible Regions of the Human Notch1 Extracellular Domain 
Revealed by High-Resolution Structural Studies. Structure 24, 555–566. https://doi.org/ 
10.1016/j.str.2016.02.010 
Weng, A.P., Ferrando, A.A., Lee, W., Morris, J.P., Silverman, L.B., Sanchez-Irizarry, C., 
Blacklow, S.C., Look, A.T., Aster, J.C., 2004. Activating Mutations of NOTCH1 in Human 
T Cell Acute Lymphoblastic Leukemia. Science (80-. ). 306, 269–271. https://doi.org/ 
10.1126/science.1102160 
Wharton, K.A., Johansen, K.M., Xu, T., Artavanis-Tsakonas, S., 1985. Nucleotide sequence from 
the neurogenic locus Notch implies a gene product that shares homology with proteins 
containing EGF-like repeats. Cell 43, 567–581. https://doi.org/10.1016/0092-8674(85)90229-
6 
WHO, 2019. Cardiovascular diseases (CVDs) [WWW Document]. URL https://www.who.int/ 
news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed 11.29.19). 
REFERENCES 
 90
Wiche, G., Osmanagic-Myers, S., Castañón, M.J., 2015. Networking and anchoring through 
plectin: a key to IF functionality and mechanotransduction. Curr. Opin. Cell Biol. 32, 21–29. 
https://doi.org/10.1016/j.ceb.2014.10.002 
Wilhelmsson, U., Faiz, M., de Pablo, Y., Sjöqvist, M., Andersson, D., Widestrand, Å., Potokar, M., 
Stenovec, M., Smith, P.L.P., Shinjyo, N., Pekny, T., Zorec, R., Ståhlberg, A., Pekna, M., 
Sahlgren, C., Pekny, M., 2012. Astrocytes Negatively Regulate Neurogenesis Through the 
Jagged1-Mediated Notch Pathway. Stem Cells 30, 2320–2329. https://doi.org/ 
10.1002/stem.1196 
Wilkin, M., Tongngok, P., Gensch, N., Clemence, S., Motoki, M., Yamada, K., Hori, K., 
Taniguchi-Kanai, M., Franklin, E., Matsuno, K., Baron, M., 2008. Drosophila HOPS and 
AP-3 Complex Genes Are Required for a Deltex-Regulated Activation of Notch in the 
Endosomal Trafficking Pathway. Dev. Cell 15, 762–772. https://doi.org/10.1016/ 
j.devcel.2008.09.002 
Windler, S.L., Bilder, D., 2010. Endocytic internalization routes required for delta/notch signaling. 
Curr. Biol. 20, 538–43. https://doi.org/10.1016/j.cub.2010.01.049 
Wu, G., Lyapina, S., Das, I., Li, J., Gurney, M., Pauley, A., Chui, I., Deshaies, R.J., Kitajewski, J., 
2001. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated 
protein degradation. Mol. Cell. Biol. 21, 7403–15. https://doi.org/10.1128/MCB.21.21.7403-
7415.2001 
Xiao, H., Bai, X.-H., Kapus, A., Lu, W.-Y., Mak, A.S., Liu, M., 2010. The Protein Kinase C 
Cascade Regulates Recruitment of Matrix Metalloprotease 9 to Podosomes and Its Release 
and Activation. Mol. Cell. Biol. 30, 5545–5561. https://doi.org/10.1128/mcb.00382-10 
Xiao, H., Liu, M., 2013. Atypical protein kinase C in cell motility. Cell. Mol. Life Sci. 
https://doi.org/10.1007/s00018-012-1192-1 
Xu, T., Park, S., Giaimo, B.D., Hall, D., Ferrante, F., Ho, D.M., Hori, K., Anhezini, L., Ertl, I., 
Bartkuhn, M., Zhang, H., Milon, E., Ha, K., Conlon, K.P., Kuick, R., Govindarajoo, B., 
Zhang, Y., Sun, Y., Dou, Y., Basrur, V., Elenitoba‐Johnson, K.S., Nesvizhskii, A.I., Ceron, 
J., Lee, C., Borggrefe, T., Kovall, R.A., Rual, J., 2017. RBPJ/CBF1 interacts with 
L3MBTL3/MBT1 to promote repression of Notch signaling via histone demethylase 
KDM1A/LSD1. EMBO J. 36, 3232–3249. https://doi.org/10.15252/embj.201796525 
Xu, Y., Xia, J., Liu, S., Stein, S., Ramon, C., Xi, H., Wang, L., Xiong, X., Zhang, L., He, D., Yang, 
W., Zhao, X., Cheng, X., Yang, X., Wang, H., 2017. Endocytosis and membrane receptor 
internalization: implication of F-BAR protein Carom. Front. Biosci. (Landmark Ed. 22, 
1439–1457. https://doi.org/10.2741/4552 
Xue, Y., Gao, X., Lindsell, C.E., Norton, C.R., Chang, B., Hicks, C., Gendron-Maguire, M., Rand, 
E.B., Weinmaster, G., Gridley, T., 1999. Embryonic Lethality and Vascular Defects in Mice 
Lacking the Notch Ligand Jagged1. Hum. Mol. Genet. 8, 723–730. https://doi.org/ 
10.1093/hmg/8.5.723 
Yamamoto, S., Charng, W.-L., Bellen, H.J., 2010. Endocytosis and Intracellular Trafficking of 
Notch and Its Ligands, in: Current Topics in Developmental Biology. pp. 165–200. 
https://doi.org/10.1016/S0070-2153(10)92005-X 
Yan, Y., Denef, N., Schüpbach, T., 2009. The Vacuolar Proton Pump, V-ATPase, Is Required for 
Notch Signaling and Endosomal Trafficking in Drosophila. Dev. Cell 17, 387–402. 
https://doi.org/10.1016/j.devcel.2009.07.001 
Yang, L.-T., Nichols, J.T., Yao, C., Manilay, J.O., Robey, E.A., Weinmaster, G., 2005. Fringe 
Glycosyltransferases Differentially Modulate Notch1 Proteolysis Induced by Delta1 and 
Jagged1. Mol. Biol. Cell 16, 927–942. https://doi.org/10.1091/mbc.e04-07-0614 
REFERENCES 
 91 
Yap, L., Lee, D., Khairuddin, A., Pairan, M., Puspita, B., Siar, C., Paterson, I., 2015. The opposing 
roles of NOTCH signalling in head and neck cancer: a mini review. Oral Dis. 21, 850–857. 
https://doi.org/10.1111/odi.12309 
Yochem, J., Weston, K., Greenwald, I., 1988. The Caenorhabditis elegans lin-12 gene encodes a 
transmembrane protein with overall similarity to Drosophila Notch. Nature 335, 547–550. 
https://doi.org/10.1038/335547a0 
Yoon, K., Gaiano, N., 2005. Notch signaling in the mammalian central nervous system: insights 
from mouse mutants. Nat. Neurosci. 8, 709–715. https://doi.org/10.1038/nn1475 
Zerial, M., McBride, H., 2001. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2, 
107–117. https://doi.org/10.1038/35052055 
Zhang, J., Liu, M., Su, Y., Du, J., Zhu, A.J., 2012. A Targeted In Vivo RNAi Screen Reveals 
Deubiquitinases as New Regulators of Notch Signaling. G3&amp;#58; 
Genes|Genomes|Genetics 2, 1563–1575. https://doi.org/10.1534/g3.112.003780 
Zhang, L.L., Cao, F.F., Wang, Y., Meng, F.L., Zhang, Y., Zhong, D.S., Zhou, Q.H., 2015. The 
protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced 
non-small cell lung cancer: meta-analysis of randomized controlled trials. Clin. Transl. Oncol. 
17, 371–377. https://doi.org/10.1007/s12094-014-1241-3 
Zhang, Y.U., Xie, Z.Y., Guo, X.T., Xiao, X.H., Xiong, L.X., 2019. Notch and breast cancer 
metastasis: Current knowledge, new sights and targeted therapy (review). Oncol. Lett. 
https://doi.org/10.3892/ol.2019.10653 
Zheng, L., Saunders, C.A., Sorensen, E.B., Waxmonsky, N.C., Conner, S.D., 2013. Notch 
signaling from the endosome requires a conserved dileucine motif. Mol. Biol. Cell 24, 297–
307. https://doi.org/10.1091/mbc.E12-02-0081 
Zhu, H., Zhou, X., Redfield, S., Lewin, J., Miele, L., 2013. Elevated Jagged-1 and Notch-1 
expression in high grade and metastatic prostate cancers. Am. J. Transl. Res. 5, 368–78. 
Zimber-Strobl, U., Strobl, L.J., 2001. EBNA2 and Notch signalling in Epstein–Barr virus mediated 
immortalization of B lymphocytes. Semin. Cancer Biol. 11, 423–434. https://doi.org/ 
10.1006/scbi.2001.0409 
 
  
Daniel Antfolk
Regulation of Notch Signaling by 
Intracellular Trafficking
D
aniel A
ntfolk  | Regulation of N
otch Signaling by Intracellular Traffi
cking | 2020
Daniel Antfolk
Regulation of Notch 
Signaling by  
Intracellular Trafficking
The Notch signaling pathway is a critical part of cell-
cell communication in all multicellular organisms. 
During the last few decades, many key aspects of 
Notch signaling have been described in develop-
ment and disease. Still, researchers struggle to under-
stand the context-dependent output of Notch. This 
PhD thesis provides new insights into the regulation 
of the Notch signaling pathway. In this thesis, a novel 
phosphorylation site is discovered on the signal-re-
ceiving Notch receptor, which regulates Notch sig-
naling activity and influences differentiation of mus-
cle and neuronal cells. Another key finding shows 
that signal-sending Jagged1 ligands interact with the 
cytoskeletal intermediate filament vimentin, which 
affects the activation potential of Jagged1. Further-
more, external addition of Jagged1 ligands can res-
cue the angiogenic sprouting defects seen from cells 
lacking vimentin. Finally, an approach to track endo-
cytosis of Jagged1 ligands is developed to identify 
other new regulators of these Notch ligands in the 
future. Collectively this thesis presents novel regula-
tors of Notch ligands and receptors, which may help 
facilitate future efforts to curtail deregulated Notch 
in disease.  
ISBN 978-952-12-3924-3
